








A Nutrigenetics approach to study the 
impact of genetic and dietary factors on 
blood lipids 
 
Submitted for the fulfilment of the degree of Doctorate of Philosophy 
 
Prepared at the Hugh Sinclair Unit of Human Nutrition, 
Department of Food and Nutritional Sciences 








Vimal KARANI S 




DECLARATION OF AUTHORSHIP  
I confirm that this is my own work and the use of all material from other sources has been 
properly and fully acknowledged.  





Abnormal lipid concentrations have been shown to be risk factors for cardiovascular disease, 
which is influenced by a complex interaction between lifestyle (such as diet) and genetic 
factors. Given that lipoprotein lipase (LPL) and apolipoprotein E (APOE) are key regulatory 
proteins in lipid metabolism, the main aims of this thesis were to examine the association of 
single nucleotide polymorphisms (SNPs) at the LPL and APOE genes with lipid-related 
outcomes and to investigate the interaction of the SNPs with dietary factors on lipids. A total 
of six studies with different study designs were used. These studies included a postprandial 
study (n=261), a case-control study (CURES, Asian India, n=1,845), three cross-sectional 
studies [PRECISE study (UK, n=468; Denmark, n=192) and CaPS study (UK, n=1,238)], a 16-
week intervention study DIVAS (n=120) and a crossover trial (n=18). For the LPL gene, the 
SNP rs328 showed a consistent association with HDL-C concentrations in the postprandial 
(P=0.015) and CURES studies (P=0.0004). In addition, in the CURES, there was an interaction 
between LPL SNP rs1121923 and fat intake (energy %) on HDL-C concentrations (P=0.003). 
For the APOE gene, significant associations were detected between the APOE haplotype (E2, 
E3, and E4) and APOE SNP rs445925 and total cholesterol (P=4x10-4 and P=0.003, 
respectively) in the PRECISE study. These associations were further replicated in the CaPS 
cohort. In the DIVAS study, the TT homozygotes of the APOE SNP rs1064725 showed a 
significant reduction in total cholesterol after the MUFA diet compared to the SFA (P=0.001). 
In the crossover trial, we examined the association vitamin D-related SNPs with lipids in 18 
men with sup-optimal vitamin D status and found that the TT homozygotes of the SNP 
rs12785878 (T/G) at nicotinamide-adenine dinucleotide synthetase 1 gene had higher HDL-C 
levels compared to G allele carriers (P=0.0003). In conclusion, our findings suggest a role of 
dietary factors in modifying the genetic effect of LPL and APOE SNPs on lipid levels. Given 
the smaller sample size of some of the cohorts studied, replication of the findings is warranted.  
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Chapter 1 Introduction to thesis 
1.1 Introduction  
Epidemiological studies have consistently shown that decreased high-density 
lipoprotein (HDL-C) levels accompanied by elevated levels of low-density lipoprotein (LDL-
C), triacylglycerol (TAG) and total cholesterol, play a key role in the development of 
cardiovascular disease (CVD) risk [1, 2]. Several biomedical studies have investigated the 
correlation between genotype and phenotype, to identify the specific genetic variants 
responsible for phenotypic variation amongst individuals [3]. Many candidate genes have 
been studied in relation to their potential role in lipid metabolism, and an association between 
these genes and lipid levels has been confirmed [4, 5]. Genome-wide association studies 
(GWAS) have identified several single nucleotide polymorphisms (SNPs) in different genes, 
which are associated with CVD risk and variations in lipid and lipoprotein concentrations [6]. 
The SNPs identified to date, however, explain a relatively small fraction of the inherited risk 
of CVD. Lipid levels are not a homogeneous phenotype and are known to be responsive to 
changes in diet, and are dependent on the quality and quantity of fat. Controlling diet is often 
the first recommendation in the outpatient setting [7, 8]. Thus, it is important to examine 
interactive effects between dietary and genetics factors on lipids.  
 The nutrigenetics or gene-diet interaction approach helps to investigate how the 
genetic makeup of an individual influences response to diet.  This approach helps to 
determine whether a diet can modulate genetic susceptibility by altering lipid responses, 
which may be beneficial in prevention and treatment of CVD [9, 10]. It also may provide 
evidence for tailoring optimal dietary recommendation, for individuals [11].  
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This chapter will: (i) discuss the evidence of the role of genes and diet separately on 
circulating lipids; (ii) outline the need for a nutrigenetics approach to promote cardiovascular 
health and reduce the burden of CVD. 
1.2 CVD prevalence and public health concerns  
CVD encompasses a broad range of disorders that affect the heart and blood vessels, 
i.e. coronary heart disease (CHD), angina, peripheral arterial disease, heart attack, congenital 
heart disease and rheumatic heart disease, and stroke [12, 13]. The circulation of blood to the 
heart, brain or body can be compromised due to a blood clot or accumulation of fat deposits 
inside an artery, leading to the hardening and narrowing of the artery (called atherosclerosis). 
Acute events usually cause heart attacks and stroke, as a result of a blockage that prevents 
blood from reaching the heart or brain respectively [13]. Every day, the number of 
individuals diagnosed with CVD is increasing, placing a huge burden on society [14]. The 
mortality rate of CVD in the UK alone, is one of the highest in the world, and approximately 
48% of deaths in Europe are due to CVD [15]. CVD is a global health problem and has been 
ranked top by the World Health Organisation (Figure 1.1) [14].  
 
















diseases  (source WHO, 2012). 
The epidemic of CVD is increasing globally in both developed and developing 
countries [16]. The cost of treating CVD patients in NHS hospitals was around £6.8 billion in 
England (between 2012-2013). Hospital statistics indicated that around 1.6 million episodes 
were related to CVD in UK hospitals, among these 10.1% of all inpatient episodes were in 
men and 6.3% in women. The number of operations performed to treat CVD in the UK, was 
>90,000 which is two times higher than a decade earlier [17]. In India, CVD contributed to 
two thirds of total number of mortality cases due to non-communicable diseases. The 
mortalities from CVD under age 70 were 52% in India compared with 23% in Western 
populations. The cost of health care spent on treating CVD was $237 billion in a period of 10 
years (from 2005-2015) [18]. Therefore, identifying risk factors for CVD and treatments 
against these factors will have a significant effect on disease prevention. 
1.3 Lipid as a risk factor for CVD 
A lipid profile that includes abnormal levels of total cholesterol, TAG and lipoprotein 
is a traditional CVD risk factor and biomarker [19]. These biomarkers can be measured in 
both fasting and postprandial states. Several observational studies have confirmed that 
increased fasting and postprandial TAG and TAG-rich particles are significant predictors of 
CVD [2]. A meta-analysis of prospective studies on a general population demonstrated that 
TAG increased CVD risk by approximately 30% in men and 75% in women (data for 46,413 
men and 10,864 women) where the relative risk remained statistically significant after 
adjustment for HDL-C and other risk factors [20]. A recent meta-analysis of 61 prospective 
studies investigated the association between TAG levels and CVD mortality and showed that 
the risk ratio of CVD mortality for the lowest TAG (< 90 mg/dl) was 0.83, borderline-high 
TAG (150–199 mg/dl) was 1.15, and high TAG (≥ 200 mg/dl) was 1.25, which confirmed 
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dose dependent effect for TAG levels [21]. The association between postprandial TAG and 
CVD was confirmed in 86,261 participants (men and women) in the Norwegian Counties 
Study [22]. Therefore, these results suggest that elevated TAG concentration is a powerful 
risk factor for CVD [23].  
Furthermore, lipoproteins (LDL-C and HDL-C) play a pivotal role in the progression 
of CVD. Their major function is to transport cholesterol, which is used for the maintenance 
of cell membranes, in the circulation system between the liver and peripheral tissues. The 
pathogenesis of atherosclerosis is highly correlated with LDL-C levels and is a therapeutic 
target to reduce the CVD risk. If there is an infection, HDL-C levels decrease rapidly; 
consequently, lower concentrations of HDL-C predict a serious CVD risk [24]. In a meta-
analysis of seven placebo-controlled statin trials, it was shown that concentrations of LDL-C 
reduced by 21% and non-HDL-C reduced by 20% thereby resulting in a reduced risk of 
coronary heart disease (CHD). Changes in LDL-C and non-HDL-C within each trial caused a 
significant risk reduction of CVD risk [25]. In a prospective study on 27,791 initially healthy 
women in the Women's Health Study, there were 899 incidents of CVD during the ten-year 
follow-up period. The risk of developing CVD was 1.47 times higher for women with 
elevated LDL-C (121mg/dl; 3.12 mmol/L) [26]. This evidence confirmed the key association 
between lipoprotein levels and CVD risk.  
The role of lipoproteins and lipids in the pathogenesis of CVD can be explained by 
increased accumulation of LDL-C particles, cholesterol, in the inner lining of the arterial 
wall. This leads to arterial plaques, which is the principal driver of the initiation for the 
pathogenesis of atherosclerosis [27]. The LDL-C and apolipoprotein B (apoB)-containing 
lipoproteins can pass the endothelial barrier and gain access to the sub-endothelial space, 
where they accumulate. Retained lipoproteins are oxidised and combined with other 
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atherogenic factors to promote activation of endothelial cells. The activated endothelial cells 
increase the recruitment of monocytes into the intima by inflammatory process and also 
promote the recruitment of other immune cells.  The monocytes differentiate into 
macrophages and express receptors that mediate the internalization of very low density 
lipoprotein, apolipoprotein E (apoE) remnants, and modified LDL to become foam cells. In 
macrophage foam cells, inflammatory signalling pathways are activated resulting in more cell 
recruitment and LDL modification. Foam cells are considered as intermediate atherosclerotic 
lesions, which occupy much of the lesion volume and leads to the progression of the 
atherosclerosis [28, 29]. On the other hand, HDL-C and apolipoprotein A-I (apoA-I) protect 
against atherosclerosis via mechanisms independent of cholesterol efflux resulting in reduced 
inflammation [28].   
Thus, this thesis aimed to study factors affecting lipid levels. Lipid concentrations are 
affected by a number of factors, which include modifiable factors such as diet, obesity and 
physical activity, and non-modifiable factors such as age, gender, and genetic factors [30, 
31]. Controlling modifiable factors may reduce the risk of developing CVD. In this thesis, 
genetic factors and dietary factors will be investigated.  
1.4 Lipid metabolism  
Following the digestion and absorption of dietary lipids into free fatty acids, TAG are 
resynthesized within the intestinal wall and combined with cholesterol and protein to form 
chylomicrons. Because of insolubility of TAG and lipids, they need to combine with protein 
to form lipoprotein [32]. Lipoproteins consist of a mixture of apolipoproteins, phospholipid, 
cholesterol, and TAG. Lipoproteins are involved in the transport of lipids through the 
circulation from intestine and liver to other tissues that require these lipids as their energy 
suppliers or use them as structural materials in their membrane. Based on the density 
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lipoproteins are mainly divided into five major classes including chylomicrons, very low 
density lipoprotein (VLDL), LDL-C, intermediate-density lipoproteins (IDL), and HDL-C 
[33]. Chylomicrons and VLDL have higher amount of TAG within their core; in contrast, 
LDL-C and HDL-C have higher amount of cholesterol ester within their core [34]. 
Apolipoproteins (APO) coat lipoprotein particles and transport lipids in the lymphatic 
and circulatory systems, for instance apoA, apoB, apoC and apoE. They have a number of 
other functions including cofactors for enzymes and ligands for cell-surface receptors. For 
example, apoC-II activates the enzyme lipoprotein lipase (LPL), which is involved in the 
hydrolysis of TAG in chylomicrons and VLDL, to convert them to remnant particles and 
remove TAG from circulation [35]. Remnant chylomicrons bind to LDL receptor-related 
protein (LRP) receptors on the surface of hepatocytes, which recognizes apoE on the surface 
of remnant chylomicrons. In the liver, VLDL is synthesized from TAG in the remnant 
chylomicrons, cholesterol and apoB-100, apoC-II and apoE. Then, VLDL is secreted into the 
plasma, where they are hydrolyzed by LPL to convert to IDL and release TAG. The IDLs are 
hydrolyzed by hepatic lipase to form LDL-C. One of the apolipoproteins components in 
LDL-C is apoB-100, which facilitates binding between the lipoprotein particles and LDL-
specific receptors on the surface of many cells. After binding, cholesterol in the LDL-C is 
used as a structural component of cell membranes or is converted to steroid hormones [34]. 
The HDL-C is synthesized by liver and gut. Cholesterol from peripheral tissues bind 
to HDL-C through apoA-I, which mediates transportation of cholesterol to the liver [36]. 
Several enzymes, proteins, and receptors are involved in HDL-C metabolism pathway. 
Lecithin cholesterol acyltransferase (LCAT) enzyme esterifies free cholesterol in nascent 
HDL-C to cholesteryl esters. ATP-binding cassette protein (ABCA1) is responsible for 
adding free cholesterol from cells to HDL-C resulting HDL-C particles that is rich in free 
cholesterol. Furthermore, cholesteryl esters and phospholipids are transferred from HDL-C to 
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apoB-containing lipoproteins, including the triglyceride rich lipoproteins (TRLs) via 
cholesteryl ester transfer protein (CETP). Scavenger receptor BI (SR-BI) binds to HDL-C in 
order to transport back cholesterol ester to the liver [37, 38].  
1.5 Factors affecting lipid levels 
1.5.1 Dietary factors   
The last few decades have seen fundamental changes in dietary patterns in almost every 
region of the world [39]. This shift has raised a global concern as an unhealthy diet is a major 
cause of the increased burden of diseases such as CVD [40]. Therefore, nutritional science 
has designed and implemented strategies to reduce the incidence of diet-related diseases [41]. 
One of the key public health strategies for CVD prevention is to reduce saturated fatty acid 
(SFA) intake to < 10 % of total energy (%TE) [42], as high intake of SFA is associated with 
elevated LDL-C concentrations [8]. A clinical trial showed that lowering intake of SFA by 
5% and 8% reduced LDL-C levels by 6.8% and 11.7%, respectively [43]. Therefore, it is 
recommended that SFA should be replaced with alternative macronutrients such as 
unsaturated fat [44]. It has been found that replacing 1% TE of SFA with either 
polyunsaturated fatty acids (PUFA) or cis-monounsaturated fatty acids (cis-MUFA) lowers 
LDL-C by 0.009 and 0.019 mmol/l respectively [8]. Furthermore, in a recent intervention 
study, it was reported that isoenergetic replacement of 9.5-9.6%TE from SFA with MUFA or 
n-6 PUFA had a beneficial effect on lipid response, with a reduction of 8.4% and 9.2% 
respectively in total cholesterol, 11.3% and 13.6% respectively in LDL-C, and total 
cholesterol to HDL-C ratio of 5.6% and 8.5% respectively [45]. In a randomised controlled 
trial, a moderate substitution 9%TE of SFA with MUFA for three months induced a reduction 
in the concentrations of cholesterol and TAG [46]. Moreover, a recent randomised controlled 
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trial suggested that intervention of n-6 PUFA diet (flax and safflower oils) for four weeks 
lowered total cholesterol [47].  
High SFA intake is linked with unfavourable lipid profiles, however if carbohydrates 
are replaced with SFA, concentrations of TAG have been shown to increase particularly 
simple carbohydrates [48, 49]. Two cross-sectional studies, have indicated that higher intakes 
of carbohydrate was associated with lower HDL-C levels and increased TAG in healthy 
adults, which may have further health implications for CHD [50, 51]. A moderate 
carbohydrate restriction (39%TE) with low SFA (9%TE) for three weeks resulted in a 
reduction in TAG, small LDL mass, and total cholesterol to HDL-C ratio [52]. Some studies 
investigated on specific type of carbohydrates such as complex carbohydrates and whole 
grains, which postulated to have positive effect on lipid levels. For complex carbohydrates, a 
randomized crossover study conducted on 16 gestational diabetes mellitus women who were 
given either lower-carbohydrate/high fat diet (40% carbohydrate/45% fat/15% protein) or 
higher-complex carbohydrate /lower-fat diet (60 carbohydrate /25 fat /15% protein) for three 
days. Complex carbohydrates defined as polysaccharides and starches primarily derived from 
grains, vegetables, and fruits. higher-complex carbohydrate /lower-fat diet significantly 
lowered postprandial free fatty acids but not postprandial TAG [53].  
Additionally a large cross sectional study, that included 12,745 men and women from 
the Polish Norwegian study, found that, among users of statin, individuals who consumed 
adequate amount of whole grains (≥3oz/day) showed an association with lower total 
cholesterol and LDL-C levels compared with individuals who consumed inadequate amount 
of whole grains [54]. Results from randomized control trial showed (total n=45 men and 
women) that healthy participants who consumed adequate amount of whole grain (corn, rice, 
and wheat) based on their caloric need for six weeks had decreased total, LDL, and non-HDL 
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cholesterol levels compared to those who received refined grains [55]. However, in a 
crossover study, where 33 men and women received either whole grain or refined grain 
(50g/1000 kcal in each diet) for 8 weeks, showed that whole grain diet significantly 
decreased diastolic blood pressure but not total and LDL cholesterol [56].  
Few studies have investigated the effect of protein-rich diets on lipid levels. In a 
randomised controlled trial, a high-protein diet (20-34%TE) was shown to reduce fasted 
TAG, LDL-C, and total cholesterol compared with a diet high in carbohydrates and a 
standard protein diet [57]. Conversely, there was no significant difference in LDL-C and 
HDL-C levels with a high-protein diet compared to a high-carbohydrate diet [58]. A recent 
study investigated the effect of milk proteins on risk markers of CVD. Thirty-eight 
participants were given either 2 × 28 g whey protein/day, 2 × 28 g calcium caseinate/day, or 
2 × 27 g maltodextrin (control)/day for 8 weeks separated by a 4-weeks washout after each 
study arm. Participants received both whey protein and calcium caseinate had significantly 
lower total cholesterol, while TAG decreased after whey protein diet only [59]. Also, another 
study looked at the effect of consuming either 25 g/day lupin protein isolate or 25g/day milk 
protein isolate for 4 weeks in 33 hypercholesterolemic participants. Findings showed that 
LDL-C was significantly decreased after both dietary interventions but LDL:HDL cholesterol 
ratio was decreased only after consuming lupin protein isolate [60].  
Overall, the effect of dietary macronutrients on lipids is still controversial [61] with 
high individual heterogeneity in serum lipid response to the same dietary intervention [10]. 
1.5.2 Genetic factors  
Lipid and lipoprotein metabolism are complex biological pathways containing 
multiple steps. A large number of nuclear factors, binding proteins, apolipoproteins, 
enzymes, and receptors involving hundreds of genes are involved in the lipid metabolism 
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pathway [4]. Between 25 % and 80 % of the inter-individual variation in lipid concentrations 
is explained by SNPs at several genes [62]. There is growing interest in the development of 
in-depth knowledge regarding how genetic factors affect the regulation of plasma lipid 
absorption, transport and catabolism [63]. Within the past two decades, a plethora of genes 
have been identified in humans, which are associated with lipid metabolism and plasma 
lipoprotein profiles [63].  
Some of the most important genes involved in lipid metabolism are APOA-I, APOE, 
LPL, hepatic lipase (LIPC), and cholesteryl ester transfer protein (CEPT) [4, 64, 65]. It has 
been confirmed that the CEPT, LPL and LIPC proteins play an important role in determining 
the circulating HDL-C levels [66-68], and many studies have implicated that selected SNPs 
within these genes are the cause of changes in HDL-C concentrations [69-71]. Moreover, 
inheritance of the levels of the fasting and postprandial TAG has been linked to SNPs at the 
LPL gene [72, 73]. Apolipoproteins are vital components of the lipoprotein molecules due to 
the role they play in the metabolism of lipoproteins. Some act as ligands for receptors and 
play roles as cofactors, activators or inhibitors of enzymes in lipid metabolism [74]. 
Therefore, genes that encode these proteins have been found to have a significant impact on 
lipid levels. It has been confirmed that common polymorphisms at the APOE gene account 
for inter-individual variation in LDL-C, TAG and total cholesterol concentrations [75-79]. 
The APOA-I protein is a principal component of HDL-C particles [80]; forty-three SNPs 
have been reported within the gene associated with low HDL-C concentrations [37] .  
Recent GWAS studies have reported a significant increase in the number of loci 
associated with lipid and lipoprotein profiles [81, 82]. Two large-scale GWAS study meta-
analyses have identified 157 genomic loci contributing to inter-individual variation in the 
lipid concentrations in >100,000 individuals [83, 84]. Of these loci, 46 demonstrated the 
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strongest evidence of associations with HDL-C, 16 with TAG, 18 with total cholesterol, and 
9 with LDL-C. Some of the identified loci affected multiple lipid outcomes, i.e. four variants 
showed associations with total cholesterol, HDL-C, LDL-C, and TAG [84]. 
Genes alone, however, do not explain the variation in lipid concentrations as lifestyle 
factors, i.e. dietary factors, also influence lipids. Therefore, this is investigated by identifying 
gene-diet interactions (also called Nutrigenetics) [85-88]. In my thesis, I aimed to investigate 
the interaction between dietary factors (modifiable factor) and genetic markers (non-
modifiable factor) on lipid outcomes.  
1.6 Nutrigenetics approach 
Nutrigenetics is the study of genetic background of an individual that effects response to diet, 
the ultimate goal of which is to generate evidence of gene-diet interactions to personalise 
dietary recommendations to help prevent or delay the onset of disease [4, 89]. Investigations 
in nutrigenetics have undergone rapid development due to the increasing demand of new 
optimal dietary strategies for general public health.  
1.6.1 Rational for studying gene-diet interactions 
Many SNPs associated with CVD risk factors have been identified [4, 5], and represent a 
small fraction of the heritability of the CVD [62]. However, environmental factors including 
dietary factors can also modulate the effect of genes on CVD and hence, interaction between 
genetic and dietary factors must be taken into account [90]. Genes can trigger the incidence 
of CVD in individuals carrying risk alleles, when these individuals are exposed to a high-risk 
environmental factor [91]. Thus, findings from gene–diet interactions will contribute to the 
identifying the involvement of both gene and diets in the development of multifactorial 
disease such as CVD. This knowledge is crucial for the primary prevention of CVD, and also 
to develop more effective dietary strategies for preventing or delaying of CVD [90].  
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Figure 1.2 shows the interaction between genetic (non-modifiable) and dietary factors 
(modifiable) on lipoprotein concentrations, which eventually leads to the development of 
cardiometabolic diseases. 
1.7 Genetic variations and ethnic background   
In humans, 99.9% of the genome is identical; variations exist in the remaining 0.1% 
of the genome,  making a person unique [92]. Approximately 85% of all SNPs are common 
to all human populations and only 15 % of SNPs are population-specific [93]. Therefore, if a 
common allele is significantly associated with a disease, it is more likely to be shared by 
multiple populations [94]. However, some gene frequencies vary across different ethnic 
groups, resulting in differences in the prevalence of disease risk across ethnicities [95]. For 
example, the highest frequency for the E4 allele (risk allele) at the APOE gene has been 
reported for African and North European populations compared to Indian and Asian 
populations [96]. Additionally, environmental factors also contribute to the disease 
prevalence. Moderate changes in lifestyle factors, such as reducing SFA intake, have an 
impact on reducing CVD risk if adopted by large groups of the population [97].  Thus, the 
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importance of studying different ethnic groups is to identify the effect of different lifestyle 
factors, mainly dietary pattern, across populations.  
1.8 Selection of candidate genes for the study  
This thesis focuses on two candidate genes, LPL and APOE, because of their key role 
in lipid metabolism (Figure 1.2).  The LPL enzyme is located on the luminal surface of the 
vascular endothelium, and regulates the lipolytic processing of TAG-rich lipoproteins. LPL 
hydrolyses the circulating TAG-rich lipoproteins, resulting in the formation of chylomicron 
remnants and intermediate density lipoproteins (IDL), the VLDL remnants, and LDL. 
Therefore, LPL modulates circulating TAG and HDL-C concentrations [67, 98]. LPL has 
another non-enzymatic function in the binding of lipoprotein particles to cell-surface 
molecules, which mediate uptake of lipoproteins [99]. Furthermore, deficiencies in LPL 
enzyme expression have been implicated in the pathogenesis of hypertriacylglycerolaemia, 
and CVD [67, 100]. Thus, LPL is suggested to have anti-atherogenic effects through clearing 
circulating lipoprotein particles and pro-atherogenic effects through enhancing the uptake of 
potentially atherogenic TAG-rich lipoproteins by the arterial wall [101].  
The APOE protein, which is a component of VLDL particles, chylomicrons, and their 
remnants, has an anti-atherogenic function.  The APOE is a ligand for the LDL receptor-
related protein, which mediates cellular removal of lipoprotein remnants and acts as a 
cofactor in VLDL synthesis, mainly hydrolysing VLDL remnants to produce LDL-C [102]. 
Thus, it is considered to be an important determinant of serum LDL-C levels [103]. 
Given these important functions of LPL and APOE in lipid metabolism, it would be 
timely to examine the interaction between SNPs of LPL and APOE genes and dietary factors 
on lipid outcomes.  
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Figure 1.3 Role of lipoprotein lipase and apolipoprotein E in lipid metabolism; LPL; 
lipoprotein lipase, APOE; apolipoprotein E, LACT; lecithin: cholesterol acyl transferase is an 
enzyme that produces cholesteryl esters in plasma and promotes the formation of HDL-C; 
CETP; cholesteryl ester transfer protein which facilitates transfer of CE and TAG between 
lipoproteins, SRB-1; scavenger receptor B-1 found in liver and facilitates uptake of CE and 
HDL-C; IDL; intermediate density lipoprotein; CE; cholesterol ester.   
1.8.1 Lipoprotein lipase 
The LPL gene is located on chromosome 8q22 and includes 10 exons encoding 475 
amino acids, of which 448 amino acids are part of the mature protein and 27 are part of the 
signal peptide [104]. The SNPs at this gene have previously been associated with changes in 
circulating TAG and HDL-C [105, 106]. Few studies have investigated the interaction 
between LPL SNPs and diet on lipids.  
The interaction between the SNP rs328 (C/G) and the intake of dietary fat (energy %) 
on HDL-C concentrations was significant in ≈ 9,000 Caucasian Americans (men and 
women). The fat intake was found to be positively correlated with fasted HDL-C among CC 























homozygotes and CG heterozygotes, but inversely correlated with GG homozygotes. 
Moreover, interactions were observed between SNP rs328 with saturated fatty acid (SFA) (as 
g/day) and monounsaturated fatty acid (MUFA) (as g/day and energy %) on HDL-C [85]. 
Unsaturated fat was shown to interact significantly with SNP rs10503669 on HDL-C 
concentrations in Korean participants (5,314 men and women) [107]. Furthermore, the 
association between SNP rs13702 (T/C) and the reduction in plasma TAG in response to 
unsaturated fat (30 grams/day during a 3-year intervention) was evaluated, and a greater 
reduction in fasted TAG was observed in C minor allele carriers [108].  
A study of 452 participants consuming their habitual diet from the European 
LIPGENE human study showed a significant gene-nutrient interaction between LPL SNPs 
(rs328 [C/G] and rs1059611 [A/G]) and total n-6 polyunsaturated fatty acid (PUFA) intake 
with fasted plasma TAG concentrations. The G minor allele carriers of both SNPs were 
associated with lowered concentrations of TAG in individuals consuming a diet low in n-6 
PUFA (35.48% of total lipid) compared with common homozygotes. This interaction was 
replicated in another population, where n-6 PUFA interacted with both SNPs (rs328 and 
rs1059611) on HDL-C [109]. In a meta-analysis based on 27,756 individuals from 10 
cohorts, a significant interaction between another SNP rs13702 at the LPL gene and PUFA 
(energy %) on TAG was identified, with an inverse association between PUFA intake and 
TAG concentrations[110].  
Data from these studies demonstrates that the strongest interaction was between LPL 
variation and PUFA intake on TAG concentrations. Replication for other fat types (SFA and 
MUFA) is required in addition to investigating other macronutrients (protein and 
carbohydrates). The diversity in ethnicity within these studies is limited and therefore, 
examining other ethnicities is warranted.  
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1.8.2 Apolipoprotein E 
The most commonly studied apolipoprotein gene polymorphism is APOE due to its 
key role in lipid metabolism [111]. The human APOE gene is located on chromosome 
19q13.2 and encodes a polymorphic protein of 299 amino acids [112]. Two SNPs in exon 4 
(rs429358, and rs7412) give rise to three major isoforms encoded by three alleles: E2, E3, 
and E4 [113]. Most populations studied reported that the E4 allele is associated with a high 
risk of CVD due to an increase in TAG and LDL-C levels, whereas E2 carriers is associated 
with low levels of circulating LDL-C [111]. Therefore, APOE is considered as a potential 
modulator of plasma lipid response, which is altered by dietary fat composition [114].  
In healthy individuals from Costa Rica, a statistically significant interaction was 
observed between the APOE common genotype (rs429358 and rs7412; E2, E3, and E4) and 
SFA intake on VLDL and HDL-C. The E2 allele carriers who consumed high SFA [13.5% 
total energy (TE)] were associated with higher VLDL and lower HDL-C concentrations, 
while the opposite association was observed in E4 allele carriers [87]. Moreover, an 
interaction was demonstrated between the APOE (rs405509) and dietary SFA intake on 
plasma LDL-C and HDL-C in an Inuit population [115]. Conversely, other studies have not 
shown a significant interaction between the APOE common genotype and dietary fat on lipid 
levels in Caucasian and Black American populations [116, 117].  
E4/E4 individuals who followed a lower-fat-cholesterol diet (34% fat, 265 mg 
cholesterol/day) showed a significant reduction in total cholesterol, but there was a 
significant increase in total cholesterol among the E4/E4 group who followed a high-fat-
cholesterol diet (38% fat, 300 mg cholesterol/day) [118]. In a chronic intervention study in 
which prospectively genotyped participants were randomised to a low-SFA diet (8% TE) 
versus a high-SFA diet (18%TE) supplemented with 3.45g docosahexaenoic acid (DHA)/day, 
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the E3/E3 and E4/E4 groups were reported to have lowered TAG with a high-SFA diet 
supplemented with DHA compared to those with a low-SFA diet [79]. In two fish oil 
supplementation studies (2-3g eicosapentaenoic acid (EPA)/DHA per day), the APOE 
genotype was demonstrated to have a significant effect on the plasma lipid profile [119, 120]. 
Individuals with the E2 allele displayed a marked reduction in postprandial TAG response 
[120], while men with the E4 allele exhibited a reduction in TAG [119]. The dependent effect 
of the APOE genotype on carbohydrates and MUFA has also been investigated, with lowered 
LDL-C found in E2 allele carriers compared with E3 and E4 allele carriers with a high-
carbohydrate diet [121].  
The most convincing evidence is the effect of fish oil supplementation on the APOE 
genotype. Despite extensive research on the interactions between the APOE genotype and 
dietary fat and fat composition (i.e. SFA, MUFA, and cholesterol), the reported outcomes are 
somewhat inconsistent.  
1.9 Other genes related to lipid outcomes  
This chapter, also, will summarize the findings from gene-diet interactions on lipid-
related outcomes focusing on the most commonly studied candidate genes including 
Adiponectin (ADIPOQ), apolipoprotein CIII (APOCIII), apolipoprotein A5 (APOA5), 
apolipoprotein AI (APOAI), cholesteryl ester transfer protein (CETP), hepatitis lipase (LIPC), 
peroxisome proliferator–activated receptor (PPARA, and PPARG), and tumour necrosis 
factor-alpha (TNFA) genes.  
1.9.1 Adiponectin gene 
The ADIPOQ, gene coding for adiponectin, is a common genetic marker associated 
with serum lipid level. Adiponectin is an adipocyte-derived hormone and the gene is  located 
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on chromosome 3q27 [122]. Adiponectin has been shown to affect energy metabolism and 
insulin sensitivity that includes increasing mitochondrial fatty acid oxidation and enhancing 
TAG catabolism and fatty acid uptake, which consequently regulates lipid metabolism in 
skeletal muscle [123]. PPARA is also activated by adiponectin and regulates APOAI and 
apolipoprotein A2, leading to increased secretion of hepatic HDL-C. Therefore, plasma levels 
of TAG are negatively associated with adiponectin, while HDL-C concentrations are 
positively correlated with adiponectin. A minimum of 53 SNPs have been identified in the 
ADIPOQ gene [124]. Among these, SNPs +274G>T (rs1501299), -11377C>G (rs266729), 
and +45T>G (rs2241766) have been shown to be associated with CVD in previous studies 
[125, 126]. 
Recent studies have investigated the interaction between these SNPs and diet on 
determining lipid profile levels. A cross-sectional study has reported that three ADIPOQ 
haplotypes of SNPs rs1501299 (G/T), rs266729 (C/G), and rs2241766 (T/G) were found to 
interact with MUFA:SFA ratio on determining TC, and LDL-C levels (P=0.002 and 0.02, 
respectively) in Korean children (n=687). Individuals carrying the G-T-G haplotype exhibited 
higher levels of TC and LDL-C than non-carriers when the ratio of MUFA:SFA was <1 
[127]. Inconsistent responses of lipids (TAG, LDL-C, HDL-C, TC) to SFA-rich diet followed 
by a carbohydrate-rich or MUFA-rich diet by SNP rs266729 (C/G) were not significant in 
healthy Caucasian individuals (n=59) [128]. Carbohydrate intake was found to interact with 
the ADIPOQ SNP rs1501299 (G/T) on HDL-C concentrations (P=0.01) in Korean patients 
with type 2 diabetes (n=673). High carbohydrate intake (>65%) was inversely related to 
HDL-C concentrations in carriers of GG homozygotes [129]. However, this finding cannot be 
generalized to other populations or ethnic groups given that the participants were type 2 
diabetic patients. Findings from ADIPOQ gene- diet interaction studies were inconsistent and 
these discrepancies in the results could be due to the type of study design, small sample size, 
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and heterogeneity in age and ethnicity of the participants. 
1.9.2 Apolipoprotein genes 
The most widely studied genetic markers, in relation to CVD risk factors and dietary 
intake, are the apolipoprotein genes (APOAI, APOCIII, APOA5, and APOE). The number of 
published articles investigating interaction of dietary factors with these genes have increased 
considerably [111].  
1.9.2.1 Apolipoprotein A5 
The APOA5 regulates plasma TAG levels by enhancing the activity of lipoprotein 
lipase and inhibiting TAG-rich lipoprotein production [111, 130].  It is located on TAG-rich 
lipoproteins and HDL-C particles [131]. Polymorphisms in the APOA5 gene, which is part of 
the apolipoprotein (APOAI-A4-A5-CIII) gene cluster on human chromosome 11q23, 
represent the most commonly studied candidate SNP with regard to lipid outcomes [132, 
133]. Genetic studies have consistently demonstrated associations of APOA5 SNPs with 
increased TAG and increased risk of CVD [134, 135]. The APOA5 SNP -1131T>C 
(rs662799) has been shown to be a strong candidate for its relevance to plasma lipid levels 
[134, 136].  
Several gene-diet interaction studies have investigated the impact of APOA5 and 
dietary intake on plasma lipid [137, 138]. Cross-sectional studies conducted on the Caucasian 
population (n=1465) and Puerto Ricans (n=802) have demonstrated that SNP rs662799 (T/C) 
interacts with total fat intake [(TE) %, and grams] in determining TAG, TC and VLDL 
concentrations (Pinteraction ranges from 0.002 to 0.03) [137, 138]. Participants with the C minor 
allele had higher TAG levels when they consumed fat >31% of TE in Puerto Ricans, while in 
Spanish Caucasians, among those who consumed high fat intake, the C allele carriers had 
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lower TAG and VLDL levels [137, 138]. This could be because the Spanish Caucasians 
consumed a traditional Mediterranean Diet, which mainly consists of MUFA from olive oil. 
In contrast, two studies from a Slavic Caucasian population (n=5487) and Mexican 
population (n=200) failed to demonstrate a significant interaction between SNPs, rs662799 
(T/C) and rs3135506 (C/G), and dietary fat (as total, SFA, or PUFA) on lipid [139, 140]. The 
lack of interaction could be because only 2% of the participants carried the minor APOA5 
gene allele, participants were relatively old [139] and the sample size of the Mexican study 
was very small [140].     
A significant interaction between SNP rs662799 (T/C) and n-6 PUFA intake, in 
determining fasted TAG concentration, was demonstrated in Caucasians (n=2418) from the 
Framingham Study. In carriers of the C allele, higher PUFA intakes (>6 % energy) were 
shown to be associated with higher TAG [141]. In a 2-year longitudinal study (multi ethnic 
majority Caucasian) in which participants (n=734) were randomised to a high fat diet or a 
low-fat-diet group, G allele carriers at SNP rs964184 (C/G) were reported to have a greater 
decrease in TC and LDL-C, and a greater elevation in HDL-C levels than non-carriers after a 
low fat diet [142]. Following a diet high in carbohydrates and low in fat (70% and 15% of 
TE, respectively), C allele carriers of the SNP rs662799 (T/C) had higher TAG and TAG-rich 
lipoprotein than TT genotype carriers [143].  
An interaction between dietary carbohydrate intake (as whole grain and legumes) and 
APOA5 SNP rs662799 (T/C) on TAG levels was reported in Korean type 2 diabetic patients 
(n=185). Individuals carrying the C risk allele had higher TAG concentrations than TT 
genotype carriers after consuming refined rice [144]. From these reported findings, 
consistencies were found in APOA5 SNP–fat interactions on lipid levels. Further studies are 
required to explore subgroups of dietary fat (SFA, MUFA, and PUFA) and carbohydrates in 
 21 
addition to investigating other ethnicities using different study designs.    
1.9.2.2 Apolipoprotein A-I 
The APOA-I is the major structural apolipoprotein component of HDL-C. Its function 
is to activate lecithin: cholesterol acyltransferase and facilitate reverse cholesterol transport. 
The APOAI genes are located in the apolipoprotein (APOAI-A4-A5-C3) gene cluster on 
chromosome 11q23-q24 [145].  The most commonly and widely studied genetic variation is 
SNP rs670 (G/A) which is located in the promoter region of the gene. The presence of the 
minor A allele has been shown to be associated with increased HDL-C and APOA-I plasma 
levels [146, 147]. The studies have reported interaction between diet and APOAI genes and 
have focused mainly on dietary fat and its subgroups (SFA, MUFA and PUFA) [115, 148].  
Fat intake and SFA was reported to interact significantly with SNP rs670 (G/A) and 
on fasted TC, LDL-C, and LDL-C/HDL-C ratio in Caucasian (n=1754) and Inuit (n=553) 
populations [115, 148]. Among those who consumed habitual high fat diet (>35% TE), GG 
genotype carriers had higher LDL-C/HDL-C ratio compared to those carrying A allele [148]. 
Additionally, SNP rs5070 at APOAI gene significantly interacted with total fat and SFA 
intake on LDL-C and HDL-C levels (P interaction range= 0.03 to 0.01) [115].  
There was significant interaction between SNP rs670 and PUFA intake on HDL-C 
(P=0.005) where higher PUFA intake (>8% TE) was associated with higher HDL-C 
concentration in women carrying the A allele compare to those carrying GG genotype [149]. 
The response to a MUFA diet (22% TE) was also investigated where healthy men carrying 
GA heterozygous genotype had increased LDL-C levels, compared to GG genotype carriers 
[150]. Although, it is apparent from previous studies that A allele carriers are presented with 
favorable lipid levels in response to various types of fat i.e. SFA and PUFA, replication of 
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these findings is warranted, as well as use of randomly controlled dietary interventions, 
which give stronger evidence for implementing dietary recommendation.  
1.9.2.3 Apolipoprotein C-III 
The APOCIII is primarily produced by the liver and is a major protein of VLDL and 
HDL particles [111, 151]. An in vitro study reported that this protein play a role in inhibiting 
activity of LPL and hepatic lipase enzymes and also the uptake of TAG-rich lipoproteins by 
hepatic receptors [152]. Thus, the APOCIII gene strongly correlates with higher TAG 
concentration [153]. A number of APOCIII gene SNPs [-455T>C (rs2854116), -625 del, 
3238C>G (rs5128)] have been described as possible genetic markers, exhibiting variability in 
lipid responsiveness to modified fat intake [115, 154].  
Cross-sectional studies have examined the interaction between the APOCIII 
polymorphisms [rs2854116 (T/C, -455T>C), -625 del, rs5128 (C/G, 3238C>G)], total fat, 
and saturated fat on lipid levels. A significant interaction was found between APOCIII SNPs, 
rs2854116, rs5128, and-625 del and total fat intake and SFA intake on TC and LDL-C in 
Puerto Ricans (n=336) and Inuit (n=553) populations [115, 154]. Carriers of the T allele at 
SNPs, rs2854116 and -625T, had lower TC and LDL-C concentrations after consuming a 
lower SFA diet (<11 % of TE) [154]. In a Chinese population (n=56), where individuals 
followed a diet high in carbohydrates and low in fat (70% and 15% of TE, respectively), T 
allele carriers of SNP rs2854117 had higher TAG and TAG-rich lipoproteins than CC 
genotype carriers [143]. Inconsistencies in the effect of T allele on lipids can be explained in 
part by different study designs, heterogeneity in ethnicity, and possibly different sources of 
fats.  
In response to a high MUFA diet (22% TE) for 28 days, carriers of the G allele of SNP 
rs5128 were reported to have a greater decrease in LDL-C (P=0.0003) and TC (P=0.009) in 
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young men (n=90) [155]. A significant interaction between SNP rs5128 and habitual western 
dietary patterns (high in fast food, salty snacks, and soft drinks) in determining HDL-C 
concentration (P = 0.02 in men) was demonstrated in metabolic syndrome (MetS) patients 
and controls from Iran. In the carriers of the G allele, higher adherence to western dietary 
patterns were shown to be associated with lower HDL-C compared to CC homozygotes 
[156]. Although there is some consistency in the reported findings regarding fat intake (SFA) 
and circulating lipids according to APOCIII gene polymorphisms, more investigations are 
required including a larger sample size to confirm these associations.  
1.9.3 Cholesteryl ester transfer protein gene 
The CETP is a plasma lipid transfer protein which plays a fundamental role in the 
metabolism of HDL-C. It has the ability to facilitate the transfer of cholesteryl esters from 
HDL to apolipoprotein B-containing lipoproteins such as TAG rich lipoproteins (CM and 
VLDL), with TAG, increasing HDL-C metabolism and clearance, resulting in lower 
circulating HDL-C concentrations [68, 157]. The most widely studied polymorphism in the 
CETP gene is the SNP rs708272 (C/T) (TaqIB) polymorphism, which has been shown to be 
associated with decreased CETP activity, resulting in greater HDL-C concentrations in 
Caucasian and Black individuals [158, 159]. Currently, a strong consistency exists among 
studies, indicating that T (B2) carriers exhibit greater HDL-C and lower CETP activity than 
CC (B1B1) subjects [69]. 
The reported interactions between CETP gene SNP rs708272 (C/T) and fat intake on 
circulating HDL-C levels have been conflicting. In diabetic Caucasian men, significant 
interactions were observed between SNP rs708272 (C/T) and total fat intake (P=0.003), SFA 
(P=0.02) and MUFA (P=0.04) intake on HDL-C [160]. However, this SNP rs708272 did not 
interact with total fat intake on HDL-C in the Framingham Study (n=12000) and in a Spanish 
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population (n=4210) [85, 161]. Conflicting findings could be due to differences in age and 
health status of the groups, and possibly the impact of habitual diets. 
A significant interaction between another SNP at CETP gene rs5882 and total fat 
intake in determining total cholesterol concentration (P=0.04) has been demonstrated in an 
Inuit population (n=553) [115]. Recently, gene-diet interactions have been reported by 
intervention studies investigating diet high in MUFA [162]. The concentrations of HDL-C, 
and TAG (P=0.006, P=0.040 respectively) were significantly affected by the interaction 
between Mediterranean diet (35% TE fat, 22% TE MUFA) and SNP rs3764261 (G/T) in 
MetS patients (n=424), with carriers of T allele displaying higher HDL-C concentration and 
lower TAG concentration compared to GG common genotype carriers [162].  Findings from 
interactions between CEPT SNPs and diet (i.e. fat intake) did confirm strong evidence for 
interactions on HDL-C, thus, further investigations are required for strong evidence and 
additional randomized clinical trials are needed.   
1.9.4 Hepatic lipase gene  
Hepatic lipase (LIPC) is a lipolytic enzyme that hydrolyzes TAG and phospholipids 
in all major classes of lipoproteins. Also, it serves as a ligand that facilitates the binding and 
uptake of lipoproteins, including HDL-C, through the proteoglycan receptor pathways. Given 
these roles, hepatic lipase has an important impact on circulating HDL-C concentrations [66, 
163], and hence, it has been studied in relation to CVD risk factors [164]. In addition, 
deficiency in hepatic lipase causes elevated HDL-C levels [165]. The common SNP 
rs1800588 (C/T; -514C→T) that is located in the promoter region of LIPC gene is the most 
commonly studied polymorphism in relation to HDL-C concentrations, where the minor T 
allele is associated with decreased activity of this enzyme and contributes to higher fasted 
HDL-C [166, 167].   
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Observational studies have reported a strong gene-nutrient interaction between SNP 
rs1800588 (C/T) at LIPC gene and total fat intake on determining HDL-C levels in different 
ethnic groups such as Caucasian, African, Inuit, and Indian populations [85, 115, 168, 169]. 
Among those who consumed a low-fat diet (< 30% TE), T allele carriers had higher HDL-C 
concentration compared to those with the CC genotype [85, 168, 169]. Additionally, SNP 
rs1800588 (C/T) at LIPC gene significantly interacted with SFA intake on HDL-C in 
Caucasian men with type 2 diabetes (n=780), where T allele carriers displayed elevated 
HDL-C concentration with low SFA intake (<11% TE) [170]. The same SNP, also, showed 
interactions with total fat and SFA intakes on TAG levels in Inuit and East Asian populations 
[115, 169].  
1.9.5 Peroxisome proliferator–activated receptor genes  
Peroxisome proliferator–activated receptors (PPARs) are ligand-activated 
transcription factors belonging to the nuclear hormone receptor superfamily, with 3 isotypes 
expressed in humans and encoded by different genes (PPARA, PPARG, and PPAR delta) 
[171].  
1.9.5.1 Peroxisome proliferator–activated receptor alpha genes 
PPARA gene is involved in numerous biological processes, and is strongly implicated 
in pathways connected with lipid metabolism, including mitochondrial fatty acid beta-
oxidation. Given these roles, PPARA is primarily expressed in tissues with high levels of 
fatty acids, such as liver, heart, and skeletal muscle. PPARA has also been stated to be 
associated with concentrations of TAG, HDL-C, and the overall plasma lipid profile [171]. In 
humans, 50 coding SNPs in PPARA gene have been described, and the SNP rs1800206 (C/G; 
Leu162Val) is the most widely studied SNP. Association between PPARA SNP rs1800206 
and lipid traits have been examined in many studies, providing evidence for an association 
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with TAG, LDL-C, and HDL-C levels [124].  
Fatty acids, primarily PUFA, have been identified as natural or synthetic ligands for 
PPARA, and studies have shown that high concentrations of fatty acids increase the 
transcriptional activation of the gene [172, 173]. Thus, extensive research has investigated the 
interaction between PUFA and the PPARA gene on lipid outcomes. A significant interaction 
between SNP rs1800206 (C/G) and n-6 PUFA intake on TAG concentrations (P=0.04) was 
shown in Caucasian Americans (n=2106). The G allele carriers had higher TAG levels than C 
allele carriers among those who consumed <4% TE n-6 PUFA, whereas the opposite was 
observed when >8% TE n-6 PUFA was consumed [174]. Also, significant gene-diet 
interactions were observed between SNP rs6008259 (G/A; in the untranslated region of gene) 
and n-6 PUFA on TC and LDL-C (P for all comparisons <0.03) in Caucasian Americans, 
where among those who consumed high n-6 PUFA intake (>8 g/d) AA genotype carriers had 
significantly lower levels of TC and LDL-C [175].  However, results obtained from 
randomised clinical trials were inconsistent. In response to a 4 week diet with a high 
PUFA:SFA ratio (10%:9% TE), G allele carries had lower TC compared to those with CC 
genotype in healthy men (n=20) [176]. While no significant interaction between the same 
SNP and n-3 PUFA (5g supplementation of fish oil for 6 weeks) on lipids was found in 
young healthy men (n=28) [177]. These discrepancies could be due to differences in the type 
of PUFA and duration of intervention.  
Besides the SNP rs1800206, which is rare in Asian and African American populations 
[178, 179], another SNP rs1800234 (T/C; V227A) has been identified in Chinese and 
Japanese populations. In Chinese women, an interaction between PUFA intake and SNP 
rs1800234 (T/C) on HDL-C concentrations (P=0.049) was reported. In women carrying the C 
allele, increased PUFA intake (g) was inversely associated with HDL-C concentration [179]. 
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In African Americans, significant gene-diet interactions were observed between SNP 
rs3892755 (C/T) and n-3 PUFA on TC and LDL-C (P= 0.03, and 0.02, respectively), where 
among those who consumed high n-3 PUFA intake (>0.32 g/d), TT genotype carriers had 
significantly lower levels of TC and LDL-C. [175].  
1.9.5.2 Peroxisome proliferator–activated receptor gamma genes 
Another member of the nuclear hormone receptor superfamily is PPARG, which has 
been shown to control the expression of genes involved in adipogenesis, regulation of insulin 
sensitivity and lipid homeostasis [180]. It acts by stimulating hydrolysis of the circulating 
TAG and the subsequent entry of fatty acids into the adipose cells [181]. PUFA is a major 
natural ligand of PPARG, which exists in two protein isoforms: PPARG1 and PPARG2. 
PPARG1 is expressed in many tissues in low levels, while PPARG2 is exclusively expressed 
in adipose tissue.  
The PPARG SNP rs1801282 (C/G; Pro12Ala) is a common polymorphism that has 
been extensively studied [124]. A significant effect of SNP rs1801282 (C/G) on the TAG 
response to a high n-3 PUFA diet (3.6g/d for 3 months) was reported, where G allele carriers 
had lower TAG levels compared to those with CC genotype [182]. Other studies have 
examined the interaction between the same SNP and PUFA:SFA ratio on lipid responses. 
Findings showed that G allele carriers had higher TC and LDL-C when PUFA:SFA ratio was 
<0.33, while G allele carriers had lower TC and TAG levels when PUFA:SFA ratio was 
>0.34 [183].  
In an Inuit population, interaction between total fat and SFA intake and SNP 
rs10865710 on TC (P= 0.01, and 0.007 respectively) and LDL-C concentrations (P= 0.01, 
and 0.008 respectively) was observed [115]. Findings from previous studies have 
demonstrated robust evidence for the interaction between PPARG gene cluster and PUFA 
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intake  
1.9.6 Tumour necrosis factor-alpha  
The pro-inflammatory cytokine, tumour necrosis factor-A (TNFA), is secreted by 
both macrophages and adipocytes and has an important effect on lipid metabolism. Elevated 
levels of TNFA are related to increased serum TAG and VLDL-C, and decreased levels of 
circulating HDL-C [184]. Studies have also shown an association of TNFA with 
dyslipidaemia [185]. In support of this, the TNFA SNP rs1800629 (G/A -308G/A) has been 
shown to increase transcription of the TNFA gene; thereby increasing TNFA production 
[186]. This association may be mediated through interactions between dietary fat intake and 
polymorphisms within the TNFA gene [187]. The SNP rs1800629 has been shown to 
modulate the relationship between dietary fat intake and lipid outcomes in various 
populations [187, 188].  
In black South African women, SNP rs1800629 (G/A) interacts with alpha linolenic 
acid and PUFA on modulating TC/HDL-C ratio (P= 0.036) and LDL-C (P= 0.026), 
respectively. Increased intake of alpha linolenic acid (% TE) was associated with increased 
TC/HDL-C ratio in those carrying GG genotype compared with A allele carriers, whereas 
increased intake of PUFA (% TE) was associated with decreased LDL-C in GG genotype 
carriers compared with A allele carriers [189]. In healthy and type 2 diabetic Caucasians, 
both SNPs rs1800629 (G/A) and rs361525 (G/A; -238G/A) significantly interacted with 
PUFA on HDL-C (P=0.04 and 0.0003, respectively). In carriers of the GG genotype of the 
SNP rs1800629, PUFA intake (%TE) was positively associated with HDL-C but negatively 
associated with A allele carries [187, 188]. The minor A allele carriers of the SNP rs361525 
(G/A) had higher HDL-C with increase in PUFA intake [187]. 
In white South African women, a significant interaction between SFA intake and SNP 
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rs1800629 (G/A) on TC (P=0.04) was reported. Increased intake of SFA (%TE) was 
associated with a decrease in TC levels in those with GG genotype compared with A allele 
carriers [88]. Furthermore, in response to a Mediterranean diet (> 35% fat TE, mostly from 
MUFA) for 12 months, MetS patients with GG genotype had significantly lower TAG 
concentrations (P=0.005) compared with A minor allele carriers (n=507) [190]. These 
findings indicate that the TNFA gene SNPs strongly interacts with dietary fat (i.e. PUFA, 
SFA, and MUFA) in determining lipid levels, where GG genotype carriers were found to 
have favourable lipid levels.  
1.10 Study designs and their role in identifying gene-diet interactions  
Study designs are generally categorised as observational studies, such as cross-
sectional, or case-control and experimental studies, such as randomized clinical trials [191]. 
One of the most common designs is a cross-sectional study, which determines the association 
between exposure and disease-related outcomes in specified populations at a given one time 
point. Disease develops over a period of time, thus, in cross sectional studies it is difficult to 
identify the causal relationship between a risk factor and disease, at a single point in time. 
Another limitation in cross sectional studies is confounding factors, which are factors 
associated with both the exposure and outcome.  Thus, when running statistical analysis, 
adjustment for these confounders can be included in the regression model to minimize their 
confounding effects. The food frequency questionnaire (FFQ), is a questionnaire consisting 
of a finite list of foods and beverages.  Participants indicate their usual frequency and portion 
size of consumption according to response categories over a period of time. The FFQ is the 
most popular measure of food consumption in large observational studies, easy to use, low 
burden on participants, and representative of a long term dietary intake [41]. Another 
example of an observational study is a case-control design, where a group of cases affected 
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with a disease of interest are collected together with a group of control individuals free from 
the disease at a given point of time [192]. This study design is similar to a cross sectional 
design, thus, it shares the same limitation. The main strength of an observational study is that 
a large number of samples can be collected [191]. From a nutrigenetics perspective, 
observational studies (cross sectional and case control) are affected by inherent bias, 
phenotypes have higher levels of variability over time, when testing gene-diet interactions. 
For example, TAG concentrations are variable over time and using fasting values at a single 
point is considered as a limitation [193]. Lack of replication of the initial findings is a 
common limitation. The other limitation includes reporting bias in FFQs, as it is self-reported 
by participants, can limit the study power. However, GWAS studies have identified disease-
predisposing variants from cross-sectional study design, and these variants are less likely to 
be affected by confounding factors [194].  
The other type of study design is experimental (randomized clinical trials), in which a 
group of volunteers, who meet specified selection/inclusion criteria, are randomly assigned to 
receive either the experimental treatment (intervention), or the control treatment (commonly 
the standard treatment for the condition). Thus, observed changes in the outcome; i.e. serum 
TAG, is a result of the intervention treatment. One of the main advantages of an experimental 
trial is the use of a blinding approach where the volunteer and/or researcher does not know 
whether he or she is receiving the treatment or control diet [191]. The common limitation in 
an intervention study is the small sample size (<200 participants) due to logistics of study 
management and costs, drop outs during the intervention period (especially with long periods 
of intervention) and insufficient volunteer adherence to their assigned treatment [41]. The 
crossover design is an alternative to the randomized clinical trial, which allows comparison 
within- and between-groups. In this type of study, half of the volunteers are randomly 
assigned to start with the control diet and then switch to the experimental treatment and the 
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other half are assigned in an opposite sequence. In this design, a washout period are generally 
required to avoid any carry-over influence of prior treatments [191]. The main strength of 
using randomized clinical trials for investigating gene-diet interaction studies is that they 
provide direct evidence to instruct genotype-based dietary modifications for future public 
health strategies. Another advantage of intervention studies is that it minimizes the effect of 
confounding factors, which introduces bias when exploring gene-diet interactions. However, 
the major concern of dietary intervention trials is  the small sample size, which can reduce the 
power of detecting gene-diet interaction effect sizes [194].  
The last study design is the postprandial study, which refers to calculation of 
variations in lipid, mainly TAG, values during follow up period after certain diet was given. 
Circulating TAG increases (postprandial lipaemia) within 2-3 hours of meal ingestion and 
can remain elevated for up to 5h after intake of a meal containing (30–60g fat). Given that 
most people usually consume fat-containing meals every 4–5h, it is clear that the most 
appropriate state of TAG metabolism is postprandially. The specificity of the postprandial 
state is an accumulation of lipoprotein particles in the circulation derived from both the liver 
and small intestine. During the postprandial state, TAG and cholesterol can be exchanged 
between lipoproteins; this is important in reverse cholesterol transport mediated by HDL-C 
particles and cholesterol homeostasis but it can also cause the generation of atherogenic lipid. 
These changes in lipid circulation during the postprandial state highlights the importance of 
the postprandial design in investigating gene-diet interactions [195].  
1.11 Relationship between vitamins D and lipid outcomes 
Vitamin D is an essential fat-soluble vitamin, which has several vital functions 
including formation of bone through regulation of calcium and phosphate homeostasis [196]. 
Besides these physiological functions, vitamin D has shown to play a role in modulating 
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immune function [197], blood pressure control, and prevention of CVD [198]. Also, vitamin 
D has been reported to be associated with lipids [199]. Lower vitamin D status has been 
shown to be associated with dyslipidemia (reduced HDL-C, elevated TAG) in adult men 
[200]. In a cross sectional study in children, it was found that each 10 nmol/L increase in 
vitamin D was associated with decreased concentrations of non-HDL-C, total cholesterol, and 
TAG [201]. This association may be, in part, explained by increased absorption of intestinal 
calcium, which could reduce synthesis and secretion of hepatic TAG [202]. Another 
explanation could be that vitamin D is associated with increased activity of LPL enzyme 
resulting in lower TAG concentrations and increase HDL-C [203]. Previous studies have 
demonstrated associations between SNPs at vitamin D binding protein (GC) and cytochrome 
P450 family 2 subfamily R member 1 (CYP2R1) genes and risk factors related to gestational 
diabetes mellitus [204].  
1.12 Personalised nutrition approach   
A beneficial approach from a nutrigenetics perspective will be the development of 
tailored nutritional advice for individuals, revising individualized dietary guidelines and 
developing personalised nutrition regimes based on their individual genomes, which will 
promote health, or prevent or reduce the incidence of disease [11]. However, at present, a 
large gap exists between nutrition recommendations and individual eating behaviour. 
Therefore, the implementation of a personalised approach could be more widely-accepted by 
the public. A recent study found that gene-based personalised nutrition to reduce SFA intake 
was more effective than general dietary guidelines for E4 allele carriers [205]. It is also 
important to determine whether individuals would agree to undergo genetic tests for the 
purpose of designing a personalised nutrition regime [15]. Ultimately, clear guidance from 
nutrigenetics studies is required for the implementation of personalised nutrition, which can 
only be achieved through the use of large, statistically powered studies, examining various 
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ethnic groups, considering the variety in dietary patterns worldwide, and conducting 
additional testing for other modifiable factors such as physical activity and smoking status. 
1.13 Conclusions 
The findings from these studies indicate that lifestyle (diet) modification, which 
attempts to optimize plasma lipid concentrations and prevent CVD, must consider underlying 
genetic factors. Gene-diet interaction studies contribute to elucidating the potential 
relationships between nutrients, genetic factors, and diseases such as CVD.  
Despite growing evidence from nutrigenetics studies, consistent challenges emerge 
which affect decisions surrounding dietary strategies to improve health. This limitation is 
seen through conflicting results in the existing literature [206, 207]. An additional limitation 
lies in the single hypothesis test; each study investigated interactions between single genetic 
variants and dietary components on a single phenotype; hence, there is considerable risk of 
overestimating the significance of positive interactions. An additional limitation is that the 
majority of published literature on nutrigenetics is secondary analysis of studies which were 
not initially conducted to investigate gene-diet interactions [4]. Moreover, the majority of 
nutrigenetics studies have been conducted in Caucasian populations, with limited research in 
South Asian and Arab populations.  
The requirements for future studies include appropriate study design including 
appropriate sample size. The effect of some of the gene variants may impact on postprandial 
metabolic stress, therefore, gene-diet interactions studies should be designed to examine the 
fasting and postprandial state [208].  
In summary, an increased number of nutrigenetics studies are needed to determine the 
link between SNPs, dietary exposure, and health outcomes in order to determine consistent 
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data for CVD prevention. Understanding how these interactions influence metabolic 
pathways at the molecular level is necessary to determine mechanisms of action. Only then 
can a personalised dietary approach become a potential therapy for the prevention of diet-
related diseases.  
1.14 Aims and outline of the thesis   
Based on the hypothesis that the dietary factors would influence lipid concentrations 
and that this may be modulated by common SNPs in the LPL and APOE genes, the aims of 
this thesis were  
• to examine the association between selected common SNPs at the LPL and 
APOE genes with lipid outcomes (TAG, HDL-C, LDL-C, and total 
cholesterol),  
• to examine the interaction between these SNPs and dietary factors (fat, 
carbohydrate, and protein as total energy %) on lipids using several study 
designs: 1) chronic dietary intervention studies, 2) acute postprandial dietary 
intervention studies, 3) case-control, 4) cohort-based cross sectional 5) dietary 
intervention crossover on two different ethnic populations (Caucasian, and 
Asian Indian).  
The aims and the hypothesis of each chapter are outlined below.  
Chapter 2: It was hypothesized that LPL gene was associated with postprandial lipid 
concentration and this association might provide a more physiological perspective of 
disturbances in lipoprotein homeostasis compared to assessment in the fasting state. 
Therefore, the aim of this chapter was to investigate the influence of two commonly studied 
LPL polymorphisms (rs320, HindIII; rs328, S447X) on postprandial lipaemia in 261 
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participants using a standard sequential meal challenge.  
Chapter 3:  It was hypothesized that LPL SNPs interacted with dietary factors on 
determining lipid concentrations. Also, given that there were no gene-diet interaction studies, 
to date, in Asian Indian populations, this chapter examined the association of four common 
LPL SNPs (rs1121923, rs328, rs4922115, and rs285) with lipid outcomes and investigated 
the interactions of these four polymorphisms with dietary factors on lipid in up to 1,845 
Asian Indian participants (788 type 2 diabetes cases and 1,057 controls) from the cross-
sectional Chennai Urban Rural Epidemiological Study (CURES).  
Chapter 4:  The hypothesis of this chapter was that APOE and LPL SNPs were associated 
with lipid levels and this association might be modulated by dietary factors. Therefore, this 
chapter investigated the association of two common SNPs (rs320 and rs328) at LPL, seven 
tagSNPs (rs405509, rs769450, rs439401, rs445925, rs405697, rs1160985, and rs1064725) at 
the APOE gene, and a common APOE haplotype (rs429358, and rs7412; E2, E3, and E4) 
with blood lipid. It also examined the interaction of these SNPs with dietary factors in 660 
Caucasians from the baseline data of the Prevention of Cancer by Intervention with Selenium 
(PRECISE) study. The findings of the PRECISE study were replicated using 1,238 
individuals from the Caerphilly cohort. 
Chapter 5: It was hypothesized that the replacement of energy from SFA with MUFA or 
PUFA would have a beneficial effect on lipid levels and that LPL and APOE genotypes 
would contribute to the individual variability. It has been revealed, however, that inter-
individual variability in lipid responses to dietary fat intake is influenced by genetic variation. 
Therefore, the aim of this chapter was to determine whether the LPL and APOE genotypes 
modified lipid responses after substituting SFAs with MUFAs or n-6 PUFAs in adults with 
moderate CVD risk. A retrospective analysis was conducted on 120 participants in the 
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Dietary Intervention and VAScular function (DIVAS) study.  
Chapter 6: The hypothesis of this chapter is that SNPs of genes involved in vitamin D may 
affect lipid levels, and this effect may be influenced by vitamin D supplementation. 
Therefore, this chapter aimed to evaluate the association of the SNPs at LPL, APOE and 4 
SNPs related to vitamin D genes with lipid and investigated the interaction between vitamin 
D fortified dairy drink and SNPs on lipid outcomes in 18 men with sub-optimal vitamin D 
status. 
Chapter 7: This chapter will focus on the discussion, which will be based on the findings 
from all the chapters, and the future prospects of this PhD work. 
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Table 1.1 Summary of SNPs that were examined in each chapter  
Chapters Study design  SNPs analyzed 
Chapter 2 Impact of 
Lipoprotein Lipase gene 
polymorphism, S447X, on 
postprandial triacylglycerol 
and glucose response to 
sequential meal ingestion 
Postprandial 
study  
LPL SNPs (rs320 and rs328) and seven 
APOE tagSNPs (rs405509, rs769450, 
rs439401, rs445925, rs405697, rs1160985, 
and rs1064725) 
Chapter 3 High fat diet 
modifies the association of 
LPL gene polymorphism 




LPL SNPs (rs1121923, rs328, rs4922115 
and rs285) 
 
APOE SNPs were not available in the 
dataset 
Chapter 4 Apolipoprotein 
E and lipoprotein lipase 
gene polymorphisms, 





LPL SNPs (rs320 and rs328), seven APOE 
tagSNPs (rs405509, rs769450, rs439401, 
rs445925, rs405697, rs1160985, and 
rs1064725), and one APOE haplotype 
(rs7412 and rs429358), 
Chapter 5 Apolipoprotein 
E gene polymorphism 
modifies fasting total 
cholesterol concentrations 
in response to replacement 
of dietary saturated with 
monounsaturated fatty acids 
in adults at moderate 
cardiovascular disease risk 
Intervention 
study  
LPL SNPs (rs320 and rs328) and seven 
APOE tagSNPs (rs405509, rs769450, 
rs439401, rs445925, rs405697, rs1160985, 
and rs1064725)  
Chapter 6 Impact of 
polymorphisms in genes 
related to vitamin D 
Crossover 
study  
LPL SNPs (rs320 and rs328), seven APOE 
tagSNPs (rs405509, rs769450, rs439401, 
rs445925, rs405697, rs1160985, and 
rs1064725), and four vitamin D-related 
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metabolism and serum 
lipids on vitamin D 
concentrations and lipid 
responses to vitamin D 
fortified test meals. 
SNPs NADSYN1 SNP rs12785878, 
CYP24A1 SNP rs6013897, GC SNP 
rs2282679, CYP2R1 SNP rs12794714  
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2.1 Abstract 
Lipoprotein lipase (LPL) is a key rate-limiting enzyme for the hydrolysis of 
triacylglycerol (TAG) in chylomicrons and very low-density lipoprotein. Given that 
postprandial assessment of lipoprotein metabolism may provide a more physiological 
perspective of disturbances in lipoprotein homeostasis compared to assessment in the fasting 
state, we have investigated the influence of two commonly studied LPL polymorphisms 
(rs320, HindIII; rs328, S447X) on postprandial lipaemia, in 261 participants using a standard 
sequential meal challenge. S447 homozygotes had lower fasting HDL-C (P=0.015) and a 
trend for higher fasting TAG (P=0.057) concentrations relative to the 447X allele carriers. In 
the postprandial state, there was an association of the S447X polymorphism with postprandial 
TAG and glucose, where S447 homozygotes had 12% higher TAG area under the curve 
(AUC) (P=0.037), 8.4% higher glucose-AUC (P=0.006) and 22% higher glucose- 
incremental area under the curve (IAUC) (P=0.042). A significant gene-gender interaction 
was observed for fasting TAG (P=0.004), TAG-AUC (Pinteraction=0.004) and TAG-IAUC 
(Pinteraction=0.016), where associations were only evident in men. In conclusion, our study 
provides novel findings of an effect of LPL S447X polymorphism on the postprandial glucose 
and gender-specific impact of the polymorphism on fasting and postprandial TAG 
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concentrations in response to sequential meal challenge in healthy participants. 
2.2 Introduction  
Large prospective cohort studies have identified elevated non-fasting triacylglycerol 
(TAG) concentrations as an independent risk factor for cardiovascular disease (CVD) [1]. 
The Copenhagen City Heart Study [2] and US Women’s Health Study [3] showed that non-
fasting TAG concentrations of ≥5.0 mmol/L were associated with myocardial infarction and 
the Norwegian Counties Study [4] showed that non-fasting TAG levels of >3.5 mmol/L were 
associated with a 5-fold increase in risk of death from coronary heart disease. Endothelial 
associated Lipoprotein lipase (LPL) (E.C. 3.1.1.34) plays an important role in the metabolism 
and clearance of triacylglycerol (TAG)-rich lipoproteins from the circulation [5] and 
atherogenesis, where it influences the interaction between atherogenic lipoproteins and 
receptors on the vascular wall [6]. Hence, enzymes such as lipoprotein lipase (LPL) (E.C. 
3.1.1.34) that regulate lipoprotein metabolism in the postprandial state [7] are of interest to 
the prevention of CVDs.  
Several polymorphisms in the LPL gene have been shown to lead to a reduction in 
enzyme synthesis and activity and, to date, rs320 [HindIII (T/G)] and rs328 [Serine 447 Stop 
S447X (C/G)] have been the most extensively studied. These variants with a prevalence of 
40-75% (rs320) and 17-22% (rs328) among Caucasians [8, 9], respectively, have been shown 
to be associated with coronary artery disease, myocardial infarction [10-12] and pronounced 
fasting hypertriacylglycerolemia [13, 14]. Only limited number of studies has examined their 
impact on postprandial lipaemia [15-17] and these studies have used only a single test meal, 
which does not reflect the habitual eating pattern in humans.  
Given that we spend nearly 75% of the time in a postprandial state, the normal 
physiological pattern of meal intake and the impact of LPL gene polymorphisms on the 
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clearance of dietary TAG may be more evident after a sequential meal challenge. Hence, in 
the present study, we investigated the association of the two commonly studied LPL 
polymorphisms [rs320 (HindIII) and rs328 (S447)] with fasting and postprandial lipid 
concentrations by using a standard sequential meal challenge and examined the penetrance of 
genotype according to gender, with gender previously shown to be a modulator of the impact 
of other variants on postprandial TAG handling [18].  
2.3 Experimental Section 
2.3.1 Subjects  
All individuals included in this study were obtained from postprandial studies using identical 
inclusion/exclusion criteria, and all underwent the same sequential meal postprandial 
protocol, at University of Reading between 1997-2007, as previously described [19]. Briefly, 
261 participants (109 women and 153 men) aged 22–71 years and BMI 17.6-37.3 kg/m2, 
were included in the dataset. The postprandial study excluded participants who had CVD, 
including angina stroke; diabetes or fasting glucose > 6.5 mmol/l, liver or other endocrine 
dysfunction; were pregnant or lactating; who were smoking > 15 cigarette per day; doing 
aerobic exercise more than three times per week; who had hemoglobin levels < 130g/L for 
men and 120g/L for women or taking medication or supplements. The University of Reading 
Ethics and Research Committee and the West Berkshire Health Authority Ethics Committees 
approved the experimental protocol. Informed consent to participate in the study was 
obtained. 
2.3.2 Sequential test meal protocols  
Details of the postprandial protocol have been described previously [19]. Briefly, study 
participants were asked to refrain from alcohol or organised exercise regimens on the 
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previous day and were provided with a relatively low fat (<10 g fat) evening meal to 
standardise short-term fat intake. After a 12 h overnight fast, the participants were cannulated 
and fasting blood sample was taken. Following a standard test breakfast (0 min; 3.9 MJ 
energy, 111 g carbohydrate, 19 g protein and 49 g fat) and lunch (330 min; 2.3 MJ energy, 
63 g carbohydrate, 15 g protein and 29 g fat), blood samples were taken from the cannula at 
30–60 min intervals until 480 min after the test breakfast.  
2.3.3 Biochemical measurements 
Plasma glucose and lipid concentrations were measured using an automated analyzer assay 
(Instrumentation Laboratory (UK) Ltd, Warrington, UK). In the fasting sample, HDL-C was 
estimated in the supernatant following precipitation of the apolipoprotein B (apoB)-
containing lipoproteins with a dextran-manganese chloride reagent. The LDL-C 
concentration was calculated using the Friedewald formula. Insulin levels were determined 
by ELISA (Dako Ltd, High Wycombe, UK). The total area under the curve (AUC, 0-480 
min) was calculated using the trapezium rule, and incremental area under the curve (IAUC) 
calculated by subtracting the fasting levels from the total AUC. For NEFA, AUC and IAUC 
were calculated from the time of suppression until the end of the postprandial period (120-
480 min) due to initial drop in NEFA concentrations after the meal. The homeostasis model 
assessment of insulin resistance (HOMA-IR) was calculated using formula: [fasting insulin 
(pmol/l) x fasting glucose (mmol/l)]/135.  
2.3.4 DNA extraction and genotyping  
DNA was isolated from the buffy coat layer of 10 ml of EDTA blood using the Qiagen DNA 
Blood Mini Kit (Qiagen Ltd, Crawley, UK). Allelic discrimination of two LPL gene 
polymorphisms (rs320, HindIII and rs328, S447) was conducted using a ‘Assay-on-Demand’ 
SNP genotyping assays (Applied Biosystems, Warrington, UK).  
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2.3.5 Statistical analyses  
The statistical significance of associations between biochemical data and genotypes 
was established using a general linear model adjusted for covariates such as age, gender, and 
BMI, which are highly correlated to lipid concentrations. Genotype distribution for LPL 
SNPs was assessed using the Hardy-Weinberg equilibrium. Given the small number of rare 
homozygotes, we applied a dominant model in which carriers of 1 or 2 copies of the minor 
allele of the two polymorphisms HindIII and S447X were grouped and compared with major 
allele homozygotes. Interaction between gender and polymorphisms on outcomes was 
examined by introducing the interaction terms into the linear regression analysis models with 
adjustment to same variables in association test. All data presented in the text and tables 
represents mean ±SD. We used SPSS software (version 21; SPSS Inc, Chicago, IL) for all 
statistical analyses. Probability values under 0.05 were considered significant. 
2.4 Results 
The study participants included 153 men (mean±SD, age 53±10 years; BMI  27.3±3.1 kg/m2) 
and 109 women (mean±SD, age 52±11 years; BMI 25.4±3.5 kg/m2). The prevalence of S447 
homozygotes was 81% (n=213) versus 18% 447X minor allele carriers (n=48). The frequency 
of carriers of 447X in this study was consistent with published reports in Caucasian 
population [20]. 56% of participants were homozygous for the H1 major allele for HindIII 
(n=131) with 43% H2 minor allele carriers (n=100).  
Table 2.1 describes the baseline characteristics of participants according to the S447X 
polymorphism. There was a borderline genotype-related association with fasting serum TAG 
levels after adjusting for age, gender, and BMI (P=0.057). Circulating HDL-C concentrations 
were markedly lower in S447 homozygotes than 447X allele carriers (P=0.015). None of the 
 
 89 
other fasting biochemical parameters were significantly associated with S447X (Table 2.1) or 
HindIII polymorphisms (Table 2.2) (all P >0.05).  
A greater TAG AUC was observed in S447 allele homozygotes following the 
sequential meals (P=0.037). The AUC and IAUC of the glucose response was 8.4% 
(P=0.006) and 22.6% (P=0.042) lower in 447X allele carriers (P=0.006), respectively than 
common homozygotes. The postprandial summary measures did not show any association 
with HindIII genotypes (Table 2.2).   
The S447X polymorphism showed a significant interaction with gender on fasting 
TAG (P=0.004) (Figure 2.1), TAG AUC (P=0.004) (Figure 2.2) and TAG IAUC (P=0.016) 
(Figure 2.3), with the major S447 allele homozygotes at S447X in men showing higher 
values for fasting and postprandial TAG compared with X minor allele carriers.  
Given the strong linkage disequilibrium between the two LPL polymorphisms [15], 
we also examined the combined effects of the polymorphisms on baseline characteristics and 
postprandial TAG and glucose. Nine possible genotype combinations were generated. 
However, given the small sample size, only 3 combinations [S447S - H1/H1 (n=131), S447S 
– H1/H2 (n= 55) and S447X – H1/H2 (n=45)] were available in our study participants. The 
frequencies of these three genotype combinations are presented in the Table 2.3. In the 
genotype-genotype analysis, we found that individuals with the S447S genotype irrespective 
of HindIII alleles (i.e., SS/H1H1 and SS/ H1H2) had higher TAG AUC (P=0.040) and 
glucose AUC (P=0.034) levels than 447X allele carriers (Table 2.4) suggesting that the 




Table 2.1: Baseline and postprandial characteristics of the participants according to 
LPL-S447X polymorphism 
Participants characteristics  S/S (n=213) S/X (n=48) Passociation 
Age (years) 53 ±11 52 ±11 0.648 
Men/Women 125/88 27/21 - 
BMI (kg/m2) 26.3 ±3.4 27.4 ±3.2 0.015 
Baseline characteristics 
TC (mmol/l) 5.78 ±1.05 5.62 ±1 0.285 
TAG (mmol/l) 1.67 ±0.90 1.48 ±0.51 0.057 
HDL-C (mmol/l) 1.29 ±0.42 1.40 ±0.33 0.015 
LDL-C (mmol/l) 3.73 ±1.02 3.53 ±0.92 0.167 
Glucose(mmol/l) 5.16 ±0.66 5.14 ±0.45 0.534 
Insulin (pmol/l) 48.3 ±31.2 50.3 ±26.2 0.517 
NEFA (μmol/l) 519 ±184 477 ±170 0.102 
HOMA-IR 1.96 ±1.40 1.99 ±1.09 0.376 
Postprandial summary measures 
TAG AUC (mmol/l × 480 min) 1193 ±593 1046 ± 429 0.037 
TAG IAUC (mmol/l × 480 min)  353 ±228 305 ±210 0.149 
NEFA AUC mmol/l × 300 min 153 ±45 149 ±32 0.410 
NEFA IAUC (mmol/l × 300 min) 96 ±39 100 ± 26  0.792 
Glucose AUC (mmol/l × 480 min) 3114 ±460 2850 ± 763 0.006 
Glucose IAUC (mmol/l × 480 min) 595 ±284 460 ± 238 0.042 
Insulin AUC (nmol/l × 480 min) 139 ±94 123 ±38 0.858 
Insulin IAUC (nmol/l × 480 min)  114 ± 89 100± 34 0.876 
Values are mean ± standard deviation. P-values are from a linear model testing the 
association with LPL-S447X, adjusted for age, gender, BMI. Abbreviations: TC, total 
cholesterol; TAG, triacylglycerol; HDL-C, high density lipoprotein cholesterol; LDL-C, low 
density lipoprotein cholesterol; NEFA, non-esterified fatty acids; HOMA-IR, homeostasis 
model assessment - insulin resistance. For the baseline analysis, the insulin and HOMA-IR 
values were available for 166 participants (men = 124, women = 42). For the postprandial 
analysis, the insulin AUC and IAUC data was available for 79 participants (men = 68, 
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women = 11). 
Table 2.2: Baseline and postprandial characteristics of the participants according to 
LPL- HindIII polymorphism 
Participants characteristics H1 (n=131) H1/H2 (n=100) Passociation 
Age (years) 53 ±11 52 ±10 0.567 
BMI (kg/m2) 26.0 ±3.4 26.6 ±3.1 0.095 
Baseline characteristics 
TC (mmol/l) 5.62 ±1.02 5.67 ±1 0.517 
TAG (mmol/l) 1.53 ±0.87 1.55 ±0.65 0.972 
HDL-C (mmol/l) 1.35 ±0.42 1.36 ±0.39 0.526 
LDL-C (mmol/l) 3.59 ±0.96 3.59 ±0.98 0.872 
Glucose(mmol/l) 5.14 ±0.69 5.10 ±0.50 0.413 
Insulin (pmol/l) 45.9 ±30.0 52.2 ±31.9 0.414 
NEFA (μmol/l) 530 ±200 498 ±173 0.177 
HOMA-IR 1.87 ±1.36 2.06 ±1.35 0.680 
Postprandial summary measures 
TAG AUC (mmol/l × 480 min) 1086 ±549 1098 ±464 0.947 
TAG IAUC (mmol/l × 480 min)  321 ±212 335 ±230 0.677 
NEFA AUC mmol/l × 300 min 155 ±40 153 ±49 0.600 
NEFA IAUC (mmol/l × 300 min) 99 ±33 94 ±45  0.231 
Glucose AUC (mmol/l × 480 min) 3109 ±408 2958 ±705 0.065 
Glucose IAUC (mmol/l × 480 min) 590 ±287 558 ± 269 0.648 
Insulin AUC (nmol/l × 480 min) 128 ±59 134 ±130 0.782 
Insulin IAUC (nmol/l × 480 min)  105 ±54 109±125 0.879 
Values are mean ± standard deviation. P-values are from a linear model testing the 
association with LPL-S447X, adjusted for age, gender, BMI. Abbreviations: TC, total 
cholesterol; TAG, triacylglycerol; HDL-C, high density lipoprotein cholesterol; LDL-C, low 
density lipoprotein cholesterol; NEFA, non-esterified fatty acids; HOMA-IR, homeostasis 
model assessment - insulin resistance. For the baseline analysis, the insulin and HOMA-IR 
values were available for 166 participants (men = 124, women = 42). The fasting and 
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postprandial insulin and HOMA-IR were not available for all participants (n= 151). 
 
Figure 2.1 Mean (SEM) for fasting triacylglycerol (TAG) according to S447X polymorphism 
in men and women. Carriers of one or two copies of X minor allele are combined and 
presented by white bars. Gene-gender interaction was statistically significant for fasting TAG 
levels (Pinteraction=0.031).  
  
Figure 2.2 Mean (SEM) for the AUC TAG response according to S447X polymorphism after 
consumption of a test breakfast (49 g fat) at 0 min and a test lunch (29 g fat) at 330 min. S447 
homozygotes (n=213) had 12% higher TAG area under the curve (AUC) (P=0.037) 
compared to 447X carriers (n=48) for men. Carriers of one or two copies of X minor allele 






























































significant for area under the TAG curve values (Pinteraction=0.004).  
 
Figure 2.3 Mean (SEM) for the IAUC TAG response according to S447X polymorphism 
after consumption of a test breakfast (49 g fat) at 0 min and a test lunch (29 g fat) at 330 min 
in men, and women. Carriers of one or two copies of X minor allele are combined and 
presented by white bars. Gene-Gender interaction was statistically significant for IAUC TAG 
(Pinteraction=0.016).  
Table 2.3: Distribution of study participants according to combined LPL HindIII and S447X 
markers 
S447X-HindIII S/S S/X X/X 
H1/H1 131 0 0 
H1/H2 55 45 0 










































Table 2.4 Association between the combined genotypes of LPL S447X-HindIII 
polymorphisms and fasting and postprandial characteristics.  







Age (years) 53 ±11 52 ±11 52 ±9 0.570 
BMI (kg/m2) 25.9 ±3.4 27.2 ±3.1 26.1±2.9 0.052 
Baseline characteristics 
TC (mmol/l) 5.62 ±1.02 5.58 ±0.99 5.75±1.01 0.649 
TAG (mmol/l) 1.53 ±0.87 1.44 ±0.47 1.64±0.76 0.230 
HDL-C (mmol/l) 1.35 ±0.42 1.41 ±0.33 1.32±0.43 0.128 
LDL-C (mmol/l) 3.59 ±0.96 3.50 ±0.91 3.67±1.04 0.596 
Glucose(mmol/l) 5.14 ±0.69 5.12 ±0.49 5.09±0.53 0.708 
Insulin (pmol/l) 45.9 ±30.0 49.9 ±26.6  54.18±36 0.298 
NEFA (μmol/l) 530 ±200 471 ±171 519±173 0.145 
HOMA-IR 1.87 ±1.36 1.97 ±1.11 2.13±1.54 0.434 
Postprandial summary measures 
TAG AUC (mmol/l × 480 min) 1086 ±549 995 ±369 1183±518 0.040 
TAG IAUC (mmol/l × 480 
min)  
321 ±212 302 ±215 361±241 0.262 
NEFA AUC mmol/l × 300 min 155 ±40 149 ±33 156±59 0.554 
NEFA IAUC (mmol/l × 300 
min) 
99 ±33 100 ±27  89±55 0.333 
Glucose AUC (mmol/l × 480 
min) 
3109 ±408 2831 ±797 3057±617 0.034 
Glucose IAUC (mmol/l × 480 
min) 
590 ±287 454 ± 248 636±260 0.051 
Insulin AUC (nmol/l × 480 
min) 
128 ±60 119 ±38 145±169 0.948 
Insulin IAUC (nmol/l × 480 
min)  
105 ±54 95±303 118±164 0.967 
Abbreviations: TC, total cholesterol; TAG, triacylglycerol; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol; NEFA, non-esterified fatty acids; 
HOMA-IR, homeostasis model assessment - insulin resistance; AUC, area under the curve; 
IAUC, incremental area under the curve. 
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2.5 Discussion  
Our postprandial study using a standard sequential meal challenge demonstrates that 
individuals homozygous for the common allele of the S447X polymorphism had significantly 
lower fasting HDL-C levels and a significantly elevated postprandial TAG and glucose 
response relative to 447X allele carriers. In addition, a gender-specific association between 
the S447X polymorphism and fasting and postprandial TAG concentrations was observed, 
where the effect of the genotype was evident only in men.  
Several studies have demonstrated the association between S447 genotype and elevated 
fasting plasma TAG levels and lower HDL-C levels [21, 22]. Our study also has shown a 
borderline association of the S447 allele with higher TAG and a significant association with 
lower HDL-C levels, which is in accordance with a meta-analysis (n=45,079) that showed 
0.05 mmol/L lower HDL-C levels and 0.15 mmol/L higher TAG among the S447 
homozygotes [12]. Furthermore, the association of the S447 genotype with postprandial TAG 
in our study has also been confirmed in previous studies (Table 3.5). However, the 
mechanism by which this polymorphism affects lipid levels still remains obscure. Functional 
studies have demonstrated that the 447X variant that results in a 2 amino acid truncation on 
the carboxyl-terminal domain of the LPL increases the ability of the cell surface receptors to 
bind with TAG-lipoproteins [8]; but it is not clear how this truncation increases the ability of 
LPL to bind TAG. While a few studies have reported that S447X polymorphism might 
increase or decrease the LPL activity [23-25], some have failed to show a significant effect 
[24, 26]. The probable mechanism by which LPL S447 allele lowers HDL-C could be related 
to higher TAG concentrations. A delayed clearance of triglyceride-rich lipoproteins (TRLs) 
drives the transfer of TAG from TRLs to both LDL and HDL by cholesteryl ester transfer 
protein (CETP), which makes them suitable substrates for lipases. This leads to the formation 
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of smaller denser HDL particles, which are rapidly removed from the circulation, thus 
decreasing HDL-C concentrations [27]. 
We also observed a novel association between LPL S447X polymorphism and 
postprandial glucose using the sequential meal challenge, where S447 homozygotes had 
higher glucose AUC and IAUC. Previous postprandial studies have shown higher 
postprandial glucose concentrations in response to three meals [28, 29]. Given that the 
postprandial studies examining the effects of LPL polymorphisms have used only a single 
meal [15-17], it is possible that the effects of LPL polymorphisms on postprandial glucose 
have been missed previously. One of the reasons for higher postprandial glucose could be due 
to the decreased insulin sensitivity in the S447 homozygotes [30]. LPL has been considered 
as a link between insulin resistance and atherosclerosis, given its role in controlling the 
delivery of free fatty acids to muscle, adipose tissue and vascular wall macrophages, wherein 
lipid uptake influences insulin sensitivity [31]. It was also shown in the Quebec Family study 
that the LPL markers (HindIII and S447X) combination influenced the insulin AUC during an 
oral glucose tolerance test [32]. In our study, we did not find any association with fasting and 
postprandial insulin and HOMA-IR, which might be due to limited power for this analysis as 
insulin concentrations were not available for all participants (n<166). However, given that 
low HDL cholesterol and high TAG are frequently found with insulin resistance [33], it is 
possible that decreased insulin sensitivity could be a possible mechanism for higher 
postprandial glucose concentrations in the S447 homozygotes. This was also shown in a 
previous study where individuals with insulin resistance had elevated fasting and postprandial 
TAG, and lower HDL-C levels [34].  
Our results also demonstrated gender-specific effect of LPL S447X polymorphism on 
fasting and postprandial TAG, where the association was significant only in men. The 
gender-specific effects of other SNPs (LEPR [35], APOA5 [18] and APOB [36]) in men have 
 
 97 
already been shown in our postprandial cohort which is characteristic of men with higher 
BMI, fasting TAG, insulin and lower HDL-C than women irrespective of the genotype. A 
postprandial study in 63 men also showed that those with low fasting HDL-C and high TAG 
concentrations had higher postprandial TAG [37]. It is possible that men from our cohort 
were at a greater metabolic stress which may be a contributory factor in the gender-specific 
effect of S447 genotype on the fasting and postprandial responses.  
Previous studies have shown associations between the HindIII polymorphism and 
elevated lipids [10]. In this study, we did not find any significant difference in fasting and 
postprandial lipid levels across the genotypes of the polymorphism. However, the 
combination of HindIII and S447X markers revealed significant associations with TAG and 
glucose AUC, which might be due to the strong linkage disequilibrium between the HindIII 
and S447X markers. In addition, previous studies have investigated the effect of this 
polymorphism on postprandial lipids using only a single meal [15]. Hence, our finding with 
HindIII polymorphism requires a replication using a sequential meal challenge, which 
reflects the habitual eating pattern.   
In conclusion, our study provides novel findings of an effect of LPL S447X 
polymorphism on the postprandial glucose and gender-specific impact of the polymorphism 
on fasting and postprandial TAG levels in response to sequential meal challenge in healthy 
participants. The elevated fasting and postprandial TAG and postprandial glucose and lower 
fasting HDL-C concentrations are likely to result in prolonged appearance of lipids, in 
particular remnant particles, which might be one of the reasons for the increased prevalence 
of CVD in participants carrying the S447 allele. Further studies are required to confirm our 
gender-specific associations between the LPL polymorphism and fasting and postprandial 
TAG levels with an assessment of serum LPL concentrations and activity using a sequential 
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meal challenge. This will further shed light on the size-effect of LPL polymorphisms on lipid 
and glucose metabolism in population subgroups.   
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Table 2.5 List of postprandial studies determining the effects of LPL gene polymorphisms (S447X and HindIII) on fasting and 
postprandial lipids.  








et al. 2004 [15] 
 
51 High fat meal (60 g fat and 420 mg 








retinyl palmitate (RP)  
P=0.030  
 
  S447X  
 
Small TRL-RP  P=0.028  
  Large TRL-B48  P=0.046 
  Small TRL-B48  P=0.048 






  Large TRL-TG  P=0.048 
  Large TRL-RP P= 0.004 
  Small TRL-RP P=0.014 
  Large TRL-B48 P=0.036 
Humphries et al. 
1998 [17] 
2181 Oral liquid lipid load (42 g saturated fat, 22 g 
protein, 56 g carbohydrate, and 417 mg 
cholesterol)  
H-/X447 Fasting TAG P=0.01 




et al. 2009 [16] 
 
80 High fat meal (5.3 g protein- 2.5%, 24.75 g 
carbohydrate- 14.0%, 240 mg cholesterol, and 
65.2 g fat—83.5% fat)  
S447X  Fasting / Postprandial 
TAG  
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3.1 Abstract  
 
Background: 
Single nucleotide polymorphisms (SNPs) in lipoprotein lipase gene (LPL) have been 
shown to influence metabolism related to lipid phenotypes. Dietary factors have been 
shown to modify the association between LPL SNPs and lipids; however, to date, there 
are no studies in South Asians. Hence, we tested for the association of four common LPL 
SNPs with plasma lipids and examined the interactions between the SNPs and dietary 
factors on lipids in 1,845 Asian Indians. 
Methods: 




chosen from the cross-sectional Chennai Urban Rural Epidemiological Study. Serum 
triacylglycerol (TAG), serum total cholesterol, and high-density lipoprotein cholesterol 
(HDL-C) were measured using a Hitachi-912 autoanalyzer (Roche Diagnostics GmbH, 
Mannheim, Germany). Dietary intake was assessed using a semi-quantitative food 
frequency questionnaire. The SNPs (rs1121923, rs328, rs4922115 and rs285) were 
genotyped by polymerase chain reaction followed by restriction enzyme digestion and 
20% of samples were sequenced to validate the genotypes obtained. Statistical Package 
for Social Sciences for Windows version 22.0 (SPSS, Chicago, IL) was used for 
statistical analysis. 
Results: 
After correction for multiple testing and adjusting for potential confounders, SNPs rs328 
and rs285 showed association with HDL-C (P=0.0004) and serum TAG (P=1x10-5), 
respectively. The interaction between SNP rs1121923 and fat intake (energy %) on HDL-
C (P=0.003) was also significant, where, among those who consumed a high fat diet 
(28.4 ± 2.5 %), the T allele carriers (TT + XT) had significantly higher HDL-C 
concentrations (P=0.0002) and 30% reduced risk of low HDL-C levels compared to the 
CC homozygotes. None of the interactions on other lipid traits were statistically 
significant.  
Conclusion: Our findings suggest that individuals carrying T allele of the SNP 
rs1121923 have increased HDL-C levels when consuming a high fat diet compared to CC 
homozygotes. Our finding warrants confirmation in prospective studies and randomized 





The Asian Indian population has a greater predisposition to non-communicable 
diseases such as type 2 diabetes (T2D) [1, 2] and cardiovascular disease (CVD) [3] 
compared to Europeans. Despite low body mass index (BMI), Indians are characterized 
by a higher frequency of hyperinsulinemia [4], insulin resistance [5], dyslipidemia with 
hypertriacylglycerolemia and low high-density lipoprotein cholesterol (HDL-C) levels [6] 
and increased visceral fat, which are referred to as ‘Asian Indian Phenotype’ or 
‘Atherogenic Lipoprotein Phenotype’ [7, 8]. Blood lipid levels are heritable phenotypes 
and findings from previous studies show that the blood concentrations of HDL-C, low 
density lipoprotein cholesterol (LDL-C) and triacylglycerol (TAG) have a strong 
inheritance [9]. 
Genetic studies have implicated several gene loci in the predisposition to dyslipidemia in 
Asian Indians [10-13], one of which is lipoprotein lipase (LPL) [14-16]. LPL plays an 
important role in the metabolism of HDL-C, where it has been shown to hydrolyze TAG 
in TAG-rich lipoproteins such as chylomicrons and very low density lipoproteins [17]. It 
has been postulated that increased activity of LPL enzyme enhances the release of 
components of TAG-rich lipoproteins which are then transferred to HDL to raise HDL 
levels; conversely, lack of LPL can retard the transfer of these components to HDL [18]. 
Several candidate gene studies have shown an association between single nucleotide 
polymorphisms (SNPs) in LPL and lipid traits in various populations including Asian 
Indians [11, 12, 19-22]. Genome wide association studies have also demonstrated strong 
evidence for the association of LPL polymorphisms with HDL-C concentrations [23-25]. 




[26-30]; however, the findings have been quite inconsistent due to variations in sample 
size, dietary factors and the selection of LPL polymorphisms.  
Given that there are no gene-diet interaction studies, to date, in Asian Indian 
populations, we examined the association of four common LPL SNPs [Val135Val C/T 
(rs1121923), Ser447Ter C/G (rs328), G/A (rs4922115) and Pvu II C/T (rs285)] with 
HDL-C and investigated the interactions of these four polymorphisms with dietary 
carbohydrate, fat and protein percentage on HDL-C in up to 1,845 participants (788 T2D 
cases and 1,057 controls) from the cross-sectional Chennai Urban Rural Epidemiological 
Study (CURES). In addition, we examined the genetic associations and interactions for 
other lipid traits such as TAG, LDL-C and total cholesterol in these participants. 
3.3 Methods 
3.3.1 Study population 
One thousand eight hundred and forty five participants comprising 788 cases 
with T2D and 1,057 controls with normal glucose tolerance (NGT) were randomly 
chosen from the urban component of the Chennai Urban Rural Epidemiological Study 
(CURES), an epidemiological study conducted on a representative population (age >20 
years) of Chennai (formerly Madras), the fourth largest city in India. The detailed 
methodology of the study participants is published elsewhere [31]. Briefly, in Phase 1 
of CURES, 26,001 individuals were recruited based on a systematic random sampling 
technique. Participants with self-reported diabetes taking drug treatment for diabetes 
were classified as “known diabetes subjects.” All known diabetes participants (n = 




individual of the 26,001 individuals without known diabetes was invited to undergo 
oral glucose tolerance tests using a 75-g oral glucose load (dissolved in 250 ml of 
water) (Phase 3 of CURES). Those who were confirmed by oral glucose tolerance test 
to have 2-h plasma glucose value ≥11.1 mmol/l based on World Health Organization 
(WHO) consulting group criteria were labeled as “newly detected diabetes subjects” 
and those with 2-h plasma glucose value <7.8 mmol/l as being NGT [32]. CURES 
participants who were on lipid lowering drugs such as statins, fibrates and niacin were 
excluded  from  the  study (n=134). On the basis of the National Cholesterol Education 
Program-Adult Treatment Panel III (NCEP-ATP III) guidelines [33] the study 
population was divided into those with normal HDL-C (≥1.03 mmol/l for men; ≥1.3 
mmol/l for women) and low HDL-C (<1.03 mmol/l for men; <1.3 mmol/l for women). 
Written informed consent was obtained from each study participant, and the study was 
approved by the Madras Diabetes Research Foundation Institutional Ethics Committee. 
  
3.3.2 Phenotype measurements 
Anthropometric measurements including weight, height, and waist were obtained using 
standardized techniques. The BMI was calculated as weight (in kg) divided by the 
square of height (in m). Biochemical analyses were performed on a Hitachi-912 Auto 
Analyzer (Hitachi, Mannheim, Germany) using kits supplied by Roche Diagnostics 
(Mannheim). Fasting plasma glucose (glucose oxidase–peroxidase method), serum total 
cholesterol (cholesterol oxidase-phenol-4-amino-antipyrene peroxidase method), serum 
TAG (glycerol phosphatase oxidase-phenol-4-amino-antipyrene peroxidase method), 




Low-density lipoprotein cholesterol was calculated using the Friedewald formula [34]. 
Glycated haemoglobin (HbA1c) was estimated by high-performance liquid 
chromatography using a Variant™ machine (Bio-Rad, Hercules, CA, USA). Serum 
insulin concentration was estimated using an enzyme-linked immunosorbent assay 
(Dako, Glostrup, Denmark).  
 
3.3.3 Dietary assessment 
Dietary intakes were assessed using a previously validated and published [35] 
interviewer administered semi-quantitative food frequency questionnaire (FFQ) 
containing 222 food items to estimate food intake over the past year. Briefly, 
individuals were asked to estimate the usual frequency (number of times per day, week, 
month or year/never) and the usual serving size of the portion of the various food items 
in the FFQ. Common household measures such as household cups, bowls, ladles, 
spoons (for the cooked foods like vegetables), wedges, circles of different diameter and 
visual atlas of different sizes of fruits (small, medium, large) were shown to assist the 
individuals in estimating portions. A detailed description of the development of FFQ 
and the data on reproducibility and validity had been published [35]. EpiNu, an in-
house database was used to assess the average daily food and nutrient intake. 
 
3.3.4 SNP selection and Genotyping 
Four common SNPs in the LPL gene (rs285, rs328, rs4922115 and rs1121923) were 
chosen for the present study. The SNPs rs328 and rs285 were chosen based on their 




SNPs rs1121923 and rs4922115 were identified from the dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/) based on their location in the exon 3 and 3’UTR 
regions, respectively, assuming that variations in the coding and regulatory regions 
might confer a functional effect on the gene expression. The SNPs were genotyped by 
polymerase chain reaction on a GeneAmp® PCR system 9700 thermal cycler (Applied 
Biosystems, Foster City, CA) followed by restriction enzyme digestion (New England 
Biolabs, Inc., Beverly, MA). The program usually had the following steps: initial 
denaturation at 95°C for 10 min, 30-35 cycles of denaturation at 95°C for 45 sec, 
primer-annealing at 58oC for rs1121923 and rs285 SNPs and 60oC for rs328 and 
rs4922115 SNPs for 45 sec, and primer extension at 72°C for 45 sec, followed by a 
final extension at 72°C for 5 min. The restrictions enzymes used for genotyping the 
SNPs were Sau96I for rs1121923, Mnl I enzyme for rs328, the Eco RV enzyme for 
rs4922115 and Pvu II for rs285. Agarose gel electrophoresis was used to detect the 
amplification of PCR reaction and the restriction enzyme digested products. To ensure 
that the genotyping was of adequate quality, we performed random duplicates in 10% 
of the samples. The assays were performed by a technician who was masked to the 
phenotype, and there was 98% concordance in the genotyping. Variants were also 
confirmed by direct sequencing using an ABI 3500 genetic analyzer (Applied 
Biosystems, Foster City, CA). Population stratification was performed using a case-
control approach at 6 unlinked marker loci believed to be unrelated to the disease under 






3.3.5 Statistical analysis 
Statistical Package for Social Sciences for Windows version 22.0 (SPSS, Chicago, IL) 
was used for statistical analysis. The effects of the variants on quantitative and 
categorical variables were analyzed. Allele frequencies were estimated by gene 
counting. Agreement with Hardy–Weinberg equilibrium (HWE) expectations was 
tested using a χ2goodness-of-fit test. Comparison of the means between the two groups 
was analyzed by independent t-test. The χ2 test was used to compare the proportions of 
genotypes or alleles. Dominant model was used, given the low frequency of minor 
allele homozygotes. Linear regression was used to examine the association of the LPL 
SNPs with various lipid outcomes. The SNP-diet interactions on lipid traits were tested 
by including the interaction term in linear regression models. Models were adjusted for 
age, gender, BMI (as continuous), T2D status and total energy intake wherever 
appropriate. Multiple testing correction using Bonferroni method was applied 
separately for the testing of main and interaction effects (i.e., association of the four 
SNPs with HDL-C and interaction with dietary factors on HDL-C levels) [P≤ 0.003 
(= 0.05/20) was considered statistically significant] and additional analyses (i.e., 
association of the four SNPs with other lipid traits and interaction with dietary factors 
on other lipid traits) [P≤ 0.001 (= 0.05/48) was considered statistically significant].  
 
3.4 Results  
Table 3.1 shows the anthropometric and biochemical characteristics of NGT and T2D 
participants. T2D cases had markedly increased levels of TAG, LDL-C and total 




(P<0.003 for all comparisons). In our study population, the genotype distributions for 
the four LPL polymorphisms were GG: 68.5%, GA: 27.5% and AA: 4.0% (rs4922115); 
CC: 87.5%, CT: 12.0% and TT: 0.5% (rs1121923); CC: 72.8%, CG: 25.2% and GG: 
2.00% (rs328); and CC: 40.9%, CT: 45.6% and TT: 13.5% (rs285).  All the four SNPs 
were in HWE (P>0.05).  
The association between LPL SNPs and HDL-C levels is presented in Table 3.2. 
Of the four LPL variants, the SNP rs328 alone showed a significant and a consistent 
association with HDL-C concentrations [both as continuous and categorical variable 
(stratified based on NCEP ATP III guidelines)] under a dominant model after 
correction for multiple testing (P=0.0004 for the continuous variable and P=0.001 for 
the categorical variable). The minor allele (G) carriers of the SNP rs328 had 5% higher 
HDL-C compared to the homozygous carriers of the common ‘C’ allele. 
In the interaction analysis, after correction for multiple testing, none of the 
interactions were statistically significant except for the interaction between SNP 
rs1121923 and fat intake (energy %) on HDL-C (P=0.003) (Table 3.3), where among 
those who consumed a high fat diet (3rd tertile: 28.4± 2.5%), the T allele carriers had 
significantly higher HDL-C concentrations compared to the CC homozygotes 
(P=0.0002) (Figure 3.1).  To test whether this interaction was significant on HDL-C as 
a categorical variable, we stratified the data based on normal and low HDL-C levels 
according to the NCEP ATP III guidelines for dyslipidemia [33] and found that among 
those who consumed a high fat diet, the individuals who carried the T allele had 30% 
reduced risk of low HDL-C levels compared to the CC homozygotes (P=0.001) 




subclass intakes on HDL-C but none of the interactions were statistically significant 
[monounsaturated (MUFA) (P=0.36), polyunsaturated (PUFA) (P=0.22) and saturated 
fatty acids (SFA) (P=0.46)]. 
Table 3.1: Baseline characteristics of the CURES study participants  




Type 2 diabetes 
(N=788) 
P value 
Age (year) 38.5 ± 13.6 50.6 ± 11.1 <0.0001 
Gender (men / women) 608/ 449 433/ 355 0.2 * 
BMI (kg/m2) 23.2± 4.5 25.2 ± 4.4 <0.0001 
Fasting Glucose (mmol/l) 4.7± 0.5 8.8± 3.8 <0.0001 
Fasting Insulin (lIU/mL) 8.2 ± 5.6 11.6 ± 7.0 <0.0001 
Total serum Cholesterol (mmol/l) 4.6± 0.9 5.2± 1.1 <0.0001 
Serum TAG (mmol/l) 1.3± 0.7 1.9± 1.3 <0.0001 
HDL-C (mmol/l) 1.12± 0.25 1.08 ± 0.24 0.003 
LDL-C (mmol/l) 2.9± 0.8 3.2± 0.9 <0.0001 
Glycated hemoglobin (%) 5.56 ± 0.47 8.64± 2.26 <0.0001 
Systolic pressure (mmHg) 117.0 ± 17.4 128.9 ± 21.5 <0.0001 
Diastolic pressure (mmHg) 73.2 ± 11.2 77.1 ±12.0 <0.0001 
Protein intake (energy %) 11.3 ± 1.2 11.4 ±1.2 0.03 
Carbohydrate intake (energy %) 64.4 ± 6.4 64.9 ± 5.8 0.1 




Total energy intake (kcal) 2627.2 ± 725.4  2533.5 ± 907.2 0.02 
Total saturated fat intake (%) 2.4 ± 0.9 2.1 ± 0.9 <0.0001 
Total monounsaturated fat (%) 1.9 ± 0.7 1.7 ± 0.8 0.0002 
Total polyunsaturated fat (%) 1.6 ± 0.8 1.7 ± 0.9 0.04 
Data shown are represented as means ± SD, wherever appropriate 
P values for the differences in the means/ proportions between cases and controls 
P values were calculated by using Independent t test.  
* P value was calculated using a Chi-square test. 
CURES, Chennai Urban Rural Epidemiological Study; TAG, triacylglycerol; HDL-C, 





Table 3.2: Association of the lipoprotein lipase single nucleotide polymorphisms 
(SNPs) with HDL-C levels 
Association of the SNPs with HDL-C levels (continuous variable) 
 
SNP   HDL-C levels  
(means ± SD) 
 
SNP rs4922115   
GG 1.1 ± 0.3  
GA 1.1 ± 0.2  
AA 1.1 ± 0.2  





SNP rs1121923   
CC 1.1 ± 0.3  
CT 1.2± 0.3  
TT 1.0 ± 0.2  





SNP rs328   
CC 1.1 ± 0.3  
CG 1.2 ± 0.3  
GG 1.2 ± 0.2  





SNP rs285   
CC 1.1± 0.3  
CT 1.1 ± 0.2  
TT 1.2 ± 0.2  





Association of the SNPs with HDL-C (categorical variable) 
 
 Low HDL-C levels  
Number (%) 
Normal HDL-C levels  
Number (%) 
SNP rs4922115   
GG 366 (65%) 497 (71.3%) 
GA 171 (30.4%) 167 (25.3%) 
AA 26 (4.6%) 24 (3.4%) 




SNP rs1121923   
CC 530 (91.7%) 642 (84.7%) 
CT 45 (7.8%) 112 (14.8%) 








SNP rs328   
CC 336 (78.3%) 540 (69.8%) 
CG 88 (20.5%) 215 (27.8%) 
GG 5 (1.2%) 19 (2.5%) 




SNP rs285   
CC 336 (45.6%) 421 (38%) 
CT 330 (44.8%) 515 (46.5%) 
TT 71 (9.6%) 171 (15.4%) 




HDL-C: High density lipoprotein cholesterol  
P values are adjusted for age, gender, body mass index, and Type 2 diabetes status 
Those p values that are in bold implicates those values that are significant after 









Table 3.3: Interaction between lipoprotein lipase single nucleotide polymorphisms 
and dietary factors on HDL-C levels 
Beta coefficients ± standard error (Pinteraction) for interaction on HDL-C (continuous 
variable) 
Interaction between 
rs4922115* fat energy 
intake (%) 
Interaction between 




energy intake (%) 
-0.01 ± 0.002 
(0.1) 
-0.02 ± 0.01 
(0.2) 
0.01 ± 0.02 
(0.06) 
Interaction between 
rs1121923* fat energy 
intake (%) 
Interaction between 




energy intake (%) 
-0.01 ± 0.01 
(0.003) 
-0.3 ± 0.01 
(0.02) 
0.01 ± 0.002 
(0.05) 
Interaction between rs328* 
fat energy intake (%) 
Interaction between rs328* 
protein energy intake (%) 
Interaction between rs328* 
carbohydrate energy 
intake (%) 
-0.01 ± 0.002 
(0.16) 
-0.02 ± 0.01 
(0.12) 
0.01 ± 0.002 
(0.07) 
Interaction between rs285* 
fat energy intake (%) 
Interaction between rs285* 
protein energy intake (%) 
Interaction between rs285* 
carbohydrate energy 
intake (%) 




(0.05) (0.04) (0.03) 
HDL-C, High density lipoprotein cholesterol 
Pinteraction values adjusted for age, gender, body mass index, type 2 diabetes and total 
energy intake 
(*) refers to the interaction between SNP and dietary factor  
Those p values that are in bold implicates those values that are significant after 
Bonferroni correction  
Figure 3.1 Interaction between Lipoprotein lipase gene SNP rs1121923 and fat energy 
intake (%) on HDL-C concentrations (Pinteraction=0.003). Among those who consumed a 
high fat diet, T allele carriers had significantly higher levels of HDL-C compared to the 




Figure 3.2 Interaction between Lipoprotein lipase gene SNP rs1121923 and fat energy 
intake (%) on HDL-C as a categorical variable (Pinteraction=0.01). Among those who 
consumed a high fat diet (28.4%), the individuals who carried the T allele have 30% 
reduced risk of low HDL-C levels compared to those who carry the CC genotype 
(P=0.001). Data shown are represented as means ± SE. Pinteraction values adjusted for age, 









The SNP rs285 alone showed a significant association with serum TAG (P=1x10-
5), where CC genotype carriers had higher TAG concentrations than T allele carriers 
(Table 3.4). In the interaction analysis, there was an interaction of the LPL SNP 
rs4922115 with fat intake (energy %) on TAG, where, among those who consumed a 
low (1st tertile: 18.1 ± 2.6 %) or medium fat (2nd tertile: 23.4 ± 1.1 %) diet, individuals 
carrying the GG genotype had significantly lower TAG concentrations compared to ‘A’ 
allele carriers (P=0.01 for low fat intake; P=0.02 for medium fat intake). However, 
after correction for multiple testing, this interaction was not statistically significant. 
None of the other interactions between the SNPs and dietary factors on total 














Table 3.4: Association between single nucleotide polymorphisms (SNPs) at 







SNP rs4922115    
GG 4.9 ± 1.1 1.6 ± 1.0 3.1 ± 0.9 
GA 4.8 ± 1.1 1.9 ± 1.8 3.0 ± 0.9 
AA 4.7 ± 0.9 1.7± 0.8 2.9 ± 0.8 
Dominant model 








SNP rs1121923    
CC 4.8 ± 1.1 1.7 ± 1.4 3.0 ± 0.9 
CT 5.1 ± 1.0 1.7± 1.0 3.2 ± 0.9 
TT 4.9 ± 0.6 1.4 ± 0.4 3.3 ± 0.4 
Dominant model 
(CC vs CT+TT) 







SNP rs328    
CC 4.9 ± 1.0 1.7± 1.1 3.1 ± 0.9 
CG 4.9 ± 1.1 1.5± 0.9 3.1 ± 0.9 
GG 5.0 ± 0.9 1.4± 0.5 3.2 ± 0.8 
Dominant model 










   
CC 4.8 ± 1.1 1.7± 1.2 3.0 ± 0.8 
CT 4.8 ± 1.1 1.5± 0.9 3.1 ± 0.9 
TT 4.8 ± 1.0 1.4± 0.8 3.0 ± 0.8 
Dominant model 








    
LDL-c, Low density lipoprotein cholesterol Results are expressed as mean ± SD. P 
values adjusted for age, gender, body mass index and type 2 diabetes Those p values that 




Table 3.5 Interaction between single nucleotide polymorphisms (SNPs) at 
lipoprotein lipase gene and dietary factors on lipids traits  
Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs4922115 with 
dietary factors on total cholesterol 
Interaction between 
rs4922115* fat energy 
intake 
Interaction between 











Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs4922115 with 
dietary factors on serum triglycerides 
Interaction between 
rs4922115* fat energy 
intake 
Interaction between 











Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs4922115 with 
dietary factors on LDL-C 
Interaction between 
rs4922115* fat energy 
intake 
Interaction between 











Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs1121923 with 
dietary factors on total cholesterol 
Interaction between 
rs1121923* fat energy 
intake 
Interaction between 















dietary factors on serum triglycerides 
Interaction between 
rs1121923* fat energy 
intake (%) 
Interaction between 











Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs1121923 with 
dietary factors on LDL-C 
Interaction between 
rs1121923* fat energy 
intake (%) 
Interaction between 











Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs328 with 
dietary factors on total cholesterol 
Interaction between rs328* 
fat energy intake (%) 
Interaction between rs328* 
protein energy intake (%) 
Interaction between rs328* 








Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs328 with 
dietary factors on serum triglycerides 
Interaction between rs328* 
fat energy intake (%) 
Interaction between rs328* 
protein energy intake (%) 
Interaction between rs328* 








Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs328 with 
dietary factors on LDL-C 
Interaction between rs328* Interaction between rs328* Interaction between rs328* 











Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs285 with 
dietary factors on total cholesterol 
Interaction between rs285* 
fat energy intake (%) 
Interaction between rs285* 
protein energy intake (%) 
Interaction between rs285* 








Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs285 with 
dietary factors on serum triglycerides 
Interaction between rs285* 
fat energy intake 
Interaction between rs285* 
protein energy intake 
Interaction between rs285* 







Beta coefficients (standard error) Pinteraction*  for interaction of SNP rs285 with 
dietary factors on LDL-C 
Interaction between rs285* 
fat energy intake 
Interaction between rs285* 
protein energy intake 
Interaction between rs285* 







Pinteraction values adjusted for age, gender, body mass index, type 2 diabetes and total 









To our knowledge, this is the first genetic epidemiological study to investigate 
the interaction between SNPs at LPL gene and dietary factors on blood lipids in an 
Asian Indian population. Our study provides evidence for a novel interaction between 
SNP rs1121923 and fat intake (energy %) on HDL-C, where the T allele carriers had 
significantly higher levels of HDL-C compared to the CC homozygotes among those 
who consumed a high fat diet. Given that the total fat intake has increased in India in 
the last few decades and Asian Indians are characterized by altered lipid levels and at a 
higher risk of premature coronary artery disease (CAD) [38], our study findings have 
significant public health implications.     
Several LPL polymorphisms have been extensively studied in association with 
various lipid traits [12, 22, 25, 26]. The most notable of these known functional 
common polymorphisms is rs328, also known as S447X (premature truncation at codon 
447). SNP rs328 is a gain-of-function polymorphism that has been shown to be 
consistently associated with higher HDL-C [12]. Our study has also shown a significant 
association of the SNP rs328 with HDL-C concentrations, where the minor ‘G’ allele 
carriers had significantly higher HDL-C compared to those with common CC genotype. 
The rs285 (Pvu II) variant located in the intron 6 of the LPL gene has been shown to be 
associated with dyslipidemic phenotypes such as low HDL-C and high TAG among 
Caucasians [39], which is in accordance with our study findings in Asian Indians where 
the CC genotype carriers of the SNP rs285 had significantly higher TAG than T allele 
carriers. The ‘A’ allele of the SNP rs4922115 (located in the 3' UTR region) and ‘C’ 




with lower HDL-C levels in our study; however, after correction for multiple testing 
they were not significant. Our findings confirm the previously reported associations 
and reveal that LPL SNPs play an important role in lipid metabolism in this Asian 
Indian population.  
Total fat intake has increased considerably in India in the last few decades [40]. 
The National Sample Survey Organization survey has reported that the fat intake of 
urban component of Indian populations has increased from 42.0 g/d/capita in 1993–
1994 to 52.5 g/d/capita in 2011–2012 [41]. Interestingly our study in this South Indian 
population has identified an interaction between LPL SNP rs1121923 and fat intake 
(energy %) on HDL-C, where, among those who consumed a high fat diet (28.4%), 
individuals carrying the T allele had significantly higher HDL-C concentrations 
compared to the CC genotype carriers. Even though our study is the first to report this 
gene-diet interaction, previous studies in developing countries have shown that the 
quantity of dietary fats can affect the lipid profile and is directly related to the 
development of metabolic diseases such as obesity and diabetes [42, 43]. Quality of 
dietary fat has also shown to alter blood lipid levels [43] but the present study failed to 
identify an interaction of the LPL SNP with MUFA, PUFA and SFA, respectively, on 
lipid traits. Vegetable oils used in Indian cooking represent 80% of the visible fat 
consumed [44] and a study in an Indian population showed that the higher ratio of n6:n3 
was attributed to the type and quantity of oil used [45]. Previous studies have shown 
that dietary fat increases HDL-C [46], which is partially explained by our study 
findings where the T allele carriers of the SNP rs1121923, who consumed a high fat 




though the exact mechanism by which T allele contributes to the increase in HDL-C 
levels under conditions of high fat diet is unknown, the finding is suggestive of the 
complex inheritance pattern of the HDL-C levels [47], where several 
genes/polymorphisms are likely to contribute to the alteration of HDL-C levels through 
gene-gene and gene-diet interactions. Our findings are supported by animal studies [48] 
where mice that are challenged with a high fat diet showed a strong correlation between 
LPL activity and HDL cholesterol suggesting the link between LPL, fat intake and 
HDL levels.   
Besides HDL-C, there were interactions of the LPL SNP rs4922115 with fat 
energy intake (%) on TAG, where, among those who consumed a low or medium fat 
diet, individuals carrying the GG genotype had significantly lower TAG concentrations 
compared to ‘A’ allele carriers. The SNP rs4922115 has not been studied previously in 
other populations except in Hispanics [49], where this SNP was identified by direct 
sequencing. However, the study did not explore the individual effect of the SNP on 
blood lipids and hence we are unable to compare our findings with the Hispanic study. 
Even though the interaction between SNP rs4922115 and fat energy intake (%) was not 
statistically significant after Bonferroni correction in our study, replication of these 
interactions in another large cohort is highly warranted.  
One of the main limitations of the study is the small sample size. Given that there 
are no previously reported effect sizes for the LPL SNP-diet interaction on blood lipids, 
we are unable to calculate the statistical power for our study. However, we were still 
able to identify significant gene-diet interactions on HDL-C even after correction for 




but not when split as PUFA, MUFA and SFA, which might be due to small sample 
size. Nevertheless, our study is well powered to identify the effect sizes for association 
between the SNPs and lipids. To increase the statistical power, individuals with and 
without T2D were included and hence it is possible that the T2D status could have 
introduced a bias in our study as the dietary pattern is likely to be changed among 
‘known’ diabetic participants. However, T2D status was adjusted in all the analyses 
and the interaction findings were borderline significant even after excluding the 
‘known’ diabetic participants from our analysis (data not shown), which could also be 
due to the small sample size after exclusion. Another limitation is that, our study was 
cross-sectional and therefore was unable to examine the casual relationship between fat 
intake and lowering of HDL-C levels; randomized controlled trials with prospective 
genotyping are required to explore the causality using genetic markers. The main 
strength of the present study is that a validated interviewer-administered FFQ was used 
to measure the usual long-term intake of the population. Furthermore, the sampling is 
representative of the overall population of Chennai. Indeed, the intake of major foods 
in our study was similar to the findings of the pooled urban data of the National 
Nutrition Monitoring Bureau for ten states in India [50] and hence, the results of the 
present study could be reasonably extrapolated to urban Indian population. 
 
3.6 Conclusions 
Our study confirms the association between LPL SNP rs328 and HDL-C 
concentrations and also provides an evidence for a novel interaction between SNP 




Given that Asian Indians have altered lipid profile and an increased predisposition to 
premature CAD [38, 40], our study suggesting that individuals carrying T allele of the 
SNP rs1121923 have increased HDL-C levels when consuming a high fat diet has 
significant public health implications. This finding warrants confirmation in 
prospective studies and randomized controlled trials.  
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Chapter 4 Apolipoprotein E and lipoprotein lipase gene polymorphisms, dietary 
factors and blood lipids  
Under review in Lipids in Health and disease   
4.1 Abstract  
Background: Several candidate genes have been identified in relation to lipid 
metabolism, and among these, lipoprotein lipase (LPL) and apolipoprotein E (APOE) 
gene polymorphisms are major sources of genetically determined variation in lipid 
concentrations. This study investigated the association of two single nucleotide 
polymorphisms (SNPs) at LPL, seven tagging SNPs at the APOE gene, and a common 
APOE haplotype (two SNPs) with blood lipids, and examined the interaction of these 
SNPs with dietary factors. Methods: The population studied for this investigation 
included 660 individuals from the Prevention of Cancer by Intervention with Selenium 
(PRECISE) study who supplied baseline data. The findings of the PRECISE study were 
further replicated using 1,238 individuals from the Caerphilly Prospective cohort (CaPS). 
Dietary intake was assessed using a validated food-frequency questionnaire (FFQ) in 
PRECISE and a validated semi-quantitative FFQ in the CaPS. Interaction analyses were 
performed by including the interaction term in the linear regression model adjusted for 
age, body mass index, sex and country. Results: There was no association between 
dietary factors and blood lipids after Bonferroni correction and adjustment for 
confounding factors in either cohort. In the PRECISE study, after correction for multiple 
testing, there was a statistically significant association of the APOE haplotype (rs7412 
and rs429358; E2, E3, and E4) and APOE tagSNP rs445925 with total cholesterol 
(P=4x10-4 and P=0.003, respectively). Carriers of the E2 allele had lower total cholesterol 
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concentration (5.54± 0.97 mmol/L) than those with the E3 (5.98± 1.05 mmol/L) 
(P=0.001) and E4 (6.09± 1.06 mmol/L) (P=2x10-4) alleles. The association of APOE 
haplotype (E2, E3, and E4) and APOE SNP rs445925 with total cholesterol (P=2x10-6 
and P=3x10-4, respectively) was further replicated in the CaPS. Additionally, significant 
association found between APOE haplotype and APOE SNP rs445925 with low density 
lipoprotein cholesterol in CaPS (P=4x10-4 and P=0.001, respectively). After Bonferroni 
correction, none of the cohorts showed a statistically significant SNP-diet interaction with 
lipid outcomes. Conclusion: In summary, our findings from the two cohorts confirm that 
genetic variations at the APOE locus influence plasma total cholesterol concentrations, 
however, the gene-diet interactions on lipids require further investigation in larger 
cohorts. 
4.2 Background 
Cardiovascular diseases (CVD) are common multifactorial conditions 
characterized by dyslipidaemia, type 2 diabetes and hypertension [1, 2]. Elevated 
triacylglycerol (TAG) and reduced high density lipoprotein cholesterol (HDL-C) 
concentrations are associated with an increased risk of developing CVD [3-5]. 
Furthermore, several studies have reported that certain genetic variants influence 
susceptibility to altered circulating lipid concentrations, leading to an increased risk of 
CVD events [6-8]. Genetic variations have been shown to be associated with lipid 
outcomes, while dietary factors appear to modulate the effect of such genes on lipid 
concentrations [9, 10]. Previous studies have shown that single nucleotide 
polymorphisms (SNPs) of the apolipoprotein E (APOE) [6, 11] and lipoprotein lipase 
(LPL) [12-14] genes contribute to significant variation in lipid concentrations.  
The APOE protein plays a key role in the transport and metabolism of cholesterol 
 142 
and TAG containing particles by serving as a receptor-binding ligand that mediates the 
clearance of dietary derived chylomicrons, and hepatically derived very low density 
lipoprotein (VLDL) and their remnants from the circulation [6]. The three most 
recognized alleles of the APOE gene are E2, E3 and E4, with carriage of E4 associated 
with CVD risk factors and increased low density lipoprotein cholesterol (LDL-C) 
concentrations [11, 15, 16], and hence increased CVD risk [17, 18].  
Genetic variations in the LPL gene have been reported to be involved with lipid 
metabolism and partly explain the phenotypic variation in blood lipid levels [19]. LPL is 
a lipolytic enzyme that catalyses hydrolysis of TAG in all of the major classes of TAG-
rich lipoproteins [20]. High enzyme activity is associated with favourable lipid levels, 
including relatively low TAG concentrations [21]. The two most widely studied LPL 
SNPs, rs328 (S447X) and rs320 (HindIII) [22, 23]. The ‘G’ minor alleles of both the 
SNPs, rs328 and rs320, are associated with decreased TAG concentrations and increased 
HDL-C concentrations, whereas the opposite association was found for the ‘C’ allele and 
‘T’ allele respectively [24-26].  
Data from several studies supports the role of genetic factors in lipid metabolism 
[27]; however, only a few studies have examined the effects of lifestyle factors such as 
diet on the association of polymorphisms with lipid-related outcomes [10, 28, 29]. 
Therefore, the present study aimed to investigate the effect of seven APOE tagSNPs 
(rs405509, rs769450, rs439401, rs445925, rs405697, rs1160985, and rs1064725), one 
APOE haplotype (rs7412 and rs429358), and two commonly studied LPL SNPs (rs328 
and rs320) on blood lipids profile in 660 participants (baseline data) from the Prevention 
of Cancer by Intervention with Selenium (PRECISE) study. As diet type and intake is 
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also known to modify lipid levels [30-32], the potential impact of the interaction between 
these SNPs and dietary factors on lipid levels was also investigated. To confirm the 
findings, the Caerphilly Prospective Study (CaPS; n=1,238) was used as a replication 
cohort.   
4.3 Material and methods 
4.3.1 PRECISE cohort 
4.3.1.1 Participants and methods 
Baseline data of 660 individuals from the PRECISE study, conducted in two 
populations [UK (n=468) and Denmark (n=192)] were used for the analysis [33, 34]. 
Briefly, study participants were selected from four general practices (study centres) in 
various areas of the UK that were affiliated with the Medical Research Council General 
Practice Research Framework (MRC GPRF). Between June 2000 and July 2001, research 
nurses recruited similar numbers of men and women from each of three age groups: 60–
64, 65–69 and 70–74 years. The Danish participants were men and women recruited from 
the same three age groups from the County of Funen in Denmark.  
The UK study obtained approval from the appropriate UK Local Research Ethics 
Committees [South Tees (ref: 99/69), Worcestershire Health Authority (ref: LREC 
74/99), Norwich District (ref: LREC 99/ 141), Great Yarmouth and Waveney (under 
reciprocal arrangements with Norwich District LREC)], and the participants provided 
written informed consent. The regional Danish Data Protection Agency and Scientific 
Ethical Committees of Vejle and Funen counties approved the Danish study (Journal 
number. 19980186).  
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4.3.1.2 Dietary information  
Information about each participant’s usual dietary intake was obtained using 
validated EPIC food frequency questionnaires (FFQ) [35]. Total energy intake and 
macronutrient composition were analysed using the FETA software program [36].  
4.3.1.3 Anthropometric measurements and biochemical analysis   
Body mass index (BMI) was calculated as body weight in kilograms divided by 
height in square metres (kg/m2). Participants provided non-fasting blood samples for 
biochemical analysis and these samples were stored at −80°C. Total cholesterol and 
HDL-C concentrations in lithium-heparin plasma were measured using an Architect 
c16000 analyser (Abbott) with dedicated reagents. Measurements were performed by 
enzymatic colorimetric analysis. Traceability for total cholesterol and HDL-C was 
ensured through participation in the National Reference System for Cholesterol 
(NRS/CHOL), as established by the Clinical and Laboratory Standards Institute, with 
isotope dilution-MS used as the reference method, and reference material taken from the 
National Institute of Standard and Technology. Evidence of equivalence in the analytical 
performance of the cholesterol-oxidase assays performed in the UK and Denmark from a 
comparison of total cholesterol on forty-four serum samples which produced a limit of 
variation of 2% [33].  
4.3.1.4 SNP selection 
The APOE gene is located on chromosome 19q13.32. It comprises four exons, 
which are transcribed into the APOE mRNA which is 1,180 nucleotides long. The seven 
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tagSNPs for the APOE gene were chosen based on International HapMap Phase II 
collected from individuals of Northern and Western European ancestry (CEU) (HapMap 
Data release 27 Phase 2+3, Feb 09, NCBI B36 assembly, dbSNP b126). The Haploview 
software V3.3 (http://www.broadinstitute.org/haploview/haploview-downloads) was used 
to assess the linkage disequilibrium between SNPs. Tagger software was used to select 
tagSNPs with the ‘pairwise tagging only’ option. Two criteria were used to filter the 
SNPs included in the analysis, minor allele frequency ≥5% and Hardy–Weinberg 
equilibrium P-value >0.01. In total, seven tagSNPs [rs405509 (G>T), rs1160985 (C>T), 
rs769450 (G>A), rs439401 (C>T), rs445925 (G>A), rs405697 (G>A), and rs1064725 
(T>G)] representing the entire common genetic variations across the APOE gene were 
selected for the study. The APOE haplotype/SNPs [6, 11, 37-44] and LPL [12, 13] SNPs 
were chosen based on their previous association with various lipid outcomes.  
4.3.1.5 DNA isolation and genotyping  
The genotyping for the selected SNPs using a KASP assay with a competitive 
allele-specific PCR assay® was performed on DNA samples by LGC Genomics 
(Hoddesdon, Herts, UK).  The eleven SNPs were in Hardy Weinberg Equilibrium (HWE) 
(P>0.05 for all comparisons) (Table 4.6). 
 
4.3.2 Caerphilly Prospective Study (CaPS) 
4.3.2.1 Participants and methods 
The CaPS was used to replicate the findings from the PRECISE study. The phase 
1 (July 1979 to September 1983) recruitment for the CaPS included 2,512 men aged 45-
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59 years who were living in the town of Caerphilly and five of its adjacent villages in the 
UK; these participants were followed up at regular intervals [45, 46]. The follow-up data 
collection included periods from 1984 to1988 (phase 2), from 1989 to 1993 (phase 3), 
from 1993 to 1997 (phase 4), and from 2002 to 2005 (phase 5). For the current study, the 
data analysed were taken from phase 3 (n=1,238), which had the maximum number of 
samples and variables appropriate to this analysis (total cholesterol and dietary 
information), and from phase 5 (n=529) (HDL-C and LDL-C). Ethical approval was 
obtained from the South Wales Research Ethics Committee D, and each subject provided 
written informed consent. 
4.3.2.2 Dietary information  
Participants completed validated semi-quantitative FFQ in phase 3 [47, 48]. The 
FFQ included 50 typical food items in the British diet in order to estimate the mean daily 
energy intake and macronutrients and micronutrients consumption.   
4.3.2.3 Anthropometric measurements and biochemical analysis   
Height and weight was recorded in order to calculate the BMI. Height was 
measured on a staidiometer and weight was measured on a beam balance. Plasma 
prepared from blood samples taken after an overnight fast were transported at 4°C to the 
laboratories on the day of venepuncture. Total cholesterol and HDL-C, LDL-C 
concentrations were measured using enzymatic procedures [49]. and the LDL-C levels 
were calculated using the Friedewald Formula [50]. 
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4.3.2.4 DNA isolation and genotyping  
DNA was extracted from blood samples collected during the period 1992–1994. 
SNP information was obtained from the Illumina Cardio Metabochip, which includes 
data on 200,000 SNPs from regions previously identified for associations with risk 
factors for cardiometabolic disease [51]. Imputation was conducted against the 1000-
genomes reference panel, providing information on approximately two million typed or 
imputed SNPs. Duplicate samples were genotyped to compute the error rate. Quality 
control on genotyped samples has been previously reported [52] and the SNPs had a call 
rate of >98%. The SNPs were in HWE (P>0.05) (Table 4.6). 
4.3.3 Statistical analysis  
Statistical analysis was performed using the SPSS software package, version 22.0. 
Univariate linear regression analysis was applied to test for association of the SNPs with 
total cholesterol and HDL-C, controlling for age, sex, BMI and country. SNP-diet 
interactions on total cholesterol and HDL-C were investigated using a univariate general 
linear model. In this model, total cholesterol and HDL-C were the dependent variables, 
SNPs were fixed factors, and dietary factors (fat energy %, protein energy %, 
carbohydrate energy %), sex, age BMI, and country were covariates. The dominant 
model was applied for all SNPs with minor allele frequency ≤0.3 and the additive model 
applied for SNPs with minor allele frequency ≥0.4. For analytical purposes, the six APOE 
genotype groups (E2/E2, E2/E3, E3/E3, E3/E4, E4/E4, and E2/E4) were classified into 
three groups. The E3/E3 genotype was classified as a group as it occurs at high frequency 
in the population (wild type). The E2/E2 and E2/E3 genotypes were combined and 
presented as E2 carriers. The E3/E4 and E4/E4 genotypes were also combined, and 
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presented as E4 carriers [29]. Previous studies have shown that the impact of the E2 allele 
on serum lipids is greater than that of the E4 allele [17], therefore, the E2/E4 genotype 
was excluded from the analysis. The Bonferroni correction was applied separately for 
association and interaction analyses. For association between phenotypic and dietary 
factors, the Bonferroni-corrected P value was 0.008 (2 lipid outcomes* 3 dietary factors) 
for the PRECISE study and P value was 0.01 for CaPS (total cholesterol was the only 
variable available). For association between SNPs and lipids, the Bonferroni corrected P 
value was 0.003 (10 SNPs*2 lipid outcomes = 20 tests). For interactions, the Bonferroni 
corrected P value was 0.001 (10 SNPs*2 lipid outcomes*3 dietary factors = 60 tests). In 
the replication analysis, the Bonferroni corrected P value for association was 0.002 (10 
SNPs*3 lipid outcomes = 30 tests), while for interactions it was 0.001 (10 SNPs*1 lipid 
outcome* 3 dietary factors = 30 tests).  
 
4.4 Results 
4.4.1 Participant characteristics  
The general characteristics of the participants by sex are presented in Table 4.1. 
In the PRECISE study, women were found to have significantly higher total cholesterol 
and HDL-C concentrations than men (P=2.31x10-10 and P= 2.71x10-16, respectively). The 
consumption of carbohydrates (P=1.42x10-9) and protein (energy %) (P=5x10-5) were 
higher in women than in men, whereas the consumption of fat (energy %) and total 
energy intake were lower in women than in men (P=0.01). Characteristics of the 
individuals from CaPS are given in Table 4.1. Elevated total cholesterol levels were 
observed among men at phase 3. Dietary-pattern data showed higher consumption of 
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energy from total fat.    
4.4.2 Association between dietary factors and blood lipids 
In both the PRECISE and CaPS, there was no association between the dietary 
factors and total cholesterol or high-density lipoprotein after Bonferroni correction and 
adjustment for confounding factors (Table 4.2). 
 
4.4.3 Genotypes and serum lipid levels in the PRECISE study 
As shown in Table 4.3, of the seven tagSNPs at APOE, tagSNP rs445925 was 
significantly associated with total cholesterol (P=0.003) after correction for multiple 
testing. The ‘A’ allele carriers (5.65± 0.98 mmol/L) had 5% lower levels of total 
cholesterol than GG homozygotes (5.99± 1.06 mmol/L).  
The levels of HDL-C were significantly different among the LPL SNP genotypes, rs328 
(P=0.04) and rs320 (P=0.02), where the carriers of the ‘G’ minor allele of both SNPs had 
higher levels of HDL-C (1.68 ± 0.41 mmol/L for rs328 and 1.66 ±0.40 mmol/L for rs320) 
than CC homozygotes (rs328) and TT homozygotes (rs320) (1.61 ± 0.38 and 1.60 ±0.39 
mmol/L) respectively. However, these associations were not statistically significant after 
Bonferroni correction.  
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Table 4.1: Baseline characteristics of the PRECISE and Caerphilly 
Prospective studies participants  
 PRECISE study Caerphilly 
Prospective 
study (CaPS) 
Characteristics Men  
(N=248 UK, 95 Danish) 
Women  
(N=220 UK, 97 
Danish) 
P value Men  
(N=1,238) 
 Age (years) 67 ± 4 67± 4 0.12 62± 4 
Body mass index (kg/m2) 27.2± 4.9 27.3± 4.9 0.82 26.8± 3.7 
Total Cholesterol (mmol/L) 5.6± 0.9 6.2± 1.1 2.31x10-10 6.1± 1.1 
High density lipoprotein 
cholesterol (mmol/L)* 
1.5± 0.3 1.7± 0.4 2.71x10-16 1.3± 0.3 
Protein intake (total energy 
%) 
17.6± 3.7 18.8± 3.7 5X10-5 14.9± 2.7 
Carbohydrate intake (total 
energy %) 
42.8± 13.3 48.2± 8.7 1.42x10-9 48.4± 7.5 
Fat intake (total energy %) 35.3± 7.1 33.9± 6.9 0.01 36.5± 6.9 
Total energy intake (kcal) 2256 ± 658 1992± 613 2.63x10-7 1964 ± 625 
Total energy intake (MJ) 9.4± 2.7 8.3± 2.6 2.63x10-7 8.2± 2.6 
Data shown are represented as means ± SD, wherever appropriate. P values are for the 
differences in the means between men and women. P values were calculated by using 
independent t-test.  
*For CaPS, HDL-C levels were obtained from phase 5 while all other variables were 
obtained from phase 3. 
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Table 4.2: Association between dietary factors and lipids in PRECISE and 
Caerphilly Prospective studies 
PRECISE study 
Association between dietary factors and total cholesterol 
Fat total energy % intake 
Beta (± S.E),  
Passociation  
Protein total energy % 
intake 
Beta (± S.E),  
Passociation 
Carbohydrate total energy % 
intake 








Association between three dietary factors and HDL-C high density lipoprotein 
Fat total energy % intake Protein total energy % 
intake 








Caerphilly Prospective study 
Association between three dietary factors and total cholesterol 
Fat total energy % intake 
Beta (± S.E),  
Passociation 
Protein total energy % 
intake 
Beta (± S.E),  
Passociation 
Carbohydrate total energy % 
intake 








P values were obtained using linear regression adjusted for age, sex, body mass index and 
country. HDL-C high density lipoprotein cholesterol. 
 
4.4.4 APOE haplotype and serum lipid levels in the PRECISE study 
The effects of APOE haplotypes (E2, E3, and E4) on serum lipids are shown in 
Table 4.3. These haplotypes (E2, E3, and E4) were significantly associated with total 
cholesterol (P=4x10-4) after correction for multiple testing. The carriers of the E2 allele 
(5.54± 0.97 mmol/L) had lower total cholesterol concentrations than the carriers of the 
E3 (P=0.001) (5.98± 1.05 mmol/L) and E4 alleles (6.09± 1.06 mmol/L) (P=2x10-4).   
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4.4.5 Interactions between genotypes and dietary factors on serum lipids in the PRECISE 
study 
None of the dietary factors significantly interacted with the APOE SNPs, 
haplotypes and LPL SNPs with plasma lipids after correction for multiple testing (P 
>0.001) (Table 4.4).  
4.4.6 Replication analysis: Effect of SNPs at APOE and LPL on serum lipids in the CaPS 
The associations of APOE and LPL SNPs with blood lipids in the CaPS are 
presented in Table 4.3. The association of APOE haplotype (E2, E3, and E4) and APOE 
SNP rs445925 with total cholesterol (P=2x10-6 and P=3x10-4, respectively) was 
replicated. The ‘A’ allele carriers of APOE SNP rs445925 had lower total cholesterol 
(5.96±1.24 mmol/l) than ‘GG’ genotypes (6.24±1.08 mmol/L). In the APOE haplotype 
analysis, the carriers of the E2 allele had 5% and 14% lower total cholesterol than carriers 
of the E3 (P=4x10-4) and E4 alleles (P=3x10-6), respectively. Additionally, significant 
association was seen between APOE haplotypes (E2, E3, and E4) and APOE SNP 
rs445925and LDL-C (P=4X10-4, 0.001, respectively). 
There was an interaction between fat (% energy) and APOE haplotype (E2, E3, 
and E4) on total cholesterol (P=0.038) in CaPS. However, after correction for multiple 
testing, all the SNP-diet interactions were consistent with chance variation (Table 4.5). 
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Table 4.3: Association of APOE and LPL SNPs with HDL-C, LDL-C and total 
cholesterol levels in the PRECISE and Caerphilly prospective studies 
 








LPL     
rs320 0.26    
TT  1.6 ±0.3 5.9 ±1.1  
T/G  1.7 ±0.4 5.8 ±1.0  
P value  0.02 0.19  
rs328 0.10    
CC  1.6 ± 0.3 5.9 ±1.1  
C/G  1.7 ± 0.4 5.7 ± 0.9  
P value  0.04 0.06  
APOE     
rs405509 0.47    
GG  1.7± 0.4 5.8± 1.1  
GT  1.5± 0.3 5.8± 1.1  
TT   1.6± 0.3 6.1± 1.0  
P value  0.07 0.23  
rs769450 0.39    
GG  1.6± 0.3 5.9± 1.1  
A allele   1.6± 0.4 5.9± 1.1  
P value  0.72 0.97  
rs439401 0.33    
CC  1.6± 0.4 5.9± 1.1  
T allele  1.6± 0.3 5.9± 1.1  
P value  0.43 0.51  
rs445925 0.11    
GG  1.6± 0.3 5.9± 1.1  
A allele  1.7± 0.4 5.6± 0.9  
P value  0.25 0.003  
rs405697 0.25    
GG  1.6± 0.4 5.9± 1.1  
A allele   1.6± 0.3 5.9± 1.0  
P value  0.71 0.96  
rs1160985 0.43    
CC  1.6± 0.3 5.9± 1.1  
CT  1.6± 0.4 5.8± 1.0  
TT  1.7± 0.4 5.9± 1.1  
P value  0.12 0.44  
rs1064725 0.04    
TT  1.6± 0.4  5.9± 1.0  
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G allele   1.7± 0.3 6.1± 1.2  
P value  0.17 0.38  
(rs7412- 
rs429358) 
E2, E3, and E4 
    
E3  1.6± 0.3 5.9± 1.1  
E4  1.5± 0.3 6.1± 1.1  
E2  1.7± 0.4 5.5± 0.9  
P value  0.09 4X10-4  
Caerphilly  
LPL     
rs320 0.26    
TT  1.3± 0.3  6.1± 1.1  2.7± 0.8  
T/G  1.4± 0.3  6.2± 1.2  2.8± 0.8  
P value  0.05 0.55 0.05 
rs328 0.10    
CC  1.3± 0.3  6.1± 1.1  2.7± 0.8  
C/G  1.3± 0.3  6.1± 1.1  2.9± 0.9  
P value  0.63 0.71 0.05 
APOE     
rs405509 0.46    
GG  1.4± 0.3  6.0± 1.1  2.7± 0.9  
GT  1.3± 0.3  6.2± 1.1  2.8± 0.8  
TT  1.3± 0.3  6.3± 1.1  2.9± 0.9  
P value  0.16 0.02 0.29 
rs769450 0.41    
GG  1.3± 0.2 6.1± 1.2 2.8± 0.9 
A allele   1.4± 0.3 6.2± 1.1 2.8± 0.8 
P value  0.10 0.41 0.82 
rs439401 0.35    
CC  1.4± 0.3  6.2± 1.1 2.8± 0.9  
T allele  1.3± 0.3  6.1± 1.1 2.7± 0.8  
P value  0.72 0.42 0.32 
rs445925 0.11    
GG  1.3± 0.3  6.2± 1.1  2.8± 0.8  
A allele  1.3± 0.3  5.9± 1.2  2.5± 0.9  
P value  0.99 3X10-4 0.001 
rs405697 0.26    
GG  1.4± 0.4  6.1± 1.1  2.8± 0.9  
A allele   1.3± 0.3  6.1± 1.1  2.8± 0.8  
P value  0.30 0.88 0.9 
rs1160985 0.45    
CC  1.34± 0.29  6.2± 1.1  2.8± 0.9  
CT  1.35± 0.35  6.2± 1.2  2.7± 0.8  
TT  1.37± 0.40  6.1± 1.0  2.8± 0.8  
P value  0.61 0.30 0.73 
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rs1064725 0.01    
TT  1.3± 0.3 6.2± 1.1 2.8± 0.8 
G allele   1.4± 0.3 6.1± 1.1 2.8± 0.7 
P value  0.18 0.60 0.68 
(rs7412- 
rs429358) 
E2, E3, and E4 
    
E3  1.4± 0.4 6.2± 1.1 2.8± 0.8 
E4  1.4± 0.3 6.4± 1.1 3.0± 0.9 
E2  1.3± 0.3 5.8± 1.3 2.4± 0.8 
P value  0.95 2X10-6 4X10-4 
 
Values are given as mean ± SD. P values for differences between genotypes were 
obtained using linear regression model adjusted for age, sex, body mass index, and 
country.  
Bonferroni corrected P value <0.003 was considered statistically significant. 
MAF; minor allele frequency. HDL-C high-density lipoprotein cholesterol, LDL-C; low-
density lipoprotein cholesterol.   
* LDL-C values available only in Caerphilly prospective study.  
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Figure 4.1 Association of APOE haplotypes (E2, E3, and E4) with total cholesterol 
concentrations in the Prevention of Cancer by Intervention with Selenium (PRECISE) 
study and Caerphilly Prospective study (CaPS). E2 allele carriers have significantly lower 
levels of total cholesterol than E3 (P=0.001 and P=4x10-4 in the PRECISE and CaPS, 
respectively) and E4 (P=2x10-4 and P=3x10-6 in the PRECISE and CaPS, respectively) 
allele carriers.   
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Table 4.4: Interaction between APOE and LPL SNPs and dietary factors on HDL-C and total cholesterol in the PRECISE 
study 
 
Interaction between rs320 at LPL*dietary factors on HDL-C 
Interaction between SNP rs320* fat energy % 
intake 
Interaction between SNP rs320* protein energy % 
intake 
Interaction between SNP rs320* carbohydrate 







Interaction between rs320 at LPL *dietary factors on Total Cholesterol 
Interaction between SNP rs320* fat energy % 
intake 
Interaction between SNP rs320* protein energy % 
intake 
Interaction between SNP rs320* carbohydrate 







Interaction between rs328 at LPL *dietary factors on HDL-C 
Interaction between SNP rs328* fat energy % 
intake 
Interaction between SNP rs328* protein energy % 
intake 
Interaction between SNP rs328* carbohydrate 







Interaction between rs328 at LPL *dietary factors on Total Cholesterol 
Interaction between SNP rs328* fat energy % 
intake 
Interaction between SNP rs328* protein energy % 
intake 
Interaction between SNP rs328* carbohydrate 







Interaction between rs405509 at APOE*dietary factors on HDL-C 
Interaction between SNP rs405509* fat energy % 
intake 
Interaction between SNP rs405509* protein energy 
% intake 
Interaction between SNP rs405509* carbohydrate 







Interaction between rs405509 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs405509* fat energy % 
intake 
Interaction between SNP rs405509* protein energy 
% intake 
Interaction between SNP rs405509* carbohydrate 
energy % intake 
0.02 (0.02) -0.04 (0.03) -0.01 (0.01) 
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0.39 0.26 0.59 
Interaction between rs769450 at APOE *dietary factors on HDL-C 
Interaction between SNP rs769450* fat energy % 
intake 
Interaction between SNP rs769450* protein energy 
% intake 
Interaction between SNP rs769450* carbohydrate 







Interaction between rs769450 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs769450* fat energy % 
intake 
Interaction between SNP rs769450* protein energy 
% intake 
Interaction between SNP rs769450* carbohydrate 







Interaction between rs439401 at APOE *dietary factors on HDL-C 
Interaction between SNP rs439401* fat energy % 
intake 
Interaction between SNP rs439401* protein energy 
% intake 
Interaction between SNP rs439401* carbohydrate 







Interaction between rs439401 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs439401* fat energy % 
intake 
Interaction between SNP rs439401* protein energy 
% intake 
Interaction between SNP rs439401* carbohydrate 







Interaction between rs445925 at APOE *dietary factors on HDL-C 
Interaction between SNP rs445925* fat energy % 
intake 
Interaction between SNP rs445925* protein energy 
% intake 
Interaction between SNP rs445925* carbohydrate 







Interaction between rs445925 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs445925* fat energy % 
intake 
Interaction between SNP rs445925* protein energy 
% intake 
Interaction between SNP rs445925* carbohydrate 







Interaction between rs405697 at APOE *dietary factors on HDL-C 
 159 
Interaction between SNP rs405697* fat energy % 
intake 
Interaction between SNP rs405697* protein energy 
% intake 
Interaction between SNP rs405697* carbohydrate 







Interaction between rs405697 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs405697* fat energy % 
intake 
Interaction between SNP rs405697* protein energy 
% intake 
Interaction between SNP rs405697* carbohydrate 







Interaction between rs1160985 at APOE *dietary factors on HDL-C 
Interaction between SNP rs1160985* fat energy % 
intake 
Interaction between SNP rs1160985* protein 
energy % intake 
Interaction between SNP rs1160985* carbohydrate 







Interaction between rs1160985 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs1160985* fat energy % 
intake 
Interaction between SNP rs1160985* protein 
energy % intake 
Interaction between SNP rs1160985* carbohydrate 







Interaction between rs1064725 at APOE *dietary factors on HDL-C 
Interaction between SNP rs1064725* fat energy % 
intake 
Interaction between SNP rs1064725* protein 
energy % intake 
Interaction between SNP rs1064725* carbohydrate 







Interaction between rs1064725 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs1064725* fat energy % 
intake 
Interaction between SNP rs1064725* protein 
energy % intake 
Interaction between SNP rs1064725* carbohydrate 







Interaction between APOE (E2, E3, and E4)*dietary factors on HDL-C 
Interaction between SNP APOE (E2, E3, and E4)* 
fat energy % intake 
Interaction between SNP APOE (E2, E3, and E4)* 
protein energy % intake 
Interaction between SNP APOE (E2, E3, and E4)* 








Interaction between APOE (E2, E3, and E4)*dietary factors on Total Cholesterol 
Interaction between SNP APOE (E2, E3, and E4)* 
fat energy % intake 
Interaction between SNP APOE (E2, E3, and E4)* 
protein energy % intake 
Interaction between SNP APOE (E2, E3, and E4)* 








Values represented β regression coefficients (± S.E), and Pinteraction. P values were obtained by using a general linear model adjusted for 
age, sex, body mass index, country and total energy intake, wherever appropriate.  
Bonferroni corrected P value <0.001 was considered statistically significant. 
HDL-C; high density lipoprotein cholesterol.  
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Table 4.5: Interaction between APOE and LPL SNPs and dietary factors on total cholesterol in the Caerphilly prospective 
study 
Interaction between rs320 at LPL *dietary factors on Total Cholesterol 
Interaction between SNP rs320* fat energy % 
intake 
Interaction between SNP rs320* protein energy % 
intake 
Interaction between SNP rs320* carbohydrate 







Interaction between rs328 at LPL *dietary factors on Total Cholesterol 
Interaction between SNP rs328* fat energy % 
intake 
Interaction between SNP rs328* protein energy % 
intake 
Interaction between SNP rs328* carbohydrate 







Interaction between rs405509 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs405509* fat energy % 
intake 
Interaction between SNP rs405509* protein energy 
% intake 
Interaction between SNP rs405509* carbohydrate 







Interaction between rs769450 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs769450* fat energy % 
intake 
Interaction between SNP rs769450* protein energy 
% intake 
Interaction between SNP rs769450* carbohydrate 







Interaction between rs439401 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs439401* fat energy % 
intake 
Interaction between SNP rs439401* protein energy 
% intake 
Interaction between SNP rs439401* carbohydrate 







Interaction between rs445925 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs445925* fat energy % 
intake 
Interaction between SNP rs445925* protein energy 
% intake 
Interaction between SNP rs445925* carbohydrate 








Interaction between rs405697 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs405697* fat energy % 
intake 
Interaction between SNP rs405697* protein energy 
% intake 
Interaction between SNP rs405697* carbohydrate 







Interaction between rs1160985 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs1160985* fat energy % 
intake 
Interaction between SNP rs1160985* protein 
energy % intake 
Interaction between SNP rs1160985* carbohydrate 







Interaction between rs1064725 at APOE *dietary factors on Total Cholesterol 
Interaction between SNP rs1064725* fat energy % 
intake 
Interaction between SNP rs1064725* protein 
energy % intake 
Interaction between SNP rs1064725* carbohydrate 







Interaction between APOE (E2,E3, and E4)*dietary factors on Total Cholesterol 
Interaction between SNP APOE (E2, E3, and E4)* 
fat energy % intake 
Interaction between SNP APOE (E2, E3, and E4)* 
protein energy % intake 
Interaction between SNP APOE (E2, E3, and E4)* 







Values represented β regression coefficients (± S.E), and Pinteraction.  
P values were obtained by using a general linear model adjusted for age, sex, body mass index, country and total energy intake, 
wherever appropriate. 
Bonferroni corrected P value <0.001 was considered statistically significant. 
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Table 4.6: Genotype distribution of SNPs at LPL and APOE genes and Hardy 










Chi square HWE P 
value 
PRECISE 
rs320  354 (0.53) 271 (0.40) 39 (0.05) 1.8 0.17 
rs328 522 (0.80) 127 (0.19) 3 (0.005) 2.6 0.11 
rs405509 183 (27.6%) 330 (49.8%) 149 (22.5%) 0.0001 0.99 
rs769450   228 (34.5%) 339 (51.4%) 92 (13.8%) 3.66 0.06 
rs439401  291 (44.2%) 290 (44.1%) 76 (11.5%) 0.08 0.77 
rs445925  506 (77.3%) 142 (21.7%) 6 (0.9%) 1.33 0.24 
rs405697 365 (54.9%) 257 (38.7%) 42 (6.3%) 0.13 0.71 
rs1160985 200 (30.2%) 344 (52%) 117 (17.7%) 2.18 0.13 
rs1064725 606 (91.4%) 56 (8.4%) 1 (0.1%) 0.06 0.81 
Caerphilly Prospective study 
rs320  721 (0.53)  536 (0.39)  86 (0.06) 1.05 0.31 
rs328 1068 (0.79)  266 (0.19) 9 (0.006) 3.01 0.08 
rs405509 381 (0.28) 675 (0.50)  287 (0.21) 0.13 0.71 
rs769450   452(0.33) 672(0.50) 219(0.16) 1.35 0.24 
rs439401  560 (0.41) 615 (0.45)  168 (0.12) 0.0018 0.96 
rs445925  1056 (0.78)  271 (0.20) 16 (0.01) 0.08 0.77 
rs405697 728 (0.54) 513 (0.38) 102 (0.07) 0.77 0.38 
rs1160985 394 (0.29)  688 (0.51)  261 (0.19) 1.61 0.20 
rs1064725 1076 (0.96) 35 (0.03) 0  0.28 0.59 
HWE; Hardy Weinberg Equilibrium 
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4.5 Discussion  
Our findings demonstrated significant associations between the APOE haplotype 
(E2, E3, and E4) and APOE SNP rs445925 with total plasma cholesterol and LDL-C 
(only CaPS) concentration, which were further replicated in an independent UK 
Caucasian cohort. The levels of total cholesterol were significantly lower in carriers of 
the APOE E2 allele and the ‘A’ allele of the SNP rs445925 than carriers of E3, E4 and 
‘GG’ genotype of the APOE SNP rs445925, respectively. Given that our findings confirm 
that genetic polymorphisms of APOE influence the inter-individual variation in total 
plasma cholesterol, a marker of dyslipidemia, changes in dietary consumption to reduce 
disease susceptibility could be implemented for individuals at genetic risk. 
  The effects of APOE polymorphisms on lipid concentrations have previously been 
investigated in different ethnic groups [11, 53, 54] and studies have shown that the APOE 
gene variants contributed to 7% variability in total cholesterol  [55]. The results of the 
current study were in line with previously reported findings that APOE haplotypes (E2, 
E3, and E4) are associated with serum total cholesterol and LDL-C, with E4 carriers 
associated with increased concentrations compared with E3/E3 wildtype and particularly 
E2 carriers [16, 53, 56]. One of the primary roles of APOE is binding the low density 
lipoprotein receptor (LDLR) and the LDLR-related protein, to facilitate cellular uptake of 
lipoprotein particles [57]. The three alleles, E2, E3, and E4, differ in their amino-acid 
sequences, resulting in functional differences in receptors-binding affinity. Amino-acid 
sequences of the E2 allele have lower binding affinity than those of the E3 and E4 alleles, 
causing decreased hepatic VLDL and chylomicron remnants clearance, thus reducing the 
uptake of postprandial lipoprotein particles [57]. E2 carriers also have an impaired 
conversion of the VLDL particles to LDL-C compare to E4 carriers [58], who have a 
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higher rate of VLDL catabolism [59], which explains in part the lower total cholesterol 
and LDL-C in E2 allele carriers.  
Furthermore, our study highlights an association between APOE SNP rs445925, 
which is one of the selected tagSNPs within the APOE gene, and total cholesterol. The 
SNP rs445925 has not been extensively studied, however, a genome-wide association 
study showed a significant association between SNP rs445925 and LDL-C levels in 3,644 
black and white individuals from the US and Europe [60]. In addition, previous genome-
wide linkage and association studies have shown linkage disequilibrium (LD) between 
APOE SNPs rs7412 and rs445925 [61] and between ‘A’ allele carriers at SNP rs445925 
and E2 haplotype [62], respectively, which could explain in part a similar function in 
cholesterol synthesis.  
Besides genetic associations, our study also identified an interaction of APOE 
haplotypes (E2, E3, and E4) with intake from fat (%) on total cholesterol in the CaPS, 
where, among those who consumed a low-fat diet (%), individuals carrying the E2 allele 
had significantly lower total cholesterol concentrations than to E4 allele carriers. 
However, this interaction was not statistically significant after correction for multiple 
testing. A previous study has examined the response of APOE genotype to fat intake in 
45 individuals using a prospective design, where after consumption of a lower-fat-
cholesterol diet (34% fat, 265 mg/day) according to modified National Cholesterol 
Education program there was a significant reduction in total cholesterol by 14%, 9%, and 
4% in E4/E4, E3/E4, and E3/E3 genotypes, respectively [63]. Another study showed that 
the response to a diet high in cholesterol increases total cholesterol in E3 and E4 
compared to E2 allele carries in a study comprising 29 healthy men [64]. By contrast, a 
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cross sectional study in European Caucasians (n=996) reported that E2 allele carriers had 
lower total cholesterol levels, but there were no reported between interactions between 
saturated fatty acids and total cholesterol [65]. Given that the previous studies have given 
inconsistent results and have used various types of fatty acids, replication of our gene-diet 
interaction finding in a large well-designed randomized controlled trial is highly 
warranted.  
Previous studies have shown that the minor allele of LPL SNP rs328 enhance 
lipolytic activity [12]. Increased activity of LPL results in enhance clearance of TAG 
from the circulation, and  associated with higher HDL-C concentrations [66]. The LPL 
SNP rs320 (HindIII) is in LD with rs328 (S447X) and they have been shown to have 
similar effects on HDL-C, where minor allele was reported to increase HDL-C [24, 67]. 
In our study, in accordance with findings from other studies, there were associations 
between LPL SNPs, rs320 and rs328, and HDL-C concentrations, where common 
homozygotes of both SNPs had lower HDL-C [22-24, 26]. However, in our study, these 
associations were no longer statistically significant after Bonferroni correction. 
Furthermore, there were no significant LPL SNP-diet interactions with HDL-C or total 
cholesterol concentrations in either cohort. To date, there has only been one study that 
has shown an interaction between LPL rs328 and total fat intake on HDL-C in 8,764 
individuals from the US population, where high fat intake associated with increase HDL-
C in CC homozygotes and CG heterozygotes carriers [28]. One of the main reasons we 
did not identify a significant interaction may be our small sample size; however, we 
cannot rule out an effect of differences in dietary fat sources between European and the 
US population. 
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The present study has some limitations. Importantly, some lipid-related outcomes, 
such as LDL-C and TAG concentrations, were not measured in the PRECISE study. The 
PRECISE study was also conducted in two populations, a UK cohort and a Danish 
cohort, which used different food frequency questionnaires and this might have 
introduced measurement bias, even though the current results were adjusted for country 
in the regression analysis to avoid confounding. Another possible limitation is the use of 
a cross-sectional design (in both studies) to investigate genetic effects at a single point in 
time, whereas a longitudinal analysis design would have captured the genetic effects on 
lipid outcomes over a specific time period. The effect-size of the minor allele of some of 
the studied SNPs was relatively small, and hence a large sample size is required to detect 
reliably detect any interaction between SNPs and dietary factors. Despite the fact that this 
study was not adequately powered to detect such an interaction, it was sufficiently 
powered to detect the main effects (association). Significant gene-diet interactions were 
identified, however these did not reach the Bonferroni-corrected P value (P=0.001) and 
hence need to be confirmed in larger cohorts. This study is strengthened by the fact that it 
is the first study to investigate the role of tagSNPs at the APOE gene in relation to dietary 
factors and lipid outcomes. The fact that genetic associations from the PRECISE study 
were replicated in another Caucasian cohort (CaPS) confirms the validity of our findings. 
Additionally, CaPS was based on a cohort with a very high response rate, and is therefore 
closely representative of the general population.  
4.6 Conclusion 
Our study, carried out in two Caucasian populations, confirmed that genetic 
variations at the APOE gene locus influence plasma lipid concentrations. Thus, our 
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results suggest that APOE gene variants affect risk of dyslipidemia in individuals who 
carry the E4 risk allele and GG genotype at SNP rs445925. Future studies with a larger 
sample size examining tagSNPs at APOE, particularly prospectively genotyped dietary 
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5.1 Abstract 
Background: Consumption of ≤10% total energy from fat as saturated fatty acids (SFA) 
is recommended for cardiovascular disease risk reduction in the UK; however there is no 
clear guidance on the optimum replacement nutrient. Lipid-associated single-nucleotide 
polymorphisms (SNPs) have been shown to modify the lipid responses to dietary fat 
interventions. Hence, we performed a retrospective analysis in 120 participants from the 
Dietary Intervention and VAScular function (DIVAS) study to investigate whether 
lipoprotein lipase (LPL) and apolipoprotein E (APOE) SNPs modify the fasting lipid 
response to replacement of SFA with monounsaturated (MUFA) or n-6 polyunsaturated 
(PUFA) fatty acids.  
Methods: The DIVAS study was a randomized, single-blinded, parallel dietary 
intervention study performed in adults with a moderate cardiovascular risk who received 
one of three isoenergetic diets rich in SFA, MUFA or n-6 PUFA for 16 weeks.  
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Results: After the 16-week intervention, a significant diet-gene interaction was observed 
for changes in fasting total cholesterol (P=0.001). For the APOE SNP rs1064725, only 
TT homozygotes showed a significant reduction in total cholesterol after the MUFA diet 
(n=33; −0.71±1.88 mmol/l) compared to the SFA (n=38; 0.34±0.55 mmol/l) or n-6 PUFA 
diets (n=37; −0.08±0.73 mmol/l) (P=0.004). None of the interactions were statistically 
significant for the other SNPs.  
Conclusions: In summary, our findings have demonstrated a greater sensitivity of the 
APOE SNP rs1064725 to dietary fat composition, with a total cholesterol lowering effect 
observed following substitution of SFA with MUFA but not n-6 PUFA. Further large 
intervention studies incorporating prospective genotyping are required to confirm or 
refute our findings. 
5.2 Background  
 
A high consumption of saturated fatty acids (SFA) has been linked to increased 
circulating concentrations of low-density lipoprotein cholesterol (LDL-C) [1], and is 
consequently associated with an increased cardiovascular disease (CVD) risk [2]. 
Therefore, dietary guidelines have focused on reducing intakes of SFA by ≤10% of total 
energy (TE) for CVD risk reduction [3]. It is important to consider the nutrients that 
replace SFA and previous findings have suggested substitution of SFA with unsaturated 
fatty acids may provide a greater reduction in CVD risk than refined carbohydrates [4, 5]. 
In particular, replacement with cis-monounsaturated fatty acids (MUFA) or 
polyunsaturated fatty acids (PUFA) has been shown to significantly lower fasting total 
and LDL-C [6, 7]. However, the inter-individual variability in fasting plasma lipid 
responses to dietary fat intake is high; evidence supports that this is influenced by lipid-
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associated single-nucleotide polymorphisms (SNPs) such as apolipoprotein E (APOE) 
and lipoprotein lipase (LPL) genotypes [8-10].  
Several genes are involved in the regulation of lipid transport and metabolism 
[11]. Among these, the most commonly studied genes with central roles in lipid 
metabolism are LPL and APOE [12-14]. The LPL SNPs, rs320 (HindIII) and rs328 
(S447X), have been proposed as important genetic determinants of the inter-individual 
variability in fasting and postprandial triacylglycerol (TAG) concentrations and high-
density lipoprotein cholesterol (HDL-C) [15-17].  Increased activity of the LPL enzyme 
in minor allele carriers of LPL SNP rs328 has been shown to be associated with lower 
plasma TAG and higher HDL-C levels [18]. To date, there has only been one study 
reporting an interaction between LPL rs328 and n-6 PUFA intake on fasting TAG 
concentrations [19]. The effect of genetic variations of APOE on lipid concentrations (i.e. 
LDL-C) [20-23] and the effect of the APOE polymorphisms on the circulating lipid 
response to dietary fat (i.e. SFA and MUFA) have been previously demonstrated; 
however, the findings have been inconsistent [24-26]. In addition, investigations into 
other SNPs of the APOE gene are limited.  
In the Dietary Intervention and VAScular function (DIVAS) study, the 
isoenergetic replacement of 9.5 - 9.6 % TE from SFA with cis MUFA or n–6 PUFA for 
16 weeks in 195 adults at moderate CVD risk resulted in significant reductions of 8.4% 
and 9.2%, respectively, in total cholesterol, and 11.3% and 13.6%, in LDL-C, in the 
fasted state [6]. To investigate whether genetic polymorphisms contributed to the 
observed reductions in total and LDL-C, a retrospective post hoc analysis of the DIVAS 
study was performed. We examined whether the two LPL and seven tagging SNPs 
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(TagSNPs) in the APOE gene modified the response of the fasting lipid profile to 
substitution of SFA with MUFA or n-6 PUFA in this study population at moderate CVD 
risk.  
5.3. Participants and methods 
5.3.1 Study participants  
A detailed description of the DIVAS study design and methods has been reported 
elsewhere [6, 27]. Briefly, participants were recruited from Reading, UK and the 
surrounding area in three cohorts between November 2009 and July 2012. Participants 
were aged between 21 and 60 years and were all non-smoking men and women with a 
moderate risk of CVD. A scoring tool [27] was used to determine CVD risk based on the 
presence of single or multiple risk factors, including elevated fasting total cholesterol or 
fasting glucose, raised blood pressure, low HDL-C, being overweight or obese, and/or 
having a family history of premature myocardial infarction or type 2 diabetes. Eligible 
participants had a risk score of ≥ 2 combined points, reflecting a moderate CVD risk 
(≥50% above the population mean). Other criteria for exclusion were the presence of 
abnormal fasting blood biochemistry, taking dietary supplements or the use of 
medications that affect lipid metabolism or hypertension, and having inflammatory 
disorders. The West Berkshire Local Research ethics committee (09/ H0505/56) and the 
University of Reading Research Ethics Committee (09/40) gave a favourable ethical 
opinion for conduct. The trial was registered at www.clinicaltrials.gov as NCT01478958. 
All participants provided written informed consent before participating. In our 
retrospective analysis, 120 of the 195 participants who completed the DIVAS study 
consented to genetic analysis, and were included in the present study. 
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5.3.2 Study design and diets  
The DIVAS study was a randomized, single-blinded, parallel design. The 
participants completed 16 weeks of dietary intervention, receiving one of three 
isoenergetic diets based on a minimization program that matched for age, sex, body mass 
index (BMI), and total CVD risk score. The three intervention diets (%TE derived from 
SFA:MUFA:n-6 PUFA) were either rich in SFAs (17:11:4), MUFAs (9:19:4), or n-6 
PUFAs (9:13:10). Given that dietary guidelines recommend limiting n-6 PUFA intake to 
≤10% TE [28], SFA were replaced with 6% TE n-6 PUFA and 2% TE MUFA in the n-6-
PUFA-rich diet. The total fat content of all three intervention diets was 36% TE, and 
intakes of protein, carbohydrates, and n-3 PUFA were unchanged. A greater SFA 
exchange than the target 8% TE was achieved: SFA vs MUFA was 9.5% TE and SFA vs 
n-6 PUFA was 9.6% TE [27]. 
Further details of the dietary intervention procedure and measures of compliance 
have been published previously [27]. In summary, these interventions were based on a 
flexible food-exchange model to achieve the target fatty acid intakes in free-living 
individuals for 16 weeks. Participants, who were randomly assigned to one of three 
intervention diets, replaced routinely consumed sources of exchangeable fats with study 
foods. The study foods included spreads, oils, dairy products, and commercially available 
snacks of a specific fatty acid composition. Specially formulated spreads (80% total fat) 
and oils (Unilever Research and Development) were used for the MUFA-rich diet 
(refined olive oil and olive oil/rapeseed oil blended spread) and n–6 PUFA-rich diet 
(safflower oil and spread). Butter (Wyke Farm) was used as both a spread and oil 
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replacement in the SFA-rich diet.  
5.3.3 Anthropometric measurements and biochemical parameters  
Clinical visits took place at the Hugh Sinclair Unit of Human Nutrition, 
University of Reading, during weeks 0 (baseline; V1) and 16 (after intervention; V2) as 
described elsewhere [6]. Alcohol and aerobic exercise were avoided 24 h before visits. 
Participants consumed a provided low-fat meal the evening before visits and fasted for 12 
h, only drinking low-nitrate water during this time. Height and weight was recorded at the 
study visits at weeks 0 and 16 in order to calculate BMI. Height was recorded to the 
nearest 0.5 cm using a wall-mounted stadiometer and weight was measured using a 
digital scale (Tanita Europe) using standard settings (normal body type and 1 kg for 
clothing).  
At weeks 0 and 16, fasting blood samples collected into a serum separator 
vacutainer and a K3EDTA-containing vacutainer (week 0 only) were used for the 
measurement of the fasting lipid profile and isolation of the buffy coat, respectively. The 
K3EDTA-containing vacutainer was kept on ice for 30 min before the blood tubes were 
centrifuged at 1700 g for 15 min at 20 °C (for serum) and 4 °C (for plasma). The buffy 
coat was stored at -20°C and serum samples stored at -80°C prior to analysis of total 
cholesterol, TAG, and HDL-C, and glucose (baseline only) concentrations using an 
autoanalyzer (reagents and analyzer: Werfen UK Ltd). Fasting LDL-C was estimated 
using the Friedewald formula [29]. With the use of A/A grade automated oscillometric 
ambulatory blood pressure (ABP) monitors (A&D Instruments Ltd.), baseline 24 h ABP 
was measured every 30 min from 07:00 to 21:59 and every 60 min from 22:00 to 06:59, 
approximately 48 h before the clinical visits.  
 186 
 
5.3.4 SNP selection and genetic analysis 
The APOE gene is located on chromosome 19q13.32 and comprises of four 
exons, which are transcribed into the 1,180 nucleotides long APOE mRNA. The seven 
tag SNPs for the APOE gene were chosen based on International HapMap Phase II 
collected in individuals of Northern and Western European ancestry (CEU) (HapMap 
Data release 27 Phase 2+3, Feb 09, NCBI B36 assembly, dbSNP b126). The Haploview 
software V3.3 (http:// www.broadinstitute.org/haploview/haploview-downloads) was 
used to assess the linkage disequilibrium structure between SNPs. Tagger software was 
used to select tag SNPs with the ‘pairwise tagging only’ option. Two criteria were used to 
filter the SNPs included in the analysis - minor allele frequency ≥5% and Hardy–
Weinberg equilibrium P-value >0.01. Seven tagSNPs (rs405509 (G>T) [30, 31], 
rs1160985 (C>T) [32], rs769450 (G>A) [33], rs439401 (C>T) [34], rs445925 (G>A) 
[35], rs405697 (G>A) [36], and rs1064725 (T>G)) representing the entire common 
genetic variations across the APOE gene were selected for the study. In addition, the two 
commonly studied LPL SNPs, rs320 and rs328, were chosen. In total, nine SNPs were 
examined in the present study.    
DNA was extracted from the buffy coat using a QIAamp DNA blood kit 
(QIAGEN) and stored at -20°C. The genotyping of the LPL and APOE SNPs was 
outsourced to LGC Genomics (http://www.lgcgroup.com/services/genotyping), which 
employs the competitive allele-specific PCR-KASP® assay.  
5.3.5 Statistical analysis  
The data are presented as mean ± standard deviation (SD) in the tables and text, 
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and as standard error in the figure. The normal distribution was tested for variables, and 
none of the variables skewed the distribution. The minor allele frequency was calculated 
by counting. The dominant models were a better fit for SNPs rs320, rs328, rs769450, 
rs439401, rs445925, rs405697, and rs1064725; thus, homozygosity for the common allele 
was compared with carriers of the minor allele (heterozygous and homozygous for the 
minor allele) in the analysis. The additive model was applied for SNPs rs405509 and 
rs1160985 (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes). 
The genotype distributions of the nine SNPs at the LPL and APOE genes were in Hardy-
Weinberg equilibrium (P>0.05) (Table 5.2). Independent t-tests were used to compare 
means between men and women at baseline. The baseline and over 16 weeks’ 
associations of the selected SNPs with continuous phenotypes were evaluated by the 
general linear model (GLM). Moreover, potential interactions between genotype and 
dietary intervention on 16-week changes of lipids were analyzed by using GLM, where 
an interaction term was included in the model. Potential confounders associated with the 
outcomes were adjusted in all GLM analyses (i.e. age, sex, BMI, and ethnicity). When a 
significant diet x genotype interaction was found, data were split by genotype group and 
analyzed further by using GLM. A Bonferroni correction was applied and the significant 
P value was 0.0013 (0.05/9 SNPs*4 lipid outcomes). For all analyses, the statistical 
package SPSS version 22.0 (SPSS, Chicago, IL, USA) was used.  
5.4 Results  
In this retrospective analysis, 120 participants (mean age, 47± 9 years; BMI, 26.4 
± 4.0 kg/m2) were included. Table 5.1 illustrates the main characteristics of the study 
participants stratified according to sex at baseline. Women had significantly lower levels 
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of fasting TAG (P<0.0001), LDL-C (P=0.01), glucose (P=0.02), blood pressure (P≤0.03), 
and higher levels of fasting HDL-C (P<0.0001) compared to men.  
The genotype distributions of both LPL and APOE polymorphisms are shown in 
Table 5.2. The participants’ characteristics at the beginning of the dietary interventions 
(week 0) are presented in Table 5.3 according to LPL and APOE genotypes. None of the 
variables (including fasting TAG, total cholesterol, LDL-C, and HDL-C) were associated 
with the LPL and APOE SNPs at baseline.  After 16 weeks of intervention, there was also 
no significant association of the LPL and APOE SNPs with changes in the lipid outcomes 
after Bonferroni correction (Tables 5.4-8).  
Table 5.1: Baseline characteristics of study participants in the whole group and 




Men (N=54) Women (N=66) P value 
Age 47±9 48± 9 46± 9 0.37 
BMI 26.3± 3.9 26.7± 3.6 26.2± 4.3 0.58 
Systolic blood pressure  122± 10 126± 9 120± 9 0.01 
Diastolic blood pressure 75± 7 77± 7 74± 7 0.03 
Total cholesterol 5.58± 1.11 5.75± 1.15 5.45± 1.06 0.16 
TAG 1.28± 0.60 1.62± 0.61 1.02± 0.44 <0.0001 
HDL-C 1.54± 0.35 1.36± 0.32 1.68± 0.32 <0.0001 
LDL-C 3.79± 0.99 4.06± 1.01 3.57± 0.93 0.01 
Glucose  5.11± 0.42 5.23± 0.44 5.03± 0.39 0.02 
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Data shown are represented as means ± SD, wherever appropriate. P values for the 
differences in the means between men and women. P values were calculated by using 
independent t-test. BMI; body mass index, TAG; triacylglycerol, HDL-C; high-density 
lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol  
 
Table 5.2: Genotype and minor allele frequencies of the SNPs at LPL and APOE 
genes in the DIVAS cohort of adults with moderate CVD risk 
 












0.30  56 (0.47) 54 (0.45) 9 (0.07) 
rs328 
(C>G) 





0.47 31 (0.25) 64 (0.53) 25 (0.20) 
rs769450   
(G>A) 
0.37 44 (0.36) 61 (0.50) 15 (0.12) 
rs439401  
(C>T) 
0.35  50 (0.42) 52 (0.44) 16 (0.13) 
rs445925  
(G>A) 
0.11  91 (0.77) 25 (0.21) 1 (0.008) 
rs405697 
(G>A) 
0.25  70 (0.58) 38 (0.31) 11 (0.09) 
rs1160985 
(C>T) 
0.45 33 (0.27) 64 (0.53) 23 (0.19) 
rs1064725 
(T>G) 
0.05 108 (0.90) 12 (0.10) - 
 
MAF; minor allele frequency, LPL; lipoprotein lipase, APOE; apolipoprotein E. 
 
At 16 weeks, after adjustment for age, sex, ethnicity and baseline BMI, a 
significant interaction between the APOE SNP rs1064725 and dietary intervention (SFA 
vs. MUFA vs. n-6 PUFA) on changes in fasting total cholesterol (Pinteraction=0.001) was 
observed (Figure 5.1). The ‘TT’ homozygotes (n=108) of SNP rs1064725 had 
significantly lower total cholesterol concentrations after the MUFA (n=33; −0.71±1.88 
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mmol/l) compared with the SFA (n=38; 0.34±0.55 mmol/l; P=0.003) and n-6 PUFA-rich 
diets (n=37; −0.08±0.73 mmol/l; P=0.15) (Passociation=0.004) (Figure 5.1).   
Figure 5.1 Mean (±SE) of changes in total cholesterol concentrations following three 
intervention diets [rich in either saturated fatty acids (SFA), monounsaturated fatty acids 
(MUFA), and n-6 polyunsaturated fatty acids (PUFA)] according to the APOE SNP 
rs1064725 genotype (Pinteraction=0.001). A general linear model analysis was performed 
with adjustments for age, sex, body mass index, and ethnicity. Individuals carrying the 
‘TT’ genotype had lower total cholesterol levels after consuming the MUFA diet 
compared to the SFA or n-6 PUFA diets (Passociation=0.004).   
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Table 5.3: Baseline characteristics of the DIVAS study participants according to the LPL and APOE genotypes 
SNP Age Sex 
(M/F) 






LPL       
rs320       
TT 46± 9 27/29 1.28± 0.63 1.54± 0.41 3.73± 0.96 5.52± 1.15 
T/G 48± 9 27/36 1.27± 0.57 1.53± 0.31 3.81± 1.01 5.59± 1.07 
P value   0.83 0.41 0.71 0.53 
rs328       
CC 46± 9 42/47 1.29± 0.63 1.52± 0.37 3.72± 1.01 5.49± 1.17 
C/G 48± 10 12/19 1.23± 0.47 1.58± 0.27 3.96± 0.88 5.79± 0.83 
P value   0.51 0.93 0.42 0.49 
APOE       
rs405509       
GG 47± 10 17/14 1.41± 0.63 1.42± 0.39 3.71± 1.01 5.41± 1.20 
GT 47± 9 21/43 1.18 ± 0.57 1.58± 0.31 3.77± 1.00 5.58± 1.05 
TT 45± 11 16/9 1.34± 0.61 1.55± 0.38 3.85± 0.94 5.67± 1.12 
P value   0.57 0.24 0.81 0.70 
rs769450       
GG 47± 10 24/20 1.30± 0.61 1.57± 0.37 3.88± 0.96 5.71± 1.11 
G/A 46± 9 30/46 1.25± 0.59 1.51± 0.34 3.71± 1.00 5.47± 1.10 
P value   0.89 0.24 0.99 0.74 
rs439401       
CC 48± 9 25/25 1.37± 0.61 1.53± 0.36 3.88± 0.84 5.68± 0.95 
T allele 46± 10 29/39 1.22± 0.59 1.53± 0.34 3.69± 1.07 5.47± 1.19 
P value   0.43 0.95 0.54 0.54 
rs445925       
GG 46± 10 40/51 1.26± 0.58 1.53± 0.35 3.72± 1.00 5.50± 1.13 
A allele 49± 8 13/13 1.36± 0.67 1.56± 0.38 3.97± 1.00 5.80± 1.04 
P value   0.95 0.77 0.64 0.61 
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rs405697       
GG 47± 9 35/35 1.32± 0.62 1.52± 0.39 3.77± 0.91 5.56± 1.01 
A allele  46± 10 19/30 1.22± 0.57 1.55± 0.31 3.77± 1.08 5.56± 1.22 
P value   0.77 0.91 0.95 0.95 
rs1160985       
CC 46± 11 17/16 1.24± 0.62 1.55± 0.34 3.73± 0.96 5.53± 1.11 
CT 47± 8 24/40 1.27± 0.61 1.57± 0.33 3.87± 0.96 5.69± 1.02 
TT 46± 11 13/10 1.35± 0.51 1.38± 0.40 3.57± 1.08 5.23± 1.30 
P value   0.98 0.58 0.51 0.49 
rs1064725       
TT 47± 9 48/60 1.26± 0.59 1.55± 0.34 3.79± 1.00 5.59± 1.11 
G allele  45± 10 6/6 1.40± 0.65 1.42± 0.46 3.60± 0.85 5.29± 1.00 
P value   0.39 0.32 0.79 0.65 
P values for association between genotypes and lipids levels were obtained by using general linear model adjusted for age, sex, body 
mass index, and ethnicity. Values are mean ± SD.  
TAG; triacylglycerol, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, LPL; lipoprotein 
lipase, APOE; apolipoprotein E.  
The dominant model was applied for all SNPs (rare homozygotes were grouped with heterozygotes and compared with common 
homozygotes), except SNPs rs405509 and rs1160985 where additive model was applied (common homozygotes vs. heterozygotes vs. 
rare homozygotes).  
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Table 5.4: Changes in lipid levels after dietary intervention over 16 weeks relative to baseline according to the APOE 
rs1064725 genotype 
 SFA  MUFA  n-6 PUFA  Pinteraction 
 TT (N=38) G allele 
(N=3)  










































P values for association between genotypes and changes of means over 16 weeks with one of three diets were obtained by using 
general linear model adjusted for age, sex, body mass index, and ethnicity. P values for interaction between genotypes and changes of 
means over 16 weeks of intervention with one of three diets were obtained by using general linear model adjusted for age, sex, body 
mass index, and ethnicity. Values are mean ± SD.  
TAG; triacylglycerol, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, SFA; saturated fatty 
acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty acids. 
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Table 5.5: Changes in lipid levels after dietary intervention over 16 weeks according to LPL rs320 genotypes 



































































P values for association between genotypes and changes of means over 16 weeks with one of three diets were obtained by using 
general linear model adjusted for age, sex, body mass index, and ethnicity. P values for interaction between genotypes and changes of 
means over 16 weeks of intervention with one of three diets were obtained by using general linear model adjusted for age, sex, body 
mass index, and ethnicity. Values are mean ± SD.  
TAG; triacylglycerol, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, SFA; saturated fatty 
acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty acids. 
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Table 5.6: Changes in lipid levels after dietary intervention over 16 weeks according to LPL rs328 genotype  





































































P values for association between genotypes and changes of means over 16 weeks with one of three diets were obtained by using 
general linear model adjusted for age, sex, body mass index, and ethnicity. P values for interaction between genotypes and changes of 
means over 16 weeks of intervention period with one of three diets were obtained by using general linear model adjusted for age, sex, 
body mass index, and ethnicity. Values are mean ± SD.  
TAG; triacylglycerol, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, SFA; saturated fatty 






Table 5.7: Changes in lipid levels after dietary intervention over 16 weeks according to APOE rs405509 and rs1160985 
genotypes 































































































































































































































0.25 0.44  
P values for association between genotypes and changes of means over 16 weeks with one of three diets were obtained by using 
general linear model adjusted for age, sex, body mass index, and ethnicity. P values for interaction between genotypes and changes of 
means over 16 weeks of intervention period with one of three diets were obtained by using general linear model adjusted for age, sex, 
body mass index, and ethnicity. Values are mean ± SD.  
TAG; triacylglycerol, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, SFA; saturated fatty 




Table 5.8: Changes in lipid levels after dietary intervention over 16 weeks according to APOE rs769450, rs439401, rs445925 
and rs405697 genotypes 







































































































































































































































































P values for association between genotypes and changes of means over 16 weeks with one of three diets were obtained by using 
general linear model adjusted for age, sex, body mass index, and ethnicity. P values for interaction between genotypes and changes of 
means over 16 weeks of intervention period with one of three diets were obtained by using general linear model adjusted for age, sex, 
body mass index, and ethnicity. Values are mean ± SD. TAG; triacylglycerol, HDL-C; high-density lipoprotein cholesterol, LDL-C; 
low-density lipoprotein cholesterol, SFA; saturated fatty acids, MUFA; monounsaturated fatty acids, PUFA; polyunsaturated fatty 
acid. 
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In addition, we also observed an interaction between LPL SNP rs320 and the 
dietary fat intervention (SFA vs. MUFA vs n-6 PUFA) on changes in LDL-C 
concentrations after 16 weeks (Pinteraction=0.005) (Table 5.5). In the n-6 PUFA diet group, 
the G allele carriers (n=19) of the LPL SNP showed a reduction in LDL-C levels 
(−1.0±2.51 mmol/l) compared to the TT genotype (n=24; 0.91±2.23 mmol/l) 
(Passociation=0.007). However, this interaction was not statistically significant after 
correction for multiple testing. None of the other SNPs showed a significant interaction 
on changes in lipid concentrations after the 16-week dietary intervention (Tables 5.6-8). 
5.5 Discussion  
To our knowledge, this is the first study to investigate the effects of SNPs in both 
LPL and APOE genes on fasting serum lipid response after substituting SFA with MUFA 
or n-6 PUFA. Our findings, from this retrospective analysis of the DIVAS study, showed 
that ‘TT’ homozygotes (90% of study population) at APOE SNP rs1064725 had 
significantly lower total cholesterol concentrations after the 16-week replacement of SFA 
with MUFA in adults at moderate risk of CVD. Our findings indicate a greater sensitivity 
of this genotype group to dietary fat composition, particularly with respect to replacement 
of SFA with MUFA, which may have important public health implications.     
Findings from cross-sectional studies are not adequate to prove the beneficial 
impact of a dietary component on disease prevention; therefore, data from chronic dietary 
intervention studies are preferable to detect changes in disease biomarkers over a period 
of time [37]. A dietary intervention study has shown a reduction of 51% in fasting total 
cholesterol in non-diabetic adults with mild abdominal obesity after two weeks of 
following a MUFA-rich diet (20% TE) compared to a SFA-rich diet (19% TE) [38]. In 
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support of the beneficial effect of MUFA-rich olive oil, a Mediterranean diet 
supplemented with extra-virgin olive oil for 4.8 years in older adults has also been shown 
to reduce the incidence of major CVD events [39], which suggests the potential role of 
MUFA and/or nutraceuticals such as polyphenols found in extra-virgin olive oil in the 
prevention of CVD-related outcomes [40]. Our retrospective data analysis has 
demonstrated a significant interaction between APOE SNP rs1064725 and a MUFA-rich 
diet on total cholesterol levels in adults at moderate CVD risk, where the MUFA-rich diet 
reduced fasting total cholesterol in ‘TT’ homozygotes compared to the SFA- and n-6 
PUFA-rich diets. Our finding is in line with a previous study that also showed APOE 
genotypes to modulate changes in plasma total cholesterol and LDL-C in healthy 
individuals after consuming MUFA- (22% TE, virgin olive oil), SFA- (20% TE), and 
carbohydrate- (55% TE) rich diets for 4 weeks, where levels were higher in the E4/E3 
carriers, intermediate in E3/E3 carriers, and lower in E3/E2 carriers [24]. Another study 
showed that a MUFA-rich dietary intervention (mainly olive oil) for 12 months increased 
the secretion of TAG-rich lipoproteins (TRL) containing apoE and decreased the 
secretion of those without apoE. As a result, a MUFA-rich diet shortened the residence 
time of very low density lipoprotein (VLDL) particles in the circulation and increased the 
direct clearance of TRL from the circulation (due to the enrichment of TRLs with apoE, a 
ligand for receptor mediated uptake), decreasing their conversion to LDLs [41]. Hence, it 
can be hypothesised that a MUFA-rich diet is likely to regulate the clearance rate of TRL 
among ‘TT’ genotype carriers of the APOE SNP rs1064725 via effects on TRL particle 
apolipoprotein composition. However, the underlying mechanism of how the ‘TT’ 
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genotype acts differently from the ‘G’ allele on TRL metabolism in response to a MUFA-
rich diet remains unclear and requires further investigation.   
In our study, the common LPL SNP rs320 was found to modify the association 
between the n-6 PUFA-rich diet with changes in LDL-C levels, where the ‘G’ allele 
carriers had a tendency for a greater reduction in LDL-C concentrations compared to TT 
homozygotes. As far as the authors are aware, there are currently no studies to compare 
our findings with, except for one which showed that minor allele (‘G’) carriers of LPL 
SNP rs328 had lower fasting TAG concentrations when the participants had n-6 PUFA 
intake below 35.48% of total fat (below 35.48% of total fat median intake of LIPGENE 
study population) [19]. Besides LPL, evidence also suggests that the genetic effect of 
SNPs in APOA5 and TNFA on lipid metabolism is modulated by n-6 PUFA [42, 43]. In 
mice, n-6 PUFA intake have been shown to play a role in the upregulation of genes 
encoding proteins involved in adipogenesis [44]. Thus, dietary n-6 PUFA may upregulate 
LPL gene expression and/or activity, leading to lower circulating lipid concentrations [19, 
45]. In addition to the role of LPL in hydrolysing TRL, LPL plays a role in binding TRL 
(i.e. VLDL) to hepatic LDL receptors, which help to mediate the clearance of these 
particles [46]. This leads to a reduced conversion of VLDL to LDL, resulting in lower 
plasma LDL-C levels [47]. Even though the interaction between the LPL SNP rs320 and 
n-6 PUFA-rich diet on LDL-C concentrations in the current data analysis was not 
statistically significant after Bonferroni correction, which could be due to the small 
sample size, further large studies are required to explore this gene-diet interaction.  
Statistically significant interactions were demonstrated in this study, however 
there are some limitations. The sample size was relatively small for some of the genotype 
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groups as the genotyping was performed retrospectively, and investigation of the lipid 
response according to APOE and LPL SNPs was not the main objective of the DIVAS 
study. Compared with cross-sectional studies, randomized clinical trials are conducted 
with smaller sample sizes. In our study, only 120 participants out of 195 consented to 
genetic analysis and hence this resulted in a small sample size for the analysis. However, 
we were able to identify significant gene-diet interactions on total cholesterol after 
Bonferroni correction. Thus, this hypothesis testing analysis has identified the need for 
suitably-powered dietary intervention trials using prospective genotyping to investigate 
the impact of dietary fat composition on plasma lipid responses according to APOE 
genotypes. A selection bias may also have existed because the participants were multi-
ethnic (Asian 7% and Black 7%). However, to reduce this potential confounding effect, 
the analyses were adjusted for ethnicity. Furthermore, the interaction between SNP 
rs1064725 at APOE and the intervention diets on total cholesterol was still significant 
(P=0.003) even after excluding other ethnic groups from the analysis (data not shown). 
One of the main strengths of our study was that it examined the effects of three types of 
dietary fat (isoenergetically) consumed for a long duration (16 weeks) on lipid 
phenotypes in a robust randomised controlled intervention study, which addressed current 
dietary fat recommendations. Furthermore, we used a tagSNP approach whereby all the 
genetic variations in the APOE gene have been investigated in this study.   
In conclusion, our study shows an interaction between APOE SNP rs1064725 and 
dietary fat intake on fasting total cholesterol concentrations, suggesting a greater 
sensitivity of the ‘TT’ homozygotes (90%) to dietary fat composition, with a total 
cholesterol lowering effect observed following substitution of SFA with MUFA but not 
 205 
with n-6 PUFA. However, given that the present study was conducted in a relatively 
small group of individuals, further large studies using prospective genotyping are 
required to confirm our findings.  
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Chapter 6: Impact of polymorphisms in genes related to vitamin D metabolism and serum 
lipids on vitamin D concentrations and lipid responses to vitamin D fortified test meals. 
6.1 Abstract 
Deficiency in vitamin D has been associated with cardiovascular disease (CVD) risk and lipid 
concentrations. Genome-wide association studies have identified single-nucleotide 
polymorphism (SNPs) of genes involved in vitamin D metabolism, which have effects on 
vitamin D status. Additionally, SNPs of apolipoprotein E (APOE) and lipoprotein lipase (LPL) 
genes demonstrated associations with lipid concentrations. Hence, we aimed to examine the 
association of four vitamin D metabolism related SNPs with blood lipids and investigate whether 
these SNPs modified lipid response to dairy drink fortified with vitamin D in 18 men with sub-
optimal vitamin D status. Also, we examined whether SNPs of APOE and LPL had an impact on 
lipid responses to dairy drinks fortified with Vitamin D The study was an acute, double-blind, 
randomised, controlled, crossover study consisting of 3 intervention arms. Men (age 49± 3 years; 
BMI 26.4± 0.6 kg/m2) with sub-optimal vitamin D status were randomly assigned to one of three 
diets: controls diet, or fortified dairy drink with either 20μg 25- hydroxycholecalciferol 
(25(OH)D3) or 20μg cholecalciferol (vitamin D3). Fasting blood samples were collected for 
genetic and lipid profile analyses at baseline and end of intervention period (24 hour). 
Genotyping was performed by competitive allele-specific PCR-KASP® assay. The 
nicotinamide-adenine dinucleotide synthetase 1 gene (NADSYN1) SNP, rs12785878 (T/G), 
showed a significant association with high density lipoprotein cholesterol (HDL-C) (P=0.0003) 
after Bonferroni correction. The TT genotype had higher HDL-C levels compared to G allele 
carriers. None of the other genetic associations were statistically significant after correction for 
multiple testing. Our study provides evidence for an association between NADSYN1 SNP 
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rs12785878 and HDL-C concentrations in men with sub-optimal vitamin D status, which 
requires confirmation in future large human intervention studies.  
 
6.2 Introduction 
Low vitamin D status is a common global health problem affecting all age groups [1]. The 
prevalence of vitamin deficiency is around 50% among older people worldwide [2], and between 
20-30% in European adults [3]. Deficiency in vitamin D has been shown to be associated with a 
number of chronic conditions including cardiovascular disease [4, 5]. Several studies have 
suggested an association between vitamin D status and lipid levels [6-8]. In a meta-analysis of 17 
cross-sectional studies, serum 25-hydroxy-vitamin D (25(OH) vitamin D; a biomarker of vitamin 
D status) was shown to be associated with fasted HDL-C, while an inverse association with 
triacylglycerol (TAG), low density lipoprotein cholesterol (LDL-C) and total cholesterol was 
found [6]. In a further study each 10 nmol/L increase in serum 25(OH) vitamin D was related to 
a significant decrease of 0.89 mg/dl of non-HDL-C, 1.08 mg/dl in total cholesterol, and 2.34 
mg/dl in TAG concentrations in multi ethnic children in Canada [7]. Furthermore, 
supplementation of vitamin D (100,000 units) was associated with increased HDL-C in 29 
children from Argentine [8].  
A genome wide association study has identified a number of SNPs in genes involved with 
cholesterol synthesis, hydroxylation and vitamin D transport which have been shown to affect 
vitamin D status. These genes include NADSYN1, CYP24A1 (encoding cytochrome P450, family 
24, subfamily A, polypeptide 1), GC (encoding group-specific component vitamin D binding 
protein) and CYP2R1 (encoding cytochrome P450, family 2, subfamily R, polypeptide 1) gene 
[9]. The functions of encoded protein of these genes are; CYP2R1 produces active vitamin D 
[1,25-dihydroxyvitamin D3 (1,25(OH)2D3)] through hydroxylation the 25-hydroxylase in the 
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liver and 1-alpha-hydroxylase in the kidney, CYP24A1 is transcriptionally stimulated in vitamin 
D target cells (liver and bones) by the action of 1,25-dihydroxyvitamin D3, its role includes 
inactivating the pathway from 1,25-dihydroxyvitamin D3 to calcitroic acid, GC is the vitamin D-
binding protein involved with the transport of vitamin D, and NADSYN1 is involved with 
cholesterol synthesis [10]. Several studies have demonstrated the association of SNPs in these 
genes with vitamin D status in different ethnic groups [11-14]. A few studies have also reported 
association between these SNPs and some diseases associated with vitamin D deficiency 
including gestational diabetes mellitus [15] and hypertension [16].  
The SNPs at LPL and APOE genes have been demonstrated to be associated with lipid 
concentrations [17-20]. Given that no study to date has examined whether SNPs in these genes 
effect lipid response to diet fortified with vitamin D, we investigated the whether LPL and APOE 
SNPs may modulate lipid response to vitamin D. Thus the aim of this study was to investigate 
whether four SNPs in genes relating to vitamin D (rs12785878 (G/T) at NADSYN1 gene, 
rs6013897 (T/A) at CYP24A1 gene, rs2282679 (A/C) at GC gene, rs12794714 (G/A) at CYP2R1 
gene), in addition to LPL and APOE SNPs (rs439401, rs405509, rs445925, rs1160985, rs405697, 
rs769450) modified the lipid responses to fortified dairy drink with either 20μg 25(OH)D3 or 
20μg vitamin D3 in this study population compared with non-fortified dairy drink control in 18 
men with sub-optimal vitamin D status. A secondary aim was to examine the association 
between vitamin D related SNPs and vitamin D status.  
6.3 Participants and methods 
6.3.1 Study participants  
A detailed description of the study design and methods has been reported elsewhere [21]. 
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Briefly, participants were recruited from Reading, UK and the surrounding area between May to 
October 2015. Participants were aged between 30 and 65 years, BMI 20-35 kg/m2 and were all 
non-smoking men with sub-optimal vitamin D status (plasma 25(OH) D <50 nmol/L). Criteria 
for exclusion were: the presence of cardiovascular, renal, gastrointestinal, respiratory and 
endocrine diseases, diabetes or cancer; hypertension, taking nutritional supplements; on long-
term medication; having milk allergy/intolerance or lactose intolerance; outdoor workers and 
those who used tanning beds; overseas holidays two months before or during the study period; 
vigorous exercise (>3 times of 30 min aerobic exercise/week) and excessive alcohol intake (>14 
units/week). The University of Reading Research Ethics Committee (approval no: 15/15) gave a 
favourable opinion for conduct and the trial was registered at www.clinicaltrials.gov 
(NCT02535910). All participants provided written informed consent.  
6.3.2 Study design  
The study was an acute, double-blind, randomised, controlled, crossover study consisting 
of three intervention arms. During the intervention period, men consumed either control, 20μg 
25(OH)D3, or 20μg vitamin D3 in a random order (see details below). There was a 2-week 
washout period between the 3 study arms. The randomization of participants to diet order was 
achieved by using a web-based random letter sequence generator (https://www.randomizer.org/). 
The 20μg dose was used in the single meal study as it approximated to the fortification level used 
in the US and Canada. Detailed dietary advice including maintenance of normal diet and 
lifestyle, avoidance of dietary supplements and to minimize sun exposure was given to 
participants. Moreover, participants were asked to complete a 4-day diet diary (including 3 
weekdays and 1 weekend day within the same week) to assess dietary intake. Dietplan 6.6 
software was used to estimate dietary intake, before the first study visit. Fasting (12-h fast) blood 
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samples were collected at the beginning (baseline) and end of each intervention arm (24 hour) to 
investigate whether lipid concentrations (TAG, total cholesterol, LDL-C, and HDL-C) were 
modified in response to fortification with vitamin D.  
6.3.3 Test meal protocols  
Details of the test meal protocol have been described previously [21]. Briefly, 
participants were asked to refrain from alcohol and caffeine consumption and excessive exercise 
and to consume a low-fat meal (<10 g fat) as their main evening meal before each clinical visit. 
Also, participants were advised not to consume any fortified food or food high in vitamin D 
(such as egg yolk, oily fish) and they were provided with a low-nitrate water to consume the day 
before the study visit and during the study visit day until 24 hours (end point of experiment).  
The manufactured crystalline vitamin D3 and 25(OH) D3 were supplied by Dishman 
Netherlands BV. Vitamin D3 and 25(OH) D3 were dissolved in refined olive oil to reach a 
concentration of 1 μg/100 μl vitamin D3 or 25(OH) D3 stock fortified oil. Aliquots of vitamin 
D3 test oil (containing 20 μg vitamin D3), 25(OH) D3 test oil (containing 20 μg 25(OH) D3), 
and control (olive oil only) were given a random code and stored at -20 °C. On the morning of 
each study visit, the dairy drink was prepared using 300 ml full fat non-fortified milk.  
After a 12 h overnight fast, the participants were cannulated and fasting blood sample 
was taken. The three study dairy drinks were control, 20μg 25(OH)D3, or 20μg vitamin D3.  
Participants were given a standard test breakfast that includes the study dairy drink, three slices 
(120 g) of toasted white bread (Hovis Ltd) with 40 g strawberry jam (Sainsbury’s Supermarkets 
Ltd) and 15 g unsalted butter (Co-operative Ltd) (4.54 MJ energy, 125 g carbohydrate, 23 g 
protein and 51 g fat).   
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6.3.4 Anthropometric measures and biochemical analysis  
Clinical visits took place at the Hugh Sinclair Unit of Human Nutrition, University of 
Reading, UK. Height was recorded to the nearest 0.5 cm using a wall-mounted stadiometer and 
weight was measured using a digital scale (Tanita Europe) using standard settings (normal body 
type and 1 kg for clothing). Fasting blood samples were collected into serum separator and 
K3EDTA-containing vacutainers. After resting at room temperature for 15 min, samples were 
centrifuged at 1700 g for 15 min after which the serum/plasma was aliquoted and stored at - 20 
°C (for serum) and -80 °C (for 25(OH)D3 and vitamin D3) until analysis. Serum total 
cholesterol, HDL-C and TAG were measured using the ILAB 600 autoanalyser with standard 
kits and appropriate quality controls (reagents and analyser: Werfen (UK) Ltd. The LDL-C  
concentration was calculated using the Friedewald formula [22]. Plasma  25(OH)D3 [as sum of 
25(OH) D3 and 3-epi-25(OH) D3] was analyzed by DSM Nutritional Products Ltd using a 
validated method [23, 24].  
6.3.5 Genotyping for selected SNP 
DNA samples collected in October 2016 and were outsourced to LGC Genomics 
Company. The genotyping was performed for the LPL gene SNPs (rs320 and rs328), APOE gene 
SNPs (rs439401, rs405509, rs445925, rs1160985, rs405697, rs769450, NADSYN1 gene SNP 
rs12785878, CYP24A1 gene SNP rs6013897, GC gene SNP rs2282679, and CYP2R1 gene SNP 
rs12794714 using a KASP assay with a competitive allele-specific PCR assay®.  
6.3.6 Statistical analysis  
The data are presented as mean ± standard deviation (SD). Before analysis, data 
distribution and normality (skewness and kurtosis) were checked. The skewed data was log10 
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transformed for normality. The minor allele frequency was calculated by counting. The dominant 
models were a better fit for all SNPs except SNPs rs405509 and rs1160985 where the additive 
model was applied. The SNP rs328 at LPL and SNP rs1064725 at APOE were excluded from 
analysis as all the 18 participants were common homozygotes. The genotype distributions of the 
SNPs were in Hardy-Weinberg equilibrium (P>0.05) (Table 6.1). The association of the selected 
SNPs on continuous phenotypes was evaluated by the general linear model (GLM). Potential 
confounders that were associated with the outcomes were adjusted in all GLM analyses (i.e. age, 
BMI). A Bonferroni correction was applied and the significant P value was 0.0004 [0.05/10 
SNPs*4 lipid outcomes* 3 times (before and after interventions and changes in values from 
baseline)], while for association with vitamin D, the significant P value was 0.001 [0.05/4 
SNPs*3 diets * 3 times vitamin D levels measured (before and after interventions and changes in 
values from baseline)]. For all analyses, the statistical package SPSS version 22.0 (SPSS, 
Chicago, IL, USA) was used.  
6.4 Results  
6.4.1 Association between SNPs at LPL, APOE, and genes related to vitamin D with lipid 
levels 
There was a significant association between SNP rs12785878 (T/G) at NADSYN1 gene and 
HDL-C levels at baseline (P=0.0003) and after intervention with control diet (P=0.0004) (Table 
7.2). The TT genotype (n=9) had higher HDL-C concentrations (1.40± 0.18 mmol/L baseline, 
and 1.45± 0.17 mmol/L after intervention) compared to G allele (n=9) (1.03± 0.11mmol/L 
baseline, and 1.12±0.11 mmol/L after intervention) (Figure 6.1). However, the change in 
circulating HDL-C from baseline was not significant (P<0.05).  
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Figure 6.1 Association between SNP rs12785878 (T/G) at NADSYN1 gene and high density 
lipoprotein at baseline and post-intervention in control group. The values are mean and stander 
errors.  
There were no other significant associations between LPL and APOE SNPs and other genes 
related to vitamin D (CYP24A1 gene, GC gene, and CYP2R1 gene) with lipid concentrations at 
baseline or after interventions (P>0.0004) (Table 6.2-5). 
 6.4.2 Association between SNPs and vitamin D concentrations 
An association was observed between SNP rs12785878 (T/G) at NADSYN1 gene and 
25(OH) vitamin D concentrations (a biomarker for vitamin D) at baseline of three diet groups 
(P=0.01) (Table 6.6), but did not remain statistically significant after Bonferroni correction 
(P>0.001). A higher 25(OH) vitamin D concentration was observed in TT genotype compared to 
G allele carriers. There were no other association observed between genes relating to vitamin D 
































TT genotype G allele
P=0.003 P=0.0004
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Table 6.1: Genotype distribution of SNPs at LPL, APOE, NADSYN1 CYP24A1, GC and 
CYP2R1 genes and Hardy Weinberg Equilibrium P values  










LPL      
rs320 0.22 11 (0.61) 6 (0.33) 1 (0.05) 0.88 
rs328  18     
APOE      
rs439401 0.36 9 (0.5) 5 (0.27) 4 (0.22) 0.09 
rs405509 0.41 6 (0.33) 9 (0.5) 3 (0.16) 0.91 
rs445925 0.11 14 (0.77) 4 (0.22)  0.59 
rs1160985 0.52 3 (0.16) 11 (0.61) 4 (0.22) 0.34 
rs405697 0.19 12(0.66) 5 (0.27) 1 (0.05) 0.63 
rs769450 0.41 5 (0.27) 11 (0.61) 2 (0.11) 0.27 
rs1160985  17    
NADSYN1 gene 
rs12785878 (T/G) 
0.66 3 (0.16) 6 (0.33) 9 (0.5) 0.28 
CYP24A1 gene 
rs6013897 (T/A) 
0.19 13 (0.72) 3 (0.16) 2 (0.11) 0.05 
GC gene 
rs2282679 (A/C) 
0.20 10 (0.58) 7 (0.41)  0.28 
CYP2R1gene 
rs12794714 (G/A) 
0.36 7 (0.38) 9 (0.5) 2 (0.11) 0.72 
MAF; minor allele frequency, HWE; Hardy Weinberg Equilibrium 
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Table 6.2: The baseline and post- intervention associations between SNPs and HDL-C (mmol/L) and HDL-C response to the 
three test meals  
 Control diet vitamin D3 fortified dairy drink 25(OH) D3 fortified dairy 












SNPs          
LPL gene          
rs320          
TT 1.24± 0.19 1.31± 0.21 0.07± 0.06 1.23± 0.26 1.28± 0.24 0.04± 0.07 1.24± 0.23 1.33± 0.25 0.08± 0.06 
G allele 1.19± 0.31 1.23± 0.25 0.04± 0.08 1.13± 0.24 1.18± 0.24 0.04± 0.03 1.21± 0.27 1.24± 0.22 0.04± 0.06 
P value 0.81 0.61 0.42 0.55 0.59 0.75 0.86 0.61 0.21 
APOE gene          
rs405509          
GG 1.10± 0.23 1.17± 0.19 0.07± 0.08 1.13± 0.19 1.21± 0.23 0.07± 0.08 1.13± 0.23 1.21± 0.20 0.07± 0.06 
GT 1.32± 0.24 1.38± 0.22 0.06± 0.06 1.26± 0.29 1.29± 0.26 0.02± 0.04 1.32± 0.25 1.39± 0.26 0.07± 0.08 
TT  1.15± 0.14 1.22± 0.16 0.06± 0.05 1.08± 0.21 1.13± 0.18 0.05± 0.04 1.14± 0.14 1.18± 0.16 0.04± 0.04 
P value 0.24 0.19 0.96 0.63 0.75 0.30 0.33 0.31 0.85 
rs439401          
CC 1.21± 0.27 1.28± 0.25 0.07± 0.07 1.21± 0.30 1.25± 0.28 0.04± 0.04 1.24± 0.27 1.30± 0.25 0.05± 0.07 
T allele 1.23± 0.21 1.29± 0.19 0.06± 0.07 1.17± 0.21 1.22± 0.21 0.05± 0.08 1.21± 0.21 1.29± 0.24 0.08± 0.06 
P value 0.71 0.67 0.98 0.85 0.83 0.54 0.96 0.84 0.37 
rs445925          
GG 1.22± 0.23 1.28± 0.22 0.06± 0.06 1.17± 0.26 1.21± 0.24 0.03± 0.03 1.21± 0.22 1.27± 0.22 0.05± 0.06 
A allele 1.21± 0.28 1.28± 0.22 0.06± 0.08 1.26± 0.24 1.35± 0.23 0.08± 0.12 1.29± 0.31 1.40± 0.31 0.11± 0.07 
P value 0.91 0.93 0.89 0.52 0.32 0.17 0.61 0.39 0.21 
rs769450          
GG 1.13± 0.21 1.22± 0.18 0.09± 0.06 1.13± 0.25 1.16± 0.20 0.03± 0.05 1.17± 0.26 1.25± 0.31 0.07± 0.06 
A allele 1.25± 0.24 1.31± 0.23 0.05± 0.06 1.21± 0.26 1.27± 0.25 0.05± 0.06 1.25± 0.23 1.31± 0.22 0.06± 0.07 
P value 0.47 0.75 0.12 0.88 0.83 0.99 0.75 0.89 0.53 
rs405697          
GG 1.20± 0.24 1.28± 0.23 0.08± 0.06 1.21± 0.27 1.27± 0.26 0.05± 0.07 1.24± 0.25 1.33± 0.25 0.08± 0.06 
A allele  1.26± 0.23 1.29± 0.20 0.03± 0.05 1.14± 0.22 1.18± 0.21 0.04± 0.02 1.21± 0.23 1.23± 0.21 0.02± 0.05 
P value 0.34 0.51 0.21 0.99 0.98 0.70 0.90 0.69 0.046 
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rs1160985          
CC 1.17± 0.17 1.25± 0.20 0.07± 0.05 1.16± 0.31 1.18± 0.24 0.01± 0.07 1.31± 0.26 1.38± 0.35 0.07± 0.08 
CT 1.31± 0.23 1.35± 0.22 0.04± 0.06 1.24± 0.26 1.28± 0.25 0.03± 0.03 1.28± 0.23 1.33± 0.22 0.05± 0.06 
TT 1.01± 0.15 1.11± 0.13 0.11± 0.07 1.07± 0.17 1.16± 0.24 0.09± 0.11 1.04± 0.18 1.14± 0.18 0.10± 0.05 
P value 0.11 0.18 0.31 0.51 0.66 0.33 0.12 0.21 0.52 
NADSYN1 
gene 
         
rs12785878          
TT 1.40± 0.18 1.45± 0.17 0.04± 0.07 1.35± 0.23 1.37± 0.22 0.02± 0.04 1.37± 0.23 1.43± 0.25 0.05± 0.07 
G allele 1.03± 0.11 1.12±0.11 0.08± 0.06 1.03± 0.15 1.11±0.18 0.06± 0.07 1.09± 0.14 1.16±0.14 0.07± 0.05 
P value 0.0003 0.0004 0.21 0.01 0.02 0.09 0.02 0.03 0.64 
CYP24A1 
gene 
         
rs6013897          
TT 1.16± 0.22 1.22± 0.18 0.05± 0.06 1.11± 0.20 1.18± 0.21 0.06± 0.06 1.16± 0.20 1.22± 0.20 0.06± 0.06 
A allele 1.36± 0.23 1.45± 0.22 0.09± 0.06 1.39± 0.27 1.40± 0.26 0.01± 0.05 1.41± 0.24 1.49± 0.24 0.08± 0.07 
P value 0.17 0.06 0.32 0.06 0.14 0.031 0.06 0.04 0.61 
GC gene          
rs2282679          
AA 1.14± 0.19 1.21± 0.16 0.06± 0.06 1.14± 0.19 1.19± 0.21 0.04± 0.07 1.18± 0.24 1.27± 0.25 0.09± 0.08 
C allele 1.27± 0.24 1.33± 0.21 0.06± 0.08 1.17± 0.24 1.23± 0.22 0.05± 0.03 1.23± 0.18 1.27± 0.18 0.03± 0.03 
P value 0.28 0.23 0.86 0.95 0.98 0.77 0.73 0.88 0.10 
CYP2R1 
gene 
         
rs12794714          
GG 1.13± 0.22 1.20± 0.18 0.06± 0.07 1.14± 0.17 1.21± 0.21 0.07± 0.08 1.14± 0.22 1.22± 0.19 0.07± 0.05 
A allele 1.27± 0.24 1.34± 0.23 0.06± 0.06 1.22± 0.29 1.25± 0.26 0.03± 0.04 1.28± 0.24 1.34± 0.26 0.06± 0.07 
P value 0.28 0.23 0.99 0.71 0.83 0.19 0.30 0.37 0.65 
HDL-C; high-density lipoprotein-cholesterol. P values for association between genotypes and HDL-C levels were obtained by using 
general linear model adjusted for age, and body mass index. Values are mean ± SD.  
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Table 6.3: The baseline and post- intervention associations between SNPs and total cholesterol levels (mmol/L) and total 
cholesterol response to the three test meals 
 Control diet vitamin D3 fortified dairy drink 25(OH) D3 fortified dairy 












SNPs          
LPL gene          
rs320          
TT 5.23± 0.86 5.76± 0.93 0.53± 0.34 5.39± 1.07 5.80± 1.25 0.41± 0.41 5.69± 1.28 0.39± 0.39 1.55± 0.74 
G allele 4.89± 1.01 5.19± 0.77 0.30± 0.34 4.75± 0.67 5.36± 0.87 0.61± 0.30 5.42± 0.74 0.51± 0.35 1.27± 0.37 
P value 0.63 0.33 0.25 0.32 0.65 0.25 0.84 0.55 0.51 
APOE gene          
rs405509          
GG 4.87± 0.84 5.26± 0.59 0.38± 0.31 5.08± 0.80 5.68± 0.98 0.60± 0.46 5.53± 0.71 0.58± 0.33 1.52± 0.83 
GT 5.33± 1.04 5.84± 1.11 0.51± 0.43 5.33± 1.18 5.83± 1.26 0.49± 0.31 5.89± 1.33 0.45± 0.39 1.35± 0.57 
TT  4.84± 0.64 5.21± 0.44 0.36± 0.19 4.67± 0.55 4.94± 0.91 0.27± 0.39 4.79± 0.59 0.07± 0.04 1.53± 0.49 
P value 0.58 0.39 0.79 0.77 0.77 0.42 0.49 0.14 0.70 
rs439401          
CC 5.13± 1.03 5.54± 1.06 0.41± 0.29 5.31± 1.18 5.78± 1.20 0.47± 0.33 5.79± 1.17 0.46± 0.31 1.32± 0.37 
T allele 5.07± 0.82 5.54± 0.76 0.46± 0.42 4.98± 0.75 5.48± 1.07 0.51± 0.42 5.39± 1.02 0.40± 0.43 1.56± 0.81 
P value 0.71 0.56 0.61 0.97 0.89 0.79 0.81 0.72 0.21 
rs445925          
GG 5.18± 0.89 5.64± 0.94 0.45± 0.37 5.14± 1.02 5.55± 1.12 0.41± 0.33 5.56± 1.16 0.37± 0.36 1.45± 0.42 
A allele 4.81± 1.04 5.21± 0.74 0.40± 0.31 5.15± 0.91 5.91± 1.19 0.74± 0.42 5.68± 0.91 0.65± 0.34 1.41± 1.20 
P value 0.49 0.41 0.81 0.96 0.61 0.18 0.82 0.17 0.76 
rs769450          
GG 4.58± 0.86 5.02± 0.59 0.44± 0.27 4.65± 0.69 4.98± 0.85 0.32± 0.28 4.91± 0.65 0.32± 0.38 1.24± 0.60 
A allele 5.30± 0.87 5.74± 0.93 0.44± 0.39 5.33± 1.02 5.88± 1.12 0.55± 0.39 5.85± 1.13 0.47± 0.36 1.51± 0.64 
P value 0.33 0.39 0.75 0.68 0.41 0.21 0.29 0.39 0.64 
rs405697          
GG 5.24± 0.84 5.76± 0.89 0.51± 0.36 5.44± 0.96 6.02± 0.97 0.58± 0.35 5.96± 0.96 0.56± 0.34 1.52± 0.68 
A allele  4.81± 1.04 5.11± 0.80 0.29± 0.31 4.54± 0.71 4.85± 1.02 0.31± 0.36 4.85± 1.02 0.17± 0.27 1.27± 0.51 
P value 0.77 0.45 0.29 0.32 0.17 0.18 0.13 0.01 0.81 
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rs1160985          
CC 4.91± 0.66 5.26± 0.45 0.35± 0.20 4.91± 0.70 5.15± 1.06 0.23± 0.36 5.19± 0.76 0.35± 0.52 1.13± 0.79 
CT 5.31± 0.94 5.77± 1.02 0.45± 0.41 5.24± 1.11 5.77± 1.19 0.53± 0.29 5.74± 1.26 0.36± 0.32 1.39± 0.45 
TT 4.65± 0.97 5.12± 0.66 0.47± 0.34 5.03± 0.90 5.60± 1.08 0.56± 0.57 5.48± 0.90 0.68± 0.37 1.81± 0.91 
P value 0.42 0.42 0.96 0.67 0.91 0.61 0.90 0.35 0.48 
NADSYN1 
gene 
         
rs12785878          
TT 5.37± 1.04 5.83± 1.10 0.46± 0.41 5.44± 1.16 5.89± 1.30 0.54± 0.27 5.75± 1.39 0.35± 0.37 1.21± 0.51 
G allele 4.83± 0.71 5.25± 0.56 0.42± 0.31 4.84± 0.63 5.37± 0.88 0.53± 0.46 5.43± 0.72 0.52± 0.35 1.67± 0.67 
P value 0.28 0.23 0.88 0.28 0.52 0.41 0.65 0.40 0.03 
CYP24A1 
gene 
         
rs6013897          
TT 4.90± 0.93 5.25± 0.78 0.35± 0.30 4.86± 0.91 5.34± 1.12 0.48± 0.41 5.39± 1.16 0.43± 0.36 1.47± 0.63 
A allele 5.62± 0.66 6.29± 0.78 0.66± 0.41 5.87± 0.79 6.38± 0.71 0.51± 0.24 6.11± 0.71 0.44± 0.42 1.36± 0.68 
P value 0.18 0.03 0.11 0.06 0.13 0.81 0.29 0.86 0.38 
GC gene          
rs2282679          
AA 4.69± 0.89 5.19± 0.85 0.49± 0.30 4.82± 0.98 5.29± 1.26 0.46± 0.41 5.44± 1.28 0.55± 0.40 1.33± 0.78 
C allele 5.44± 0.53 5.78± 0.57 0.34± 0.44 5.30± 0.56 5.85± 0.51 0.55± 0.36 5.56± 0.59 0.28± 0.30 1.53± 0.36 
P value 0.11 0.22 0.37 0.53 0.59 0.96 0.93 0.18 0.91 
CYP2R1 
gene 
         
rs12794714          
GG 4.71± 0.77 5.13± 0.54 0.42± 0.28 4.78± 0.72 5.35± 1.11 0.56± 0.45 5.25± 0.85 0.48± 0.38 1.51± 0.78 
A allele 5.35± 0.93 5.81± 1.00 0.45± 0.41 5.37± 1.07 5.81± 1.12 0.44± 0.32 5.81± 1.21 0.41± 0.37 1.40± 0.54 
P value 0.18 0.15 0.92 0.26 0.49 0.42 0.36 0.73 0.61 
P values for association between genotypes and total cholesterol levels were obtained by using general linear model adjusted for age, 
and body mass index. Values are mean ± SD.  
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Table 6.4: The baseline and post-intervention associations between SNPs and TAG levels (mmol/L) and TAG response to the 
three test meals 
 Control diet vitamin D3 fortified dairy drink 25(OH) D3 fortified dairy 












SNPs          
LPL gene          
rs320          
TT 1.66± 0.73 1.63± 0.62 -0.03± 
0.33 
1.62± 0.85 1.73± 1.02 0.11± 0.27 1.55± 0.74 1.55± 1.02 0.01± 0.19 
G allele 1.21± 0.38 1.32± 0.43 0.11± 0.27 1.26± 0.53 1.57± 0.62 0.31± 0.17 1.27± 0.37 1.41± 0.62 0.14± 0.14 
P value 0.22 0.31 0.51 0.39 0.94 0.17 0.51 0.91 0.25 
APOE gene          
rs405509          
GG 1.55± 0.69 1.61± 0.54 0.06± 0.39 1.60± 0.81 1.78± 0.71 0.18± 0.26 1.52± 0.83 1.69± 0.76 0.16± 0.13 
GT 1.38± 0.63 1.40± 0.54 0.01± 0.32 1.26± 0.41 1.45± 0.61 0.19± 0.23 1.35± 0.57 1.34± 0.51 -0.01± 
0.16 
TT  1.67± 0.79 1.63± 0.82 -0.04± 
0.15 
1.90± 1.38 2.10± 1.79 0.20± 0.41 1.53± 0.49 1.60± 0.75 0.06± 0.27 
P value 0.68 0.69 0.66 0.49 0.53 0.83 0.70 0.46 0.05 
rs439401          
CC 1.40± 0.53 1.40± 0.42 0.003± 
0.41 
1.39± 0.51 1.61± 0.54 0.22± 0.25 1.32± 0.37 1.41± 0.30 0.08± 0.18 
T allele 1.57± 0.76 1.61± 0.68 0.04± 0.18 1.57± 0.95 1.72± 1.14 0.15± 0.27 1.56± 0.81 1.59± 0.84 0.03± 0.18 
P value 0.41 0.41 0.83 0.61 0.83 0.14 0.21 0.83 0.12 
rs445925          
GG 1.49± 0.61 1.51± 0.53 0.01± 0.34 1.45± 0.74 1.63± 0.91 0.18± 0.28 1.45± 0.42 1.49± 0.47 0.03± 0.19 
A allele 1.46± 0.88 1.53± 0.76 0.07± 0.20 1.58± 0.88 1.81± 0.82 0.22± 0.18 1.41± 1.20 1.55± 1.11 0.14± 0.11 
P value 0.87 0.97 0.76 0.91 0.81 0.98 0.76 0.95 0.35 
rs769450          
GG 1.45± 0.67 1.50± 0.66 0.05± 0.18 1.63± 1.06 1.86± 1.35 0.23± 0.31 1.24± 0.60 1.37± 0.68 0.13± 0.21 
A allele 1.50± 0.66 1.51± 0.55 0.1± 0.35 1.42± 0.63 1.60± 0.67 0.17± 0.24 1.51± 0.64 1.55± 0.62 0.03± 0.16 
P value 0.83 0.99 0.64 0.46 0.78 0.47 0.64 0.59 0.98 
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rs405697          
GG 1.59± 0.59 1.61± 0.46 0.02± 0.37 1.53± 0.59 1.74± 0.61 0.21± 0.25 1.52± 0.68 1.59± 0.62 0.06± 0.18 
A allele  1.27± 0.76 1.30± 0.72 0.02± 0.15 1.38± 1.05 1.52± 1.31 0.13± 0.27 1.27± 0.51 1.32± 0.64 0.04± 0.18 
P value 0.55 0.26 0.42 0.66 0.23 0.07 0.81 0.45 0.11 
rs1160985          
CC 1.54± 0.92 1.51± 0.92 -0.04± 
0.15 
1.79± 1.46 2.03± 1.85 0.23± 0.38 1.13± 0.79 1.27± 0.93 0.14± 0.28 
CT 1.33± 0.58 1.38± 0.48 0.05± 0.30 1.20± 0.43 1.41± 0.56 0.21± 0.22 1.39± 0.45 1.40± 0.41 0.01± 0.17 
TT 1.86± 0.63 1.86± 0.49 -0.01± 
0.47 
2.01± 0.58 2.12± 0.58 0.11± 0.31 1.81± 0.91 1.94± 0.83 0.13± 0.09 
P value 0.32 0.38 0.50 0.050 0.17 0.85 0.48 0.35 0.43 
NADSYN1 
gene 
         
rs12785878          
TT 1.20± 0.58 1.28± 0.50 0.08± 0.28 1.13± 0.31 1.23± 0.34 0.09± 0.11 1.21± 0.51 1.21± 0.41 -0.01± 
0.15 
G allele 1.77± 0.61 1.74± 0.55 -0.03± 
0.34 
1.83± 0.90 2.11± 1.03 0.28± 0.32 1.67± 0.67 1.80± 0.67 0.13± 0.18 
P value 0.03 0.05 0.35 0.02 0.004 0.05 0.03 0.01 0.11 
CYP24A1 
gene 
         
rs6013897          
TT 1.47± 0.66 1.51± 0.60 0.03± 0.31 1.58± 0.85 1.76± 1.00 0.18± 0.27 1.47± 0.63 1.56± 0.65 0.08± 0.16 
A allele 1.52± 0.68 1.51± 0.52 -0.01± 
0.34 
1.22± 0.23 1.43± 0.38 0.20± 0.23 1.36± 0.68 1.35± 0.56 -0.01± 
0.22 
P value 0.88 0.83 0.92 0.29 0.36 0.98 0.38 0.26 0.36 
GC gene          
rs2282679          
AA 1.31± 0.68 1.48± 0.64 0.14± 0.24 1.34± 0.71 1.53± 0.75 0.19± 0.21 1.33± 0.78 1.44± 0.78 0.10± 0.16 
C allele 1.62± 0.54 1.56± 0.51 -0.05± 
0.31 
1.71± 0.85 1.91± 1.09 0.20± 0.34 1.53± 0.36 1.58± 0.42 0.04± 0.17 
P value 0.46 0.81 0.24 0.51 0.61 0.83 0.91 0.65 0.76 




rs12794714          
GG 1.40± 0.61 1.52± 0.54 0.12± 0.25 1.42± 0.77 1.61± 0.75 0.18± 0.19 1.51± 0.78 1.61± 0.76 0.10± 0.18 
A allele 1.54± 0.69 1.50± 0.60 -0.04± 
0.34 
1.51± 0.77 1.71± 0.97 0.19± 0.30 1.40± 0.54 1.43± 0.54 0.03± 0.18 
P value 0.74 0.89 0.34 0.82 0.98 0.92 0.61 0.52 0.49 
 
TAG; triacylglycerol. P values for association between genotypes and TAG levels were obtained by using general linear model 
adjusted for age, and body mass index. Values are mean ± SD.  
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Table 6.5: The baseline and post-intervention associations between SNPs and LDL-C (mmol/L) and LDL-C response to the 
three tests meals 
 Control diet vitamin D3 fortified dairy drink 25(OH) D3 fortified dairy 












SNPs          
LPL gene          
rs320          
TT 3.23± 0.57 3.70± 0.67 0.46± 0.26 3.41± 0.83 3.73± 0.94 0.32± 0.31 3.35± 0.86 3.65± 1.00 0.30± 0.31 
G allele 3.14± 0.75 3.35± 0.60 0.21± 0.22 3.04± 0.57 3.46± 0.77 0.41± 0.26 3.13± 0.44 3.53± 0.57 0.40± 0.29 
P value 0.91 0.45 0.09 0.54 0.83 0.38 0.76 0.98 0.46 
APOE gene          
rs405509          
GG 3.06± 0.69 3.35± 0.56 0.28± 0.19 3.22± 0.61 3.65± 0.73 0.43± 0.36 3.11± 0.38 3.55± 0.39 0.43± 0.28 
GT 3.38± 0.65 3.82± 0.74 0.43± 0.34 3.49± 0.87 3.87± 0.95 0.37± 0.22 3.49± 0.90 3.88± 1.03 0.39± 0.28 
TT  2.92± 0.42 3.24± 0.22 0.31± 0.19 2.72± 0.20 2.85± 0.49 0.13± 0.29 2.87± 0.51 2.87± 0.42 -0.001± 
0.09 
P value 0.54 0.24 0.55 0.45 0.41 0.39 0.42 0.31 0.12 
rs439401          
CC 3.27± 0.73 3.62± 0.79 0.34± 0.24 3.46± 0.91 3.78± 0.98 0.32± 0.23 3.47± 
0.387 
3.84± 0.96 0.37± 0.25 
T allele 3.12± 0.54 3.51± 0.52 0.38± 0.32 3.08± 0.53 3.47± 0.76 0.38± 0.34 3.06± 0.49 3.37± 0.67 0.31± 0.35 
P value 0.85 0.75 0.45 0.77 0.97 0.43 0.52 0.52 0.79 
rs445925          
GG 3.28± 0.57 3.66± 0.63 0.38± 0.31 3.30± 0.77 3.60± 0.88 0.29± 0.24 3.32± 0.78 3.61± 0.93 0.29± 0.30 
A allele 2.92± 0.82 3.22± 0.67 0.30± 0.17 3.17± 0.73 3.73± 0.94 0.56± 0.36 3.08± 0.45 3.57± 0.51 0.49± 0.28 
P value 0.31 0.27 0.63 0.82 0.74 0.14 0.64 0.95 0.23 
rs769450          
GG 2.78± 0.66 3.11± 0.48 0.33± 0.19 2.77± 0.49 2.96± 0.66 0.19± 0.23 2.84± 0.41 3.03± 0.49 0.18± 0.31 
A allele 3.36± 0.56 3.74± 0.64 0.37± 0.31 3.46± 0.75 3.88± 0.81 0.42± 0.29 3.42± 0.76 3.83± 0.85 0.40± 0.28 
P value 0.22 0.27 0.76 0.41 0.22 0.18 0.41 0.24 0.22 
rs405697          
GG 3.31± 0.61 3.74± 0.68 0.42± 0.28 3.52± 0.75 3.95± 0.77 0.43± 0.25 3.45± 0.73 3.91± 0.75 0.44± 0.26 
 231 
A allele  2.97± 0.66 3.22± 0.46 0.25± 0.24 2.77± 0.41 2.98± 0.70 0.21± 0.32 2.88± 0.56 3.01± 0.72 0.12± 0.26 
P value 0.71 0.41 0.49 0.24 0.14 0.25 0.36 0.11 0.03 
rs1160985          
CC 3.03± 0.50 3.32± 0.28 0.28± 0.21 2.92± 0.51 3.04± 0.78 0.11± 0.27 3.01± 0.47 3.23± 0.59 0.21± 0.41 
CT 3.40± 0.60 3.78± 0.68 0.38± 0.34 3.45± 0.82 3.85± 0.91 0.40± 0.21 3.45± 0.84 3.76± 0.99 0.31± 0.25 
TT 2.78± 0.69 3.16± 0.59 0.37± 0.13 3.04± 0.65 3.46± 0.76 0.41± 0.45 2.93± 0.30 3.45± 0.45 0.52± 0.32 
P value 0.21 0.19 0.98 0.51 0.64 0.58 0.40 0.76 0.43 
NADSYN1 
gene 
         
rs12785878          
TT 2.98± 0.55 3.34± 0.48 0.35± 0.23 2.97± 0.48 3.31± 0.64 0.33± 0.35 3.05± 0.34 3.44± 0.46 0.38± 0.32 
G allele 3.42± 0.65 3.79± 0.74 0.37± 0.33 3.57± 0.86 3.95± 0.97 0.38± 0.22 3.47± 0.94 3.77± 1.11 0.29± 0.28 
P value 0.21 0.15 0.98 0.09 0.13 0.99 0.23 0.42 0.57 
CYP24A1 
gene 
         
rs6013897          
TT 3.06± 0.67 3.34± 0.57 0.28± 0.21 3.02± 0.66 3.36± 0.83 0.33± 0.33 3.13± 0.75 3.46± 0.91 0.32± 0.31 
A allele 3.56± 0.30 4.14± 0.49 0.57± 0.34 3.91± 0.57 4.33± 0.53 0.41± 0.13 3.62± 0.52 3.99± 0.51 0.37± 0.28 
P value 0.15 0.01 0.05 0.01 0.03 0.89 0.22 0.24 0.74 
GC gene          
rs2282679          
AA 2.96± 0.69 3.32± 0.66 0.36± 0.24 3.06± 0.72 3.39± 0.92 0.32± 0.32 3.10± 0.83 3.51± 0.99 0.41± 0.31 
C allele 3.42± 0.36 3.73± 0.51 0.31± 0.31 3.34± 0.55 3.75± 0.61 0.41± 0.27 3.33± 0.37 3.56± 0.51 0.23± 0.29 
P value 0.17 0.25 0.52 0.66 0.71 0.97 0.64 0.94 0.24 
CYP2R1 
gene 
         
rs12794714          
GG 2.93± 0.65 3.24± 0.50 0.31± 0.20 2.99± 0.55 3.41± 0.82 0.41± 0.37 2.94± 0.42 3.29± 0.58 0.35± 0.32 
A allele 3.37± 0.58 3.77± 0.67 0.40± 0.32 3.45± 0.82 3.77± 0.91 0.32± 0.23 3.47± 0.81 3.81± 0.94 0.33± 0.29 
P value 0.18 0.10 0.56 0.22 0.45 0.43 0.15 0.24 0.88 
LDL-C; low-density lipoprotein cholesterol. P values for association between genotypes and low density lipoprotein levels were 
obtained by using general linear model adjusted for age, and body mass index. Values are mean ± SD.  
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Table 6.6: The baseline and post-intervention associations of SNPs at NADSYN1 CYP24A1, GC, and CYP2R1 genes with 
25(OH)D levels and 25(OH)D response to three test meals 
 25(OH)D (nmol/L) 
 Control diet vitamin D3 fortified dairy drink 25(OH) D3 fortified dairy drink 














         














G allele 21.97± 
8.03 











P value 0.01 0.01 0.81 0.01 0.01 0.65 0.01 0.01 0.79 
CYP24A1 
gene 
         



























P value 0.58 0.86 0.17 0.91 0.71 0.22 0.96 0.97 0.42 
GC gene          


















1.72± 6.17 27.98± 
10.28 





P value 0.62 0.62 0.79 0.28 0.41 0.73 0.39 0.25 0.84 
CYP2R1 
gene 
         








5.29± 2.71 24.26± 9 34.25± 
11.52 
9.99± 3.27 













P value 0.13 0.15 0.43 0.25 0.34 0.82 0.12 0.18 0.15 
25(OH)D; 25-hydroxy-vitamin D, P values for association between genotypes and vitamin D levels were obtained by using general 
linear model adjusted for age, and body mass index. Values are mean ± SD. 
 
 234 
6.5 Discussion   
In this study, we investigated whether SNPs in LPL, APOE and vitamin D related genes 
modified lipid responses to fortified dairy drink (20μg 25(OH)D3, or 20μg vitamin D3). A 
significant association between SNP rs12785878 (T/G) at NADSYN1 gene and circulating HDL-
C was observed at baseline of control diet, where individuals carrying the TT genotype had 
higher HDL-C concentrations compared to G allele carriers. Our result suggested a favorable 
effect of TT genotype in SNP rs12785878 (T/G) at NADSYN1 gene on HDL-C levels, however, 
due to the small sample size replication of our result in larger groups are required for robust 
finding.  
 Evidence from cross-sectional and intervention studies reported association between 
vitamin D levels and lipid concentrations (i.e TAG, HDL-C, and total cholesterol) [6, 7]. In a 
cohort of 3240 middle age and elderly European adults increased 25-hydroxyvitamin D was 
associated with higher fasted HDL-C [25]. The results of the current study were in line with 
previously reported finding from a cross-sectional study conducted in 323 non-diabetic African 
[26], which reported that GG genotype of SNP rs12785878 (T/G) in NADSYN1 gene was 
associated with dyslipidemia (defined as higher total cholesterol, TAG, and LDL-C or lower 
HDL-C concentrations). However, another study in 36 Egyptian men (controls and patients with 
coronary artery disease) did not find SNP rs12785878 in NADSYN1 as a risk marker for coronary 
artery disease, which could be due to a small sample size [27].  A proposed function of vitamin 
D is related to increased activity of LPL enzyme, which is associated with higher HDL-C levels 
[28]. However, the underlying mechanism of how the TT genotype could differentially influence 
HDL-C concentrations compared to G allele remains unclear and requires further investigation.  
Furthermore, our study highlights an association between the SNP rs12785878 (T/G) at 
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NADSYN1 and circulating 25(OH) vitamin D, where the TT homozygotes had higher 25(OH) 
vitamin D concentrations compared to G allele carriers. A similar association was also 
demonstrated in previous studies [26, 29]. NADSYN1 gene is located close to the gene 
dehydrocholesterol reductase (DHCR7), which encodes for dehydrocholesterol reductase 
enzyme, that converts 7-dehydrocholesterol into cholesterol, essential for vitamin D synthesis [9, 
30]. Thus, it could be speculated that the TT genotype could enhance the activity of 
dehydrocholesterol reductase enzyme, thus increasing vitamin D synthesis. However, this 
association was not statistically significant in our study possibly due to the small sample size.  
In this study, we examined whether lipid response to 20μg 25(OH)D3 or 20μg vitamin 
D3 were modulated by SNPs at LPL or APOE, or vitamin D related genes. There was significant 
association between SNP rs12785878 (T/G) at NADSYN1 gene and HDL-C levels after the 
control diet, but the changes from baseline was not significant. However we did not observe any 
significant effects of the other SNPs on lipid responses after test meals of varying vitamin D 
composition.  
This study has some strengths and limitations. A crossover study design was considered a 
strength as it allowed for comparison within- and between-groups which minimised the influence 
of cofounding factor as each participant acted as his/her matched control [31]. Overall, although 
a significant association was achieved between SNP rs12785878 (T/G) at NADSYN1 and HDL-
C, our sample size was relatively small, which is the main limitation and further investigation is 
required to confirm our findings.  Another limitation is that the participants were retrospectively 
genotyped which resulted in unequal numbers in each genotype group. Ideally a prospective 
genotyping should be performed. This study included only men and hence may not be 
extrapolated to women.  
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In conclusion, the TT genotype of the SNP rs12785878 (T/G) at NADSYN1 was found to 
be associated with higher HDL-C concentrations. Given that our study was conducted in a small 
group of men with sub-optimal vitamin D status, further statistically powered studies are 
required to replicate or refute these findings.  
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Chapter 7 Discussion and conclusion 
 
7.1 Discussion  
 
The field of nutrigenetics contributes to the understanding of the interactive effects of 
genes and diet on lipid outcomes. The knowledge of nutrigenetics will help to develop and 
implement better dietary guidelines and health strategies based on the genotype of individuals 
to improve healthcare and reduce the burden of chronic diseases such as cardiovascular 
disease (CVD) [1, 2]. However, multiple challenges are being faced in nutrigenetics research 
as many genes and environmental factors are involved in the development of chronic diseases 
[3]. This thesis has set out to examine the interaction between candidate genes involved in 
lipid metabolism and dietary factors on lipid outcomes. Two lipid metabolism-related genes, 
lipoprotein lipase (LPL) and apolipoprotein E (APOE), were considered as candidates for this 
study, given that the single nucleotide polymorphisms (SNPs) of the APOE [4, 5] and LPL 
[6-8] genes have been extensively studied and shown to be significantly associated with 
variation in lipid concentrations. 
In this thesis, we investigated the association of common SNPs at the LPL gene and 
seven tagging SNPs (tagSNPs) at APOE with various lipid outcomes. Also, we the examined 
interaction between these SNPs and dietary factors (fat, carbohydrates, and protein) on lipid 
concentrations. Given that one of the aims of this thesis was to replicate findings obtained 
from one study in another independent cohort, various studies were used. A total of six 
different study designs from two populations [Chennai Urban Rural Epidemiological Study 
(CURES) Asian Indian, and European Caucasian from the UK and Denmark] were used to 
test our study objectives. The studies used were a postprandial study (n=261), a case-control 
study (Asian India, n=1,845), three cross-sectional studies [Prevention of Cancer by 
Intervention with Selenium (PRECISE study; UK, n=468; Denmark, n=192), and the 
Caerphilly prospective study (CaPS; UK, n=1,238)], a 16-week dietary intervention Dietary 
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Intervention and VAScular function (DIVAS) study (n=120) and a randomized, controlled, 3-
way crossover, double-blind vitamin D trial (n=18). The statistical analysis for examining the 
associations and interactions was carried out applied using the general linear regression 
model using SPSS version 22. Potential cofounders were adjusted in the analyses such as age, 
sex, body mass index and ethnicity (wherever appropriate). A summary of findings obtained 
in this project are discussed below.  
 
7.1.1 Findings relating to LPL gene 
The main function of the LPL enzyme is hydrolysis of triacylglycerol (TAG) from 
chylomicrons and very low density lipoprotein (VLDL) [9]. Several SNPs at the LPL gene 
have been shown to be associated with TAG and high density lipoprotein cholesterol (HDL-
C) [10, 11]. In my PhD work, I found that there was a tendency for the G minor allele at LPL 
SNP rs328 (C/G) to be positively associated with HDL-C compared with CC common 
homozygotes in the Asian Indian and Caucasian (postprandial and PRECISE cohorts) 
populations; however, this association was not statistically significant after Bonferroni 
correction in the PRECISE study. The LPL SNP rs320 (T/G) was also associated with HDL-
C in the PRECISE study, where the G minor allele carriers had higher HDL-C. In the Asian 
Indian population, LPL SNP rs285 showed a significant association with TAG levels, while 
the association between rs328 and TAG in the CaPS (Caucasian population) was not 
statistically significant after Bonferroni correction (see Appendix Table 9.4). Given that 
postprandial TAG concentrations are identified as an independent risk factor for CVD [12], 
we examined association between two LPL SNPs (rs320 and rs328) and postprandial TAG 
levels. We found a significant association between SNP rs328 (C/G) and postprandial TAG 
in the postprandial study, where CC homozygotes had 12% higher TAG area under the curve. 
The findings from this thesis have demonstrated evidence for the association between the 
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LPL gene SNPs and HDL-C and TAG concentrations in the Asian Indian and Caucasian 
populations, although these need confirmations in further RCTs.  
A novel finding of the thesis is the potential interaction between LPL SNP rs1121923 
(C/T) and dietary intake of fat (energy %) as a determinant of HDL-C concentration in an 
Asian Indian population after adjustment for age, sex, BMI, and type 2 diabetes. Carriers of 
the T allele of the LPL SNP rs1121923 were associated with a greater increase in HDL-C 
when they consumed a high fat diet compared to the CC homozygotes. There are no previous 
studies that have reported an interaction between SNP rs1121923 at LPL and fat intake on 
lipids. However, a study in Caucasian Americans found that another LPL SNP rs328 (C/G) 
was found to interact with fat intake (energy %) on HDL-C levels, where, among those who 
consumed a high fat diet, the CC homozygotes and CG heterozygotes had significantly 
higher HDL-C concentrations compared to the GG homozygotes [13]. Although these two 
studies (our Asian Indian study and the study in Caucasian Americans [13]) were conducted 
in two different ethnic groups, both of them reported the protective effect of T allele at SNP 
rs1121923 and CC homozygotes at SNP rs328 of LPL gene in those who consumed a high 
fat. However, in the PRECISE and CaPS studies, we did not observe the interaction between 
LPL SNPs rs328 and rs320 and fat intake on HDL-C. This could be due to the fact that the 
sample size (n=660 and 1238, respectively) of these two cohorts was small and hence the 
study did not have the statistical power to detect the small interaction effect sizes. 
Furthermore, the DIVAS study found a tendency for a lower serum low density lipoprotein 
cholesterol (LDL-C) concentrations in G allele carriers of the SNP rs320 (T/G) at LPL than in 
TT homozygotes in response to n-6 polyunsaturated fatty acid (PUFA); however, this effect 
was not statistically significant after Bonferroni correction. Previous results from cross 
sectional studies support the interaction between LPL SNPs and PUFA intake on TAG and 
HDL-C [14, 15]. The role of n-6 PUFA is to upregulate LPL gene expression, leading to 
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lower circulating concentrations of TAG and LDL-C [16, 17]. The LPL plays a role in 
binding TAG- rich lipoprotein (TRL) (i.e. VLDL) to LDL receptors, which helps to mediate 
clearance of these particles [18]. This action reduces the conversion of VLDL to LDL-C, 
which explains the reduction in LDL-C levels [19]. No other significant interactions were 
observed between LPL SNPs and dietary factors in other studies investigated in this thesis.  
7.1.2 Findings related to APOE gene 
The APOE protein plays a key role in the transport and metabolism of cholesterol and 
TRL particles by serving as a receptor-binding ligand that mediates the clearance of dietary 
derived chylomicrons, and hepatically derived VLDL and their remnants from the circulation 
[4]. Thus, the effects of seven tagSNPs (rs405509, rs769450, rs439401, rs445925, rs405697, 
rs1160985, and rs1064725) in the APOE gene along with the common haplotype (rs7412 and 
rs429358; E3, E2, E4) on lipid concentrations in the PRECISE (Caucasian participants), 
CaPS (Caucasian participants), DIVAS (majority Caucasian participants), and postprandial 
studies were examined. The APOE haplotypes (E2, E3, and E4) and APOE SNP rs445925 
were associated with total cholesterol in the PRECISE study and CaPS study. Around 7% of 
the variance in the total cholesterol levels have been shown to be determined by the APOE 
gene polymorphism [20]. Similarly, Suwalak et al. and El-Lebedy et al. [21, 22] found a 
significant association between APOE haplotypes (E2, E3, and E4) and total cholesterol. In 
addition, a genome-wide association scan has reported a significant association between 
APOE SNP rs445925 and LDL-C levels [23]. The mechanism explaining the differences in 
total cholesterol levels in the APOE alleles, is related to differences in APOE protein binding 
affinity to receptors such as LDL receptors. The E2 allele has reduced binding affinity, 
causing lower efficiency of the clearance of VLDL and chylomicron remnants from the blood 
to the liver, therefore slowing the uptake of postprandial lipoprotein particles compared with 
carriers of the E3 and E4 alleles [24]. Impaired conversion of the intestinal VLDL particles to 
 245 
LDL-C in E2 [25] compared with E4, which have a higher rate of catabolism of VLDL 
particles [26], also, could explains the lower total cholesterol in E2 allele carriers. None of 
the other SNPs (rs405509, rs769450, rs439401, rs1160985, rs405697 and rs1064725) in the 
APOE gene showed an association with lipid concentrations in studies examined in my PhD 
work (PRECISE, Caerphilly, and DIVAS). Even in the postprandial cohort, the APOE SNPs 
did not show any association with fasting lipid concentrations and postprandial TAG (see 
Appendix Table 9.2 and 9.3) after sequential meal challenge [breakfast (0 min; 49 g fat) and 
lunch (330 min; 29 g fat)], which could be due to a small sample as analysis was performed 
retrospectively. In contrast, a previous postprandial study in 51 healthy European Caucasian 
men showed that the TT homozygotes of the APOE SNP rs405509 (G/T) had higher 
postprandial TAG in response to a fatty meal rich in vitamin A (1g of fat/ kg body weight and 
60,000 IU vitamin A) compared to G allele carriers [27]. From my PhD work, I have 
demonstrated and confirmed the association between APOE haplotypes (E2, E3, and E4) and 
APOE SNP rs445925 and total cholesterol in the Caucasian population.   
In terms of the APOE gene-diet interaction analysis, in the DIVAS study, 
isoenergetically substituting a high saturated fatty acid (SFA) diet with high monounsaturated 
fatty acid (MUFA) diet had a significant effect on reducing total cholesterol concentrations in 
the TT homozygotes of the APOE SNP rs1064725 (T/G). A previous study showed that a 
MUFA-rich dietary intervention (mainly olive oil) for 12 months increased the secretion of 
TRL containing APOE and decreased the secretion of those without APOE. As a result, a 
MUFA-rich diet shortened the residence time of VLDL particles in the circulation and 
increased the direct clearance of TRL from the circulation by APOE, a ligand for receptor 
mediated uptake, which eventually decreased their conversion to LDLs [28]. In the CaPS 
study, a tendency for an interaction between APOE haplotypes (E2, E3, and E4) and fat 
energy intake (%) on total cholesterol was observed, where, among those who consumed a 
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low fat diet (%), individuals carrying the E2 allele had significantly lower total cholesterol 
concentrations compared to E4 allele carriers. However, this interaction was not considered 
statistically significant after correction for multiple testing. The PRECISE study, also failed 
to show a significant interaction between APOE SNPs and dietary factors on lipid 
concentrations. Given that PRECISE and CaPS studies were relatively small and CaPS was 
only in men, future replication of these findings is warranted.  
7.1.3 Findings from vitamin D intervention trial  
In this thesis, given that vitamin D status has been shown to be associated with CVD 
related traits and lipid-related outcomes [29, 30], we examined the association between 
vitamin D related SNPs (rs12785878 (G/T) at nicotinamide-adenine dinucleotide synthetase 1 
(NADSYN1) gene, rs6013897 (T/A) at encoding cytochrome P450, family 24, subfamily A, 
polypeptide 1 (CYP24A1) gene, rs2282679 (A/C) at encoding group-specific component 
vitamin D binding protein (GC) gene, rs12794714 (G/A) at encoding cytochrome P450, 
family 2, subfamily R, polypeptide 1 (CYP2R1) gene) and lipid outcomes using a crossover 
study in 18 Caucasian men with sup-optimal vitamin D status. The study was an acute, 
double-blind, randomised, controlled, crossover study consisting of 3 intervention arms. 
Participants were randomly assigned to one of three diets: a control diet, or fortified diary 
drink with either 20μg 25(OH)D3 or 20μg vitamin D3. In this study, the TT genotype of the 
SNP rs12785878 (T/G) at NADSYN1 gene showed an association with higher HDL-C levels 
compared to G allele carriers. This is in line with a previous study  in 323 non-diabetic 
Africans, where TT  genotype of the SNP rs12785878  was associated with decreased risk of 
dyslipidemia [31]. In the present study, we also found that TT homozygotes of the SNP 
rs12785878 had higher vitamin D levels, but not after Bonferroni correction. It was found 
that the fortified diary drink with either 20μg 25(OH)D3 or 20μg vitamin D3 did not affect 
lipid levels. From this study, I conclude that the TT genotype of the SNP rs12785878 (T/G) 
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at NADSYN1 may have a favorable effect on HDL-C levels, however, the finding requires a 
replication in a similar independent study.  
7.1.4 Limitations and strengths   
A major limitation was that some of these studies had a small sample size and hence 
did not have sufficient statistical power to detect an interaction effect. However, despite this 
limitation, we found significant interactions of the SNPs at LPL and APOE with dietary 
factors on lipid outcomes in Asian Indian and Caucasian populations. In this PhD project, the 
cross-sectional study design was predominantly used (PRECISE, Caerphilly, and CURES) 
which examined the genetic effects at a single point in time compared to a longitudinal study 
design, which captures the genetic effects that vary during a specific time period. Thus, it is 
difficult to identify the causal relationship between a risk factor and disease outcome.  Also, 
there were some factors that could have introduced bias in the studies that were used, such as 
type 2 diabetes participants in CURES (selection bias), the use of two different food 
frequency questionnaires in the PRECISE cohort as this study was conducted in two different 
countries (UK and Denmark) (measurement bias), and use of multi-ethnic (Asian 7% and 
Black 7%) participants in the DIVAS study (selection bias); therefore, to reduce these 
potential bias, the analyses were adjusted for these factors (diabetes status, country and 
ethnicity, wherever appropriate) in the statistical analysis. The data was limited in some of 
the studies, for example, lipid outcomes were limited by HDL-C and total cholesterol in the 
PRECISE cohort, and dietary information was not available for phase 5 of the CaPS study 
and I was not able to run the SNP-diet interaction analysis. The main strengths of this thesis 
was that consistent associations were found between the LPL SNP rs328 and HDL-C and 
between APOE haplotypes (E2, E3, and E4) and the APOE SNP rs445925 and total 
cholesterol. Also, in this thesis, I used different study designs (cross sectional, intervention, 
postprandial, crossover) to confirm the observed findings. The use of the tagging approach 
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helped me to select seven tagSNPs representing the entire common genetic variations across 
the APOE gene. Furthermore, my study was the first to report a gene-diet interaction on lipid 
outcomes in an Asian Indian population.  
7.2 Conclusion 
In conclusion, my thesis work has confirmed significant interactions between LPL 
and APOE SNPs and dietary factors (in particular, fat intake) on lipid outcomes. Given that 
reduced intake of fat, especially SFA, is recommended for CVD prevention [32], my gene-
diet interaction findings will have significant public health implications where people with 
the risk alleles of the LPL and APOE genes could be advised to consume a low fat diet. These 
findings add to the evidence base for possible associations between increased fat intake and 
elevated lipids which may be used to inform personalised dietary guidance Also, findings 
obtained in this thesis contributes to a better understanding of the interaction between genetic 
and dietary factors in relation to the progression of CVD. Replication of these findings in 
other studies with a larger sample size and with participants of different ethnic origin is 
required to confirm or refute the study findings. Additionally, prospective genotyping should 
be performed to prevent imbalance in the different genotype groups which could confound 
the results and randomized control trials should be carried out to identify the cause and the 
effect.  This thesis addressed only lipid outcomes as one of the risk factors of CVD and 
hence, other risk factors need to be taken into consideration in order to implement dietary 
strategies for the prevention of CVD. Furthermore, a genetic risk scoring approach also 
provides evidence for the genetic effect on phenotypes. A recent study showed that the 
genetics risk score (comprising 6 SNPs) was associated with lipid levels and coronary artery 
disease in a Chinese population [33].  
In conclusion, my study has demonstrated a consistent association between LPL rs328 
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and HDL-C, and APOE haplotypes (E2, E3, and E4) and APOE SNP rs445925 and total 
cholesterol. However, the gene-diet interactions require a replication in an independent larger 
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7.3 Future prospects  
Although remarkable improvements have been achieved in epidemiological studies in 
the field of nutrigenetics, future research should focus on understanding the metabolic 
pathways underlying gene-diet interactions [34-36]. Therefore, the science that identifies the 
connection between compounds in food and diet, and genetic susceptibility is needed [37]. 
Food scientists and nutritionists have described a new discipline called “Foodomics”, which 
is defined as the application of new methodologies, or “omics”, to improve individual health 
[36, 38]. This field has helped to identify the interactions of bioactive compounds from the 
diet at a molecular and cellular level to provide evidence on their health benefits, and to 
understand variations and differential response to nutrition interventions [36]. For instance, 
several studies have investigated the therapeutic activities of dietary polyphenols with respect 
to their ability to control intracellular signalling and biochemical mechanisms for the 
prevention of cancer [39, 40].  
Another approach is nutrigenomics, which investigates the effect of diet and its 
bioactive components on gene expression. This field of research will help in understanding 
how diet interacts with the metabolic pathways, which may have a role in diet-related 
diseases [41]. While nutrigenetics investigates gene-diet interaction or in other words, 
explores how the genes (at the levels of SNPs) causes the disease in response to a particular 
diet [42, 43]. The knowledge from these two fields will help in designing optimal diets that 
allow health maintenance and disease prevention in an individual [41, 44]. However, at 
present, a large gap exists between nutrition recommendations and individual eating 
behaviour. Therefore, the implementation of a personalised approach could be more widely-
accepted by the public [45]. Personalised nutrition advice has been found to be more effective 
in improving dietary behaviours compared to population-based ‘one size fits all’ advice [46]. 
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A recent study has also reported that gene-based personalised nutrition was more effective in 
reducing SFA intake than standard dietary advice in APOE gene carriers [47]. Besides 
personalised nutrition, Precision nutrition is another approach, which is aimed to develop 
more comprehensive nutritional recommendations based on the interaction between internal 
and external parameters of an individual’s environment throughout life. Precision nutrition 
takes into account the genetic factors, dietary habits, food behavior, physical activity, the 
microbiota and the metabolome [48].  
In summary, clear guidance from nutrigenetics studies is required for the 
implementation of personalised nutrition and foodomics, which can only be achieved by 
using large and well powered studies, examining various ethnic groups, considering the 
variety in dietary patterns globally, and conducting additional testing for other modifiable 
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Chapter 8 Appendices  
8.1 Appendix A: Genotype and minor allele frequencies of the SNPs at APOE genes in 
postprandial study  












0.46 47 (0.28) 85 (0.51) 34 (0.20) 0.69 
rs769450   
(G>A) 
0.40  53 (0.31) 92 (0.55) 21 (0.12) 0.05 
rs439401  
(C>T) 
0.39  62 (0.37) 77 (0.46) 26 (0.15) 0.79 
rs445925  
(G>A) 
0.12  125 (0.75) 38 (0.23) 2 (0.01) 0.63 
rs405697 
(G>A) 
0.28  87 (0.51) 68 (0.40) 14 (0.08) 0.88 
rs1160985 
(C>T) 
0.42 49 (0.29) 94 (0.56) 24 (0.14) 0.05 
rs1064725 
(T>G) 
0.05 149 (0.89) 17 (0.10) - 0.48 
MAF; minor allele frequency, HWE; Hardy Weinberg Equilibrium 
 
8.2 Appendix B: Baseline and postprandial characteristics of the participants according 
to APOE SNP rs405509 
Participants 
characteristics 
GG GT TT P value 
TC (mmol/l) 5.62± 0.96 5.58± 1.05 5.81± 0.88 0.47 
TAG (mmol/l) 1.66± 0.73 1.48± 0.75 1.48± 0.65 0.68 
HDL-C (mmol/l) 1.35± 0.42 1.37± 0.43 1.34± 0.42 0.43 
LDL-C (mmol/l) 3.51± 0.98 3.53± 1.01 3.79± 0.85 0.20 
TAG AUC (mmol/l 
× 480 min) 
1164.46± 
501.37 
1063.48± 493.24 1114.72± 527.02 0.93 
TAG IAUC 
(mmol/l × 480 min)  
358.96± 230.39 327.35± 200.28 321.32± 233.20 0.75 
 
Abbreviations: TC, total cholesterol; TAG, triacylglycerol; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol; AUC, area under the curve; IAUC, 
incremental area under the curve. P values were obtained by using a general linear model 




8.3 Appendix C: Baseline and postprandial characteristics of the participants according 
to APOE SNPs rs439401, rs769450, rs445925, rs405697, rs1160985, and rs1064725 
 
rs439401 
Participants characteristics CC T allele  P value 
TC (mmol/l) 5.79± 1.02 5.53± 0.97 0.34 
TAG (mmol/l) 1.59± 0.72 1.48± 0.73 0.39 
HDL-C (mmol/l) 1.38± 0.42 1.34± 0.43 0.47 
LDL-C (mmol/l) 3.68± 1.01 3.51± 0.94 0.64 
TAG AUC (mmol/l × 480 min) 1137.58± 499.21 1081.99± 507.15 0.61 
TAG IAUC (mmol/l × 480 min)  359.28± 233.62 322.01± 204.52 0.26 
rs769450 
 GG A allele   
TC (mmol/l) 5.69± 0.97 5.60± 1.00 0.43 
TAG (mmol/l) 1.44± 0.63 1.57± 0.77 0.44 
HDL-C (mmol/l) 1.42±0.50 1.33± 0.38 0.39 
LDL-C (mmol/l) 3.59± 1.01 3.57± 0.95 0.66 
TAG AUC (mmol/l × 480 min) 1078.26± 535.27 1116.99± 485.51 0.94 
TAG IAUC (mmol/l × 480 min)  311.81± 218.52 347.76± 213.94 0.47 
rs445925 
 GG A allele   
TC (mmol/l) 5.65± 0.95 5.62± 1.17 0.41 
TAG (mmol/l) 1.54± 0.76 1.55± 0.68 0.61 
HDL-C (mmol/l) 1.32± 0.39 1.48± 0.51 0.07 
LDL-C (mmol/l) 3.64± 0.88 3.39± 1.27 0.04 
TAG AUC (mmol/l × 480 min) 1089.13± 490.48 1186.13± 578.20 0.08 
TAG IAUC (mmol/l × 480 min)  329.93± 211.65 362.44± 271.47 0.21 
rs405697 
 GG A allele   
TC (mmol/l) 5.65± 0.99 5.61± 1.00 0.72 
TAG (mmol/l) 1.53± 0.71 1.56± 0.78 0.95 
HDL-C (mmol/l) 1.41± 0.44 1.29± 0.40 0.05 
LDL-C (mmol/l) 3.56± 0.98 3.60± 0.96 0.83 
TAG AUC (mmol/l × 480 min) 1086.61± 493.85 1125.83± 505.76 0.76 
TAG IAUC (mmol/l × 480 min)  331.65± 222.34 340.16± 206.45 0.99 
rs1160985 
 CC T allele  
TC (mmol/l) 5.65± 0.97 5.63± 1.00 0.76 
TAG (mmol/l) 1.39± 0.62 1.58± 0.76 0.33 
HDL-C (mmol/l) 1.45± 0.51 1.31± 0.38 0.18 
LDL-C (mmol/l) 3.56± 1.03 3.60± 0.95 0.94 
TAG AUC (mmol/l × 480 min) 1052.45± 532.46 1125.55± 484.90 0.97 
TAG IAUC (mmol/l × 480 min)  312.56± 223.84 346.91± 210.43 0.67 
rs1064725 
 TT G allele  
TC (mmol/l) 5.69± 0.98 5.17± 1.00 0.35 
TAG (mmol/l) 1.59± 0.76 1.24± 0.54 0.49 
HDL-C (mmol/l) 1.33± 0.43 1.50± 0.32 0.64 
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LDL-C (mmol/l) 3.65± 0.97 3.17± 0.89 0.58 
TAG AUC (mmol/l × 480 min) 1126.06± 501.45 906.14± 455.51 0.51 
TAG IAUC (mmol/l × 480 min)  341.57± 217.13 288.72± 203.65 0.82 
 
Abbreviations: TC, total cholesterol; TAG, triacylglycerol; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol; AUC, area under the curve; IAUC, 
incremental area under the curve. P values were obtained by using a general linear model 
adjusted for age, sex, BMI.  
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8.4 Appendix D: Association of the APOE and LPL SNPs with triacylglycerol in the 
Caerphilly prospective study 
SNP Triacylglycerol (mmol/L) 
LPL  
rs320  
TT 1.82± 0.90  
T/G 1.74± 0.89  
P 0.055 
rs328  
CC 1.82± 0.91  




GG 1.77± 0.91  
GT 1.82± 0.91  
TT 1.71± 0.87  
P 0.47 
rs769450  
GG 1.77± 0.93 
A allele  1.79± 0.88 
P  0.73 
rs439401  
CC 1.82± 0.89  
T allele 1.76± 0.90  
P 0.11 
rs445925  
GG 1.76± 0.86  
A allele 1.86± 1.01  
P 0.043 
rs405697  
GG 1.80± 0.90  
A allele  1.77± 0.89  
P 0.64 
rs1160985  
CC 1.73± 0.87  
CT 1.82± 0.91  
TT 1.77± 0.91  
 0.40 
rs1064725  
TT 1.79± 0.91 
G allele  1.53± 0.65 
P 0.09 
(rs7412- rs429358) E2, E3, and E4 
E3 1.79± 0.85  
E4 1.82± 0.90  
E2 1.88± 0.99  
P 0.025 
Values are given as mean ± SD. P values for differences between genotypes were obtained 
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using linear regression model adjusted for age, and BMI. Adjusted P value after correction 
for multiple testing was 0.001. MAF; minor allele frequency.  
 
8.5 Appendix E: Interaction between APOE and LPL SNPs and dietary factors on 
triacylglycerol in the Caerphilly prospective study 
Interaction between rs320 at LPL*dietary factors on Triacylglycerol 
Interaction between SNP 
rs320* fat energy % intake 
Interaction between SNP 
rs320* protein energy % 
intake 
Interaction between SNP 








Interaction between rs328 at LPL *dietary factors on Triacylglycerol 
Interaction between SNP 
rs328* fat energy % intake 
Interaction between SNP 
rs328* protein energy % 
intake 
Interaction between SNP 








Interaction between rs405509 at APOE *dietary factors on Triacylglycerol 
Interaction between SNP 
rs405509* fat energy % 
intake 
Interaction between SNP 
rs405509* protein energy % 
intake 
Interaction between SNP 
rs405509* carbohydrate 







Interaction between rs769450 at APOE *dietary factors on Triacylglycerol 
Interaction between SNP 
rs769450* fat energy % 
intake 
Interaction between SNP 
rs769450* protein energy % 
intake 
Interaction between SNP 
rs769450* carbohydrate 







Interaction between rs439401 at APOE *dietary factors on Triacylglycerol 
Interaction between SNP 
rs439401* fat energy % 
intake 
Interaction between SNP 
rs439401* protein energy % 
intake 
Interaction between SNP 
rs439401* carbohydrate 







Interaction between rs445925 at APOE *dietary factors on Triacylglycerol 
Interaction between SNP 
rs445925* fat energy % 
intake 
Interaction between SNP 
rs445925* protein energy % 
intake 
Interaction between SNP 
rs445925* carbohydrate 







Interaction between rs405697 at APOE *dietary factors on Triacylglycerol 
Interaction between SNP 
rs405697* fat energy % 
intake 
Interaction between SNP 
rs405697* protein energy % 
intake 
Interaction between SNP 
rs405697* carbohydrate 







Interaction between rs1160985 at APOE *dietary factors on Triacylglycerol 
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Interaction between SNP 
rs1160985* fat energy % 
intake 
Interaction between SNP 
rs1160985* protein energy 
% intake 
Interaction between SNP 
rs1160985* carbohydrate 







Interaction between rs1064725 at APOE *dietary factors on Triacylglycerol 
Interaction between SNP 
rs1064725* fat energy % 
intake 
Interaction between SNP 
rs1064725* protein energy 
% intake 
Interaction between SNP 
rs1064725* carbohydrate 







Interaction between APOE (E2,E3, and E4)*dietary factors on Triacylglycerol 
Interaction between SNP 
APOE (E2, E3, and E4)* fat 
energy % intake 
Interaction between SNP 
APOE (E2, E3, and E4)* 
protein energy % intake 
Interaction between SNP 
APOE (E2, E3, and E4)* 








Values represented β regression coefficients (± S.E), and Pinteraction. P values were obtained by 
using a general linear model adjusted for age, sex, BMI, country and total calorie whenever 
appropriate. 
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8.6 Appendix F: Genotype, and major and minor allele frequencies of the SNPs at LPL and APOE genes of all SNPs studied in various 













Chi square  Hardy 
Weinberg 
Equilibrium 
 P value 
Postprandial study  
rs320 131 (0.56) 100 (0.43) 0 0.78 0.22 2.69 0.10 
rs328 213 (0.81) 48 (0.18) 0 0.91 0.09 2.67 0.10 
CURES 
rs4922115 864 (0.68) 347 (0.27) 50 (0.39) 0.82 0.17 4.02 0.05 
rs1121923 1147 (0.87) 157 (0.12) 7 (0.005) 0.93 0.06 0.4 0.52 
rs328 877 (0.72) 303 (0.25) 24 (0.02) 0.85 0.14 0.13 0.71 
rs285 758 (0.41) 845(0.45) 252 (0.13) 0.63 0.36 0.45 0.50 
PRESICE study  
rs320 354 (0.53) 271 (0.40) 39 (0.05) 0.74 0.26 1.8 0.17 
rs328 522 (0.80) 127 (0.19) 3 (0.005) 0.89 0.10 2.6 0.11 
rs405509 183 (27.6%) 330 (49.8%) 149 (22.5%) 0.52 0.47 0.0001 0.99 
rs769450 228 (34.5%) 339 (51.4%) 92 (13.8%) 0.60 0.39 3.66 0.06 
rs439401 291 (44.2%) 290 (44.1%) 76 (11.5%) 0.66 0.33 0.08 0.77 
rs445925 506 (77.3%) 142 (21.7%) 6 (0.9%) 0.88 0.11 1.33 0.24 
rs405697 365 (54.9%) 257 (38.7%) 42 (6.3%) 0.74 0.25 0.13 0.71 
rs1160985 200 (30.2%) 344 (52%) 117 (17.7%) 0.56 0.43 2.18 0.13 
rs1064725 606 (91.4%) 56 (8.4%) 1 (0.1%) 0.95 0.04 0.06 0.81 
Caerphilly prospective study  
rs320 721 (0.53)  536 (0.39)  86 (0.06) 0.73 0.26 1.05 0.31 
rs328 1068 (0.79)  266 (0.19) 9 (0.006) 0.89 0.10 3.01 0.08 
rs405509 381 (0.28) 675 (0.50)  287 (0.21) 0.53 0.46 0.13 0.71 
rs769450 452(0.33) 672(0.50) 219(0.16) 0.58 0.41 1.35 0.24 
rs439401 560 (0.41) 615 (0.45)  168 (0.12) 0.64 0.35 0.0018 0.96 
rs445925 1056 (0.78)  271 (0.20) 16 (0.01) 0.88 0.11 0.08 0.77 
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rs405697 728 (0.54) 513 (0.38) 102 (0.07) 0.73 0.26 0.77 0.38 
rs1160985 394 (0.29)  688 (0.51)  261 (0.19) 0.54 0.45 1.61 0.20 
rs1064725 1076 (0.96) 35 (0.03) 0  0.98 0.01 0.28 0.59 
DIVAS study 
rs320 57 (0.46) 57 (0.46) 9 (0.07) 0.69 0.30 1.07 0.30 
rs328 93 (0.75) 30 (0.24) 1 (0.008) 0.87 0.12 0.72 0.39 
rs405509 31 (0.25) 65 (0.52) 28 (0.22) 0.51 0.48 0.29 0.59 
rs769450 47 (0.37) 62 (0.5) 15 (0.12) 0.62 0.37 0.63 0.42 
rs439401 50 (0.40) 53 (0.43) 19 (0.15) 0.62 0.37 0.61 0.43 
rs445925 95 (0.78) 25 (0.20) 1 (0.008) 0.88 0.11 0.21 0.64 
rs405697 71 (0.57) 38 (0.30) 14 (0.11) 0.73 0.26 5.58 0.01 
rs1160985 36 (0.29) 65 (0.52) 23 (0.18) 0.55 0.44 0.44 0.51 
rs1064725 111 (0.89) 13 (0.05) 0 0.94 0.05 0.37 0.54 
Vitamin D study  
rs320 11 (0.61) 6 (0.33) 1 (0.05) 0.77 0.22 0.02 0.88 
rs328 18     NS  
rs405509 9 (0.5) 5 (0.27) 4 (0.22) 0.63 0.36 0.014 0.91 
rs769450 5 (0.27) 11 (0.61) 2 (0.11) 0.58 0.41 1.19 0.27 
rs439401 6 (0.33) 9 (0.5) 3 (0.16) 0.58 0.41 2.85 0.09 
rs445925 14 (0.77) 4 (0.22) 0 0.88 0.11 0.28 0.59 
rs405697 3 (0.16) 11 (0.61) 4 (0.22) 0.47 0.52 0.23 0.63 
rs1160985 12(0.66) 5 (0.27) 1 (0.05) 0.80 0.19 0.91 0.34 
rs1064725 17 (0.94) 0 0   NS  
rs12785878  3 (0.16) 6 (0.33) 9 (0.5) 0.33 0.66 1.12 0.28 
rs6013897 13 (0.72) 3 (0.16) 2 (0.11) 0.80 0.19 3.94 0.05 
rs2282679 10 (0.58) 7 (0.41) 0 0.79 0.20 1.14 0.28 
rs12794714 7 (0.38) 9 (0.5) 2 (0.11) 0.63 0.36 0.12 0.72 
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Abstract
Recent evidence suggests that lifestyle factors influence the association between the Mela-
nocortin 4 receptor (MC4R) and Transcription Factor 7-Like 2 (TCF7L2) gene variants and
cardio-metabolic traits in several populations; however, the available research is limited
among the Asian Indian population. Hence, the present study examined whether the associ-
ation between the MC4R single nucleotide polymorphism (SNP) (rs17782313) and two
SNPs of the TCF7L2 gene (rs12255372 and rs7903146) and cardio-metabolic traits is modi-
fied by dietary factors and physical activity. This cross sectional study included a random
sample of normal glucose tolerant (NGT) (n = 821) and participants with type 2 diabetes
(T2D) (n = 861) recruited from the urban part of the Chennai Urban Rural Epidemiology
Study (CURES). A validated food frequency questionnaire (FFQ) was used for dietary
assessment and self-reported physical activity measures were collected. The threshold for
significance was set at P = 0.00023 based on Bonferroni correction for multiple testing [(0.05/
210 (3 SNPs x 14 outcomes x 5 lifestyle factors)]. After Bonferroni correction, there was a sig-
nificant interaction between the TCF7L2 rs12255372 SNP and fat intake (g/day) (Pinteraction =
0.0001) on high-density lipoprotein cholesterol (HDL-C), where the ‘T’ allele carriers in the
lowest tertile of total fat intake had higher HDL-C (P = 0.008) and those in the highest tertile
(P = 0.017) had lower HDL-C compared to the GG homozygotes. In a secondary analysis of
SNPs with the subtypes of fat, there was also a significant interaction between the SNP
rs12255372 and polyunsaturated fatty acids (PUFA, g/day) (Pinteraction <0.0001) on HDL-C,
where the minor allele carriers had higher HDL-C in the lowest PUFA tertile (P = 0.024) and
those in the highest PUFA tertile had lower HDL-C (P = 0.028) than GG homozygotes. In addi-
tion, a significant interaction was also seen between TCF7L2 SNP rs12255372 and fibre intake
(g/day) on HDL-C (Pinteraction<0.0001). None of the other interactions between the SNPs and
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lifestyle factors were statistically significant after correction for multiple testing. Our findings indi-
cate that the association between TCF7L2 SNP rs12255372 and HDL-C may be modified by die-
tary fat intake in this Asian Indian population.
Introduction
Genetic variants, unhealthy dietary intake, physical inactivity and their multiple interactions
are considered to be contributory factors to the development of obesity and type 2 diabetes
(T2D) [1–3]. After China, India has the highest number of people with T2D in the world and
according to the Indian Council of Medical Research–INdia DIABetes (ICMR–INDIAB)
study, T2D cases have reached 62.4 million and 77.2 million people are pre-diabetic [4]. Fur-
thermore, obesity and T2D are risk factors for non-communicable diseases (NCDs) such as
cardiovascular disease (CVD) and it is estimated that India will have the highest rate of CVD
mortality in the world [5]. Asian Indians have different biochemical characteristics from other
populations from birth, often referred to as the ‘Asian Indian Phenotype’ which consists of
increased visceral fat and waist circumference, hyperinsulinemia and insulin resistance [6].
The association between several genes and metabolic diseases has been identified by the
candidate gene approach and genome-wide scans; to date, besides the FTO (Fat mass and obe-
sity associated) gene, the strongest obesity risk loci known so far [1, 3, 7, 8], two commonly
studied candidates for obesity and T2D have been the Melanocortin 4 Receptor (MC4R) and
Transcription Factor 7-Like 2 (TCF7L2) genes. Strong association between the MC4R gene
and risk of obesity was identified by a genome-wide association (GWAS) study [9] whereas the
association between the Transcription Factor 7-Like 2 (TCF7L2) gene and risk of T2D was
identified by a genome wide linkage study [10]. MC4R is expressed in the hypothalamus within
the brain and therefore it is suggested that it contributes to body weight regulation by its effect
on food intake and energy homeostasis [11]. A strong association was identified between
MC4R rs17782313 genetic variant and risk of obesity in a European population [12] which was
then replicated in other populations [13–15], including Asian Indians [16]. The TCF7L2 gene
is involved in the Wnt signalling pathway where it affects the expression of pro-glucagon and
consequently blood glucose regulation [10]. In addition, the effect of pro-glucagon on Gluca-
gon-like peptide 1 (GLP-1) also influences blood glucose regulation with insulin [17].
Decreased insulin secretion and increased glucose production in the liver is suggested to be
the result of over expression of the TCF7L2 gene [18]. A couple of studies [19, 20] have shown
strong associations between the two TCF7L2 single nucleotide polymorphisms (SNPs)
(rs7903146, rs12255372) and risk of T2D among Asian Indians living in India, in addition to a
meta-analysis [17].
In recent years, several studies have examined whether the association between the genetic
variants of MC4R and TCF7L2 genes and cardio-metabolic traits is modified by lifestyle factors
such as diet and physical activity in various populations [21–25], however there are no studies
to date among Asian Indians [26]. Whilst most studies in European populations found no sig-
nificant interactions between the MC4R SNP rs17782313 and dietary factors on obesity traits
[11, 22, 23], a prospective cohort study reported significant interactions between the SNP and
fat and protein intake on body mass index (BMI) and risk of T2D [27]. Similarly some studies
identified significant interactions between TCF7L2 SNPs and fibre and fat intake on T2D[28–
30]; however there were discrepancies between the studies which could be due to differences
in sample size, study design, dietary assessment and genetic heterogeneity. The objectives of
TCF7L2 polymorphism interacts with dietary fat intake on HDL cholesterol
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this paper were to determine whether the MC4R SNP rs17782313 and TCF7L2 SNPs
(rs7903146, rs12255372) were associated with cardio-metabolic traits and whether the associa-
tion was modified by diet and physical activity in a sample size of up to 1,682 adults from the
Chennai Urban Rural Epidemiology Study (CURES).
Materials and methods
Study participants
A random, unrelated sample of normal glucose tolerant (NGT) (n = 821) and T2D (n = 861)
participants were recruited from the urban part of the cross sectional Chennai Urban Rural
Epidemiology Study (CURES) which included 26,001 individuals in total as a representative
sample of Chennai city. Full details of the methodology have been explained previously [31].
Briefly 26,001 adult subjects (>20 years of age) were recruited in Phase 1 of CURES using a
systematic random sampling method covering the whole Chennai city. This included 1,529
‘self-reported’ diabetic subjects. In Phase 2, all self-reported or ‘known diabetic’ subjects were
invited to our centre for detailed studies of whom 1382 responded (response rate: 90.4%). In
Phase 3, every tenth subject from Phase 1, excluding those with self-reported diabetes, under-
went an oral glucose tolerance test (OGTT). Subjects who had fasting plasma glucose<5.6
mmol/l (100mg/dl) and 2 hr plasma glucose value 7.8 mmol/l (140mg/dl) were categorized as
having NGT [32]. Those who were confirmed by OGTT to have 2 hr plasma glucose value 11.1
mmol/l (200 mg/dl) were classed as ‘newly detected diabetic subjects’ (n = 222).For the present
study, the NGT subjects were selected from Phase 3 and subjects with T2D which included
‘known diabetic’ and ‘newly detected diabetic’ subjects were selected from Phase 2 and Phase 3
of the Chennai Urban Rural Epidemiology Study. The Madras Diabetes Research Foundation
Institutional Ethics Committee granted the ethical approval and informed consent was
obtained from the study participants.
Anthropometric and biochemical measurements
Weight, height and waist circumference were measured by standard methods. The BMI calcu-
lation was based on the body weight (kg) divided by the square of body height (m). Roche
Diagnostics (Mannheim) provided the equipments in order to be able to carry out the bio-
chemical analyses on a Hitachi-912 Auto Analyzer (Hitachi, Mannheim, Germany)(8). Fasting
plasma glucose, serum cholesterol, serum triglycerides (TG) and high-density lipoprotein cho-
lesterol were measured by glucose oxidase-peroxidase, cholesterol oxidase-phenol-4-amino-
antipyrene peroxidase, glycerol phosphatase oxidase-phenol-4-amino-antipyrene peroxidise
and polyethylene glycol-pretreated enzyme methods respectively(8). The Friedewald formula
was used to estimate low-density lipoprotein cholesterol concentrations [33]. Glycated haemo-
globin (HbA1c) and serum insulin were determined by high-performance liquid chromatogra-
phy (HPLC) on a Variant instrument (Bio-Rad, Hercules, CA, USA) and an enzyme-linked
immunosorbent assay (Dako, Glostrup, Denmark) respectively [8].
Assessment of dietary intake and physical activity
A validated, interviewer administered semi-quantitative food frequency questionnaire (FFQ)
[34] consisting of a list of 222 different foods was used in order to evaluate dietary intake for
the previous year including macronutrient and total energy intake. Frequencies (per day,
week, month, year, never) and portion sizes were estimated by the participants with the help of
visual aids of measurement equipments and food sizes. Daily average food and nutrient intake
was calculated by the EpiNu database system.
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A validated self-report questionnaire was used to measure physical activity [5]. Individuals
were divided into the vigorously active group when they both exercised and engaged in
demanding work activities whereas within the moderately active group the participants either
exercised or carried out heavy physical work. The remainder of the study participants were
separated into the sedentary group.
SNP selection and genotyping
A strong association was identified between MC4R rs17782313 genetic variant and risk of obe-
sity in a European population [12] which was then replicated in other populations (13–15),
including Asian Indians [16]. Strong associations have also been found between TCF7L2 SNPs
(rs12255372 and rs7903146) and risk of T2D in a meta-analysis [17] in the Japanese population
[35] as well as in Asian Indians [19, 20]. Although the TCF7L2 SNPs (rs12255372 and rs7903
146) have showed significant linkage disequilibrium (r2 = 0.746), the rs7903146 variant has
been shown to have the strongest effect in Caucasian populations [36, 37]. Based on the previ-
ous studies, the above mentioned three SNPs were selected for the present study.
Phenol-chloroform method was used to extract DNA from whole blood. The methodology
for genotyping TCF7L2 rs12255372 (G/T) and rs7903146 (C/T) SNPs has been previously pub-
lished [20]. Direct sequencing by an ABI 310 genetic analyzer (Applied Biosystems, Foster
City, CA) helped to confirm the efficiency of the genotyping which was in 99% concordance
based on random duplicates of 20% of the samples [20].
MC4R rs17782313 (T/C) SNP: PCR volume (10 μl) consisted of 1X reaction buffer, 200
mmol of dNTP, 1.5 mmol of MgCl2, 1 U taq DNA polymerase and 100 ng of genomic DNA.
The concentrations for primers included 15 pmol of common primer, 15 pmol of allele 1
primer and 1 pmol of allele 2 primer, equal to a 15:1 ratio of short primers to long primer.
Cycles for PCR were carried out at 96˚C for 12 min, then 35 cycles at 94˚C for 30 sec, followed
by 30 sec at 57˚C, 30 sec at 72˚C and finally for 10 min at 72˚C. Electrophoresis was carried
out with a 3% agarose gel.
Inner primers
F: AAGTTTAAAGCAGGAGAGATTGTATACC (C allele 222bp)





Statistical analyses were carried out by using SPSS software (version 21). BMI  25 kg/m2 was
categorised as obese and BMI< 25 kg/m2 as non-obese. Descriptive statistics for continuous
variables are shown as means and standard deviation (SD). Fasting serum insulin and triglyc-
eride values were log transformed to obtain normal distribution. Genotype frequencies
between cases and controls were compared by Chi Square test. The difference in the means of
continuous variables between the genotypes was analysed by independent sample t test. Based
on an additive model of analysis, dominant models were used for all 3 single nucleotide poly-
morphisms (SNPs) where the common homozygous allele was compared to the combined het-
erozygous and rare homozygous alleles due to the low allele frequency of rare homozygotes.
Association analyses between SNPs and continuous and categorical variables were carried out
by linear and logistic regression models, respectively, adjusting for age, gender with the addi-
tion of BMI, when T2D was the outcome, and, adjusting for T2D, when obesity was the out-
come. Linear and logistic regression models were also used for interaction analyses between
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SNPs and dietary factors (continuous variables) / physical activity (categorical variable) on
continuous and categorical outcomes respectively, where the interaction terms were included
into the models and were adjusted for age, gender, BMI, T2D and total energy intake when
appropriate. Bonferroni correction for multiple testing was calculated by multiplying 3 SNPs
with 14 outcomes (T2D, obesity, BMI, waist circumference, fasting blood glucose, HbA1c, fast-
ing insulin, systolic and diastolic blood pressure, HDL, LDL, VLDL, TG and total cholesterol)
and 4 dietary factors (carbohydrate, protein, fat, fibre) and physical activity level. The P value
of 0.05 was then divided by 210 (3 SNPs x 14 outcomes x 5 lifestyle factors) which set the sig-
nificant p value for all results at P = 0.00023.
As a secondary analysis, given the significant SNP-fat intake interaction, individuals were
grouped into tertiles based on the fatty acid subtypes [monounsaturated (MUFA) and polyun-
saturated (PUFA) fatty acids] for testing the interaction between SNPs and these fatty acid sub-
types on lipids. In addition, PUFA was further stratified into ALA (alpha linolenic acid) and
LA (linoleic acid) for the interaction analysis.
Given that there are no previously reported effect sizes for the gene-diet interaction, we
were unable to perform a prospective power calculation. However, based on the most signifi-
cant interaction observed in the present study, we performed retrospective power calculations
using QUANTO software, Version 1.2.4 (May 2009). We performed power calculations in the
form of least detectable effects based on the assumption of significance levels and powers of 5
and 80%, respectively. At 80% power, the minimum detectable effects ranged from beta 0.02
mg/dl (HDL-C) for a SNP with MAF of 5% to beta 1.0 mg/dl for a SNP with MAF 50% in the
case-control analysis. For the TCF7L2 SNP–fat intake interaction on HDL-C (most significant




Based on the clinical and biochemical characteristics of the individuals from the CURES
study as illustrated in Table 1, individuals with T2D were older (P<0.0001), had higher
BMI (P<0.0001), waist circumference (P<0.0001), fasting plasma glucose (P<0.0001),
HbA1c (P<0.0001), fasting plasma insulin (P<0.0001), systolic and diastolic blood pressure
(P<0.0001), low density and very low density lipoproteins (P<0.0001), total cholesterol
(P<0.0001), TG (P<0.0001) and lower high density lipoprotein (P = 0.001) than NGT
individuals.
Genetic associations
The minor allele (‘T’) of SNPs (rs12255372 and rs7903146) of TCF7L2 gene showed significant
susceptibility to T2D; however, in the present study after correction for multiple testing only
the association between SNP rs7903146 and T2D remained statistically significant (P = 0.0001)
(S1 Table).After Bonferroni correction, statistically significant association between the ‘C’
allele of theMC4R SNP rs17782313 and T2D was also observed (P = 0.00022) (S2 Table). None
of the associations between the three SNPs and continuous variables remained significant after
correction for multiple testing (P>0.00023) (S1 and S2 Tables).
TCF7L2 –dietary fat intake interactions on HDL-C
Individuals were grouped into tertiles based on their fat and subtypes of fat intake (g/day). The
means for fat intake in the 1st tertile: 41 g/d; 2nd tertile: 62 g/d; 3rd tertile: 95 g/d. Means for
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PUFA intake in the 1st tertile: 9g/d; 2nd tertile: 17 g/d; 3rd tertile: 29 g/d. Means for MUFA
intake in the 1st tertile: 12 g/d; 2nd tertile: 18 g/d; 3rd tertile: 29 g/d. Means for ALA intake in
the 1st tertile: 0.38 g/d; 2nd tertile: 0.58 g/d; 3rd tertile: 0.89 g/d. Means for LA intake in the 1st
tertile: 8 g/d; 2nd tertile: 17 g/d; 3rd tertile: 29 g/d.
The interaction between the TCF7L2 SNP rs12255372 and fat intake (g/day) on HDL-C was
statistically significant after correction for multiple testing (Pinteraction = 0.0001). The ‘T’ allele
carriers of the TCF7L2 SNP rs12255372 had 2.26 mg/dl higher HDL-C level in the lowest tertile
of fat intake (mean: 41 g/day) than the ‘GG’ homozygotes (P = 0.008) and in the highest tertile
of fat intake (mean: 95 g/day), HDL-C was 1.87 mg/dl lower in the risk ‘T’ allele carriers in
comparison to the ‘GG’ homozygotes (p = 0.017) (Fig 1).
Stratification to fat subgroups showed significant interactions between the SNP rs12255372
and PUFA (g/day) on HDL-C (Pinteraction<0.0001), where the ‘T’ allele carriers had 1.96 mg/dl
higher HDL-C (P = 0.024) in the low PUFA tertile (mean: 9 g/day) in comparison to the ‘GG’
homozygotes and in the 3rd tertile (mean: 29 g/day), the HDL-C level of the ‘T’ allele carriers
was 1.64 mg/dl lower than the ‘GG’ homozygotes (P = 0.028) (Fig 1). A similar interaction was
also found between the SNP rs12255372 and MUFA (g/day) on HDL-C (Pinteraction = 0.0003),
Table 1. Anthropometric and biochemical characteristics of T2D and NGT participants.
NGT T2D P value*
N 821 861
(men/women) (345/476) (398/463) 0.08
Age (yrs) 41.31±11.73 50.57±10.49 <0.0001
BMI (kg/m2) 23.66±4.69 25.34±4.30 <0.0001
WC (cm) 83.55±11.66 90.60±9.84 <0.0001
FPG (mg/dl) 84.82±8.36 161.73±69.13 <0.0001
HbA1c (%) 5.58±0.48 8.78±2.36 <0.0001
INS (μIU/ml) 8.41±5.81 11.78±7.69 <0.0001
Log INS (μIU/ml) 6.85±1.87 9.68±1.90 <0.0001
Systolic BP (mmHg) 117.72±18.05 129.16±21.65 <0.0001
Diastolic BP (mmHg) 74.06±11.32 76.76±11.85 <0.0001
HDL (mg/dl) 43.36±9.91 41.71±9.50 0.001
LDL (mg/dl) 113.13±30.55 124.49±35.38 <0.0001
VLDL (mg/dl) 23.95±14.30 35.96±27.37 <0.0001
TC (mg/dl) 180.02±36.02 199.51±42.40 <0.0001
TG (mg/dl) 120.18±71.46 180.31±137.12 <0.0001
Log TG (mg/dl) 105.68±1.62 152.75±1.71 <0.0001
Total energy (Kcal/day) 2622.43±702.77 2468±893.75 <0.0001
Total Carbohydrate (g) 419.69±112.33 399.96±147.98 0.002
Fat (g) 68.57±24.29 64.25±27.31 0.001
Total PUFA (g) 18.22±9.09 18.75±10.04 0.25
Total MUFA (g) 20.51±7.77 18.79±8.37 <0.0001
Protein (g) 73.82±20.97 69.93±24.56 0.001
Dietary fibre (g) 31.41±9.83 31.66±12.19 0.64
Data presented as Mean±SD.
*P values are showing the differences in mean values between NGT and T2D participants.
Abbreviations: NGT, normal glucose tolerance; BMI, Body mass index; WC, waist circumference; HbA1C, glycated haemoglobin; FPG, Fasting plasma
glucose; INS, Fasting plasma insulin; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; TC, Total Cholesterol;
TG, triglycerides.
https://doi.org/10.1371/journal.pone.0188382.t001
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where the ‘T’ allele carriers had 1.77 (mg/dl) higher HDL-C in the lowest MUFA tertile (mean:
12 g/day) (P = 0.03) and had 1.61 (mg/dl) higher HDL-C in the 2nd tertile (mean: 18 g/day)
(P = 0.045) than the ‘GG’ carriers, however in the highest MUFA tertile (mean: 29 g/day) the
‘T’ allele carriers had 1.59 (mg/dl) decreased HDL-C (P = 0.041) than individuals with the
‘GG’ genotype.
PUFA was further stratified to linoleic acid (LA) and alpha linolenic acid (ALA) to investi-
gate whether omega-3 and omega-6 fatty acids modified the association between the TCF7L2
SNP rs12255372 and HDL-C. Significant interaction was found between the SNP and ALA
on HDL-C (Pinteraction = 0.012), where the ‘T’ allele carriers had 2.42 (mg/dl) higher HDL-C
than the ‘GG’ homozygotes (P = 0.004) in the lowest tertile (mean: 0.38 g/day) (Fig 1).A
similar interaction was also found between the SNP rs12255372 and LA (g/day) on HDL-C
(Pinteraction<0.0001). S1 Table shows the interactions of TCF7L2 SNP rs12255372 with fat,
PUFA and ALA intakes on HDL-C under an additive and dominant model.
Additional gene-diet interactions
In addition to the main significant findings, there was a significant interaction between TCF7L2
SNP rs12255372 and fibre intake (g/day) on HDL-C (Pinteraction< 0.0001), where in the lowest
tertile (mean: 20 g/day) individuals carrying the ‘T’ allele had 1.95 (mg/dl) higher HDL-C
(P = 0.02), in the 2nd tertile (mean: 30 g/day), the ‘T’ allele carriers had 2.39 (mg/dl) higher
HDL-C (P = 0.003) and in the highest tertile (mean: 44 g/day), the HDL-C level of the ‘T’ allele
carriers was 2.37 mg/dl lower in comparison to the ‘GG’ homozygotes (P = 0.002). There were
several other interactions which did not reach statistical significance after correction for multi-
ple testing and these interactions are shown in the Table 2 and S2 and S3 Tables).
Gene-physical activity interactions on cardio-metabolic traits
No statistically significant interactions were observed after correction for multiple testing between
the three SNPs and physical activity on obesity- and T2D- related traits (Pinteraction>0.0002).
Fig 1. Interaction of the TCF7L2 gene polymorphism (rs12255372) with fat (g) intake, PUFA intake and
Alpha Linolenic Acid (g) intake on HDL-C. Individuals carrying the ‘XT’ genotype had 2.26 mg/dl higher
HDL-C in the lowest fat tertile (P = 0.008), while those in the highest tertile had 1.87 mg/dl lower HDL-C
(P = 0.017) than those who carry the ‘GG’ allele. Carriers of the ‘XT’ genotype had 1.96 mg/dl higher HDL-C in
the 1st tertile of PUFA intake (g) (P = 0.024), while those in the 3rd tertile had 1.64 mg/dl lower HDL-C in
comparison to the carriers of the ‘GG’ genotype (P = 0.028). In the 1st tertile of Alpha Linolenic acid intake (g),
individuals with the ‘XT’ genotype had 2.42 mg/dl higher HDL-C than the ‘GG’ homozygotes (P = 0.004).
https://doi.org/10.1371/journal.pone.0188382.g001
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Interactions observed between TCF7L2SNP rs7903146 and physical activity on VLDL (Pinteraction =
0.012) and TG (Pinteraction = 0.014), where the risk ‘T’ allele carriers had higher TG and VLDL levels,
did not reach statistical significance after correction for multiple testing (S4 Table).
Discussion
This is the first study to investigate interactions between TCF7L2 and MC4R SNPs and lifestyle
factors on cardio-metabolic traits among Asian Indians. The main findings suggest that total
fat and PUFA intakes may modify the association between the TCF7L2 SNP rs12255372 and
HDL-C. In the lowest total fat and PUFA tertiles, participants carrying the ‘XT’ genotype (GT
+TT) had significantly higher HDL-C, whereas in the highest tertile participants carrying the
‘XT’ genotype had lower HDL-C, as compared to those with the GG genotype. This finding is
of public health significance given that Asian Indians tend to have low HDL-C which puts
them at markedly increased risk for CVD [38, 39].
The fat intake consists of invisible, hidden and visible fat (vegetable oils, ghee, butter) in
India where in the urban areas the minimum average daily intake of visible fat is approxi-
mately 22–45 g/day [40]. The recommended omega 3 PUFA intake is 0.1 gram/day, however
the median of combined intake of LA and ALA is 13 g/day and the recommended ratio
between LA and ALA is 5:1 to 10:1 [40]. In comparison, the results of our study suggest that
total fat intake below 53 g/day, PUFA intake below 13 g/day, and ALA intake below 0.49 g/day
may help maintain high levels of HDL-C in the ‘T’ allele carriers of the TCF7L2 SNP rs1225
5372. The findings that MUFA intake above 22 g/day reduces HDL-C and only ALA intake
below 0.5 g/day maintains high HDL-C level in risk carriers are unexpected results; however,
the effect of polygenic traits cannot be ruled out.
HDL-C is generally considered to be protective against CVD due to its role in the reverse
cholesterol transport; however, the recent Mendelian randomization (MR) studies [41, 42]
have failed to show a causal effect of low HDL-C on cardiovascular disease risk. But, none of
these MR studies have taken dietary factors into account. Furthermore, fatty acids have shown
to have different modulating effect on HDL-C for which the mechanism is not fully under-
stood [43]. On the other hand, it is argued that the total fat intake is more influential on post-
prandial lipoprotein abnormalities, which is a characteristic of T2D, than the type of fatty
acids [44]. However, studies have also shown that different fatty acids can have differential
effects on postprandial TG [45–47]. In our study, we found that those in the lowest fat intake
Table 2. Interactions of TCF7L2 SNPs rs12255372 and rs7903146 with carbohydrate, fibre and protein intake on HDL-C, fasting blood glucose and
diastolic blood pressure.
rs12255372 SNP*Carbohydrate (g) SNP*Fibre (g) SNP*Protein (g) SNP*Fat (g)
β ± SE** (P for interaction on FPG) 0.039 ± 0.019 (0.041) 0.437 ± 0.222 (0.049) 0.132 ± 0.108 (0.222) 0.119 ± 0.095 (0.210)
β ± SE** (P for interaction on HDL-C) 0.009 ± 0.003 (0.007) 0.168 ± 0.041 (<0.0001) 0.072 ± 0.020 (0.0003) 0.067 ± 0.017 (0.00017)
β ± SE** (P for interaction on DBP) -0.003 ± 0.004 (0.551) -0.107 ± 0.050 (0.033) -0.028 ± 0.024 (0.251) -0.032 ± 0.021 (0.130)
rs7903146 SNP*Carbohydrate (g) SNP*Fibre (g) SNP*Protein (g) SNP*Fat (g)
β ± SE** (P¥ for interaction on T2D) 0.002 ± 0.001 (0.011) 0.014 ± 0.010 (0.180) 0.011 ± 0.005 (0.024) 0.008 ± 0.004 (0.071)
β ± SE** (P for interaction on HDL-C) 0.006 ± 0.003 (0.057) 0.128 ± 0.040 (0.002) 0.050 ± 0.020 (0.010) 0.052 ± 0.017 (0.003)
*Interaction term
**P values are adjusted for age, gender, BMI, T2D and Total energy intake.
¥ P values are adjusted for age, gender, BMI and Total energy intake.
Abbreviations: SNP, Single nucleotide polymorphism; HDL-C, High density lipoprotein cholesterol; FPG, Fasting plasma glucose; DBP, Diastolic blood
pressure.
https://doi.org/10.1371/journal.pone.0188382.t002
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subgroups had higher HDL-C while those in the highest tertile groups had lower HDL-C
among the risk allele carriers. A previous intervention study in the US population [30] also
found significant interaction between SNP rs12255372 and fat intake where positive changes
in body composition were observed in the ‘T’ risk allele carriers only on the low-fat diet (20%
from total energy). Other studies only reported significant interactions between SNP
rs7903146 and high saturated fat intake on increased metabolic syndrome risk [29] and high
(n-6) PUFA intake ( 6.62% of energy intake) on increased VLDL and TG [24] among the risk
‘T’ allele carriers.
High omega 6 to omega 3 ratio has been shown to increase HDL in mice [43], whereas the
results from this study in humans contradict those findings. It has been shown in cell and ani-
mal studies that high omega 6 PUFA intake is pro-inflammatory leading to an increased risk
for CVD and diabetes [48] and in the present study reduced HDL was observed in the minor
allele carriers in response to high intake of omega 6 PUFA (>21.6 g/d). According to our find-
ings, a low omega 6 (<12.8 g/d) and a low ALA intake (<0.5 g/d) may help maintain HDL
above 44 (mg/dl) in the risk allele carriers.
Though there was no significant difference in mean HDL levels in the different tertiles of
total fat and PUFA intakes in the study participants (data not shown), in the presence of
TCF7L2 rs12255372 genotype, a clear interaction between the genotype and fat/ PUFA intake
on HDL-C was observed. While the carriers of ‘XT’ genotype had increased HDL-C in the
presence of a low fat/ low PUFA diet, there was a decrease in HDL-C levels in the carriers of
‘XT’ genotype in the presence of a high fat / high PUFA diet. It is to be noted that among those
who carry the GG genotype, irrespective of the dietary fat/PUFA intake, there is no effect on
HDL-C levels.
Another interesting interaction was the one between TCF7L2 SNP rs12255372 and fibre
intake on HDL-C. The results suggest that low and medium fibre intake (means: 20, 30 g/day),
respectively, increase HDL-C whereas high fibre intake (mean: 44 g/day) may reduce HDL-C
among risk allele carriers of the TCF7L2 SNP rs12255372. The average fibre intake in India is
30–40 g/day [40] which is consistent with the mean intake in the medium and high tertiles and
also higher compared to the mean fibre intake in the UK (~18g/day) and the US (~16g/day). A
previous study investigated interaction between SNP rs7903146 and fibre intake on T2D risk
[28],where the minor allele carriers had increased T2D risk with higher fibre intake (mean
intake: 13.1 ± 2.2 g/4,184 kJ). High fibre intake is generally recommended to improve glycemic
control in T2D individuals [49] and to reduce total and LDL-C in order to reduce CVD risk. A
meta-analysis of data from clinical studies (n = 2,990) [50] indicated that high fibre diets (20–
30 g/day) reduced HDL-C. Similarly, another meta-analysis of data from 24 clinical studies
also suggested that medium and high carbohydrate, high fibre ( 20 g/day) diets also decreased
HDL by 4% [51].However, it was argued, that the decrease in LDL-C and TG values would
reduce CVD risk by 16.4% which would outweigh the increased risk of CVD by 11.9% due to
decreased HDL [51]. But it is of note that these meta-analyses did not consider the genetic
component and, furthermore, we also observed gene-diet interaction on other lipid outcomes
such as VLDL and TG, which did not remain significant after correction for multiple testing.
The risk of coronary artery disease is increased in individuals with circulating HDL-C con-
centration of<40 mg/dl [52]. In our study, within the high fibre intake tertile ( 35g/day), the
mean HDL-C level of the minor risk allele carriers was 39.46 mg/dL in comparison to 42.27
mg/dl of the ‘GG’ carriers of the TCF7L2 SNP rs12255372. The results of our study suggest that
high fibre intake (35–102 g/day) may help maintain HDL-C level above 40 mg/dl whereas
below 35 g/day may lower HDL-C in the ‘GG’ genotype carriers of SNP rs12255372. Mecha-
nisms on how low/high fibre intake decreases/increases HDL-C are not well understood and
more research is needed to clarify the effects of dietary fibre on HDL-C metabolism [52, 53].
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No studies, to date, have investigated interactions between the TCF7L2 SNPs
(rs12255372 and rs7903146) and MC4R SNP rs17782313 and physical activity on cardio-
metabolic traits in Asian Indians. Despite the fact that the majority of people are physically
inactive in India [54], no significant interactions were found after correction for multiple
testing between the three polymorphisms and physical activity on cardio-metabolic traits,
which could be due to a small sample size and measurement bias associated with self-
reported physical activity questionnaire. However, our finding is in support of the previ-
ous study in a Spanish population [21] with a much larger sample size (n = 7,052) which
also did not find a significant interaction between MC4R SNP rs17782313 and physical
activity on obesity traits. Though the inclusion of a representative sample of Chennai for
analysis and the use of a comprehensive, validated, interviewer administered semi-quanti-
tative FFQ for dietary assessment could be considered the strengths of this study, there are
some underlying limitations. The data used to calculate the measures of dietary intake and
physical activity came from self-report and hence, measurement bias associated with self-
reported questionnaire cannot be ruled out. Given that obesity and diabetes are multifac-
torial traits, several genetic and lifestyle factors are likely to contribute to the disease.
While 97 loci have been shown to be associated with body weight [55], the present study
examined only three common variants, given their consistent associations with obesity
and diabetes, respectively, in Europeans and Asian Indians. The cross sectional study
design gives only a snapshot of the prevalence and cause—effect cannot be established due
to lack of follow up which is another limitation of this study. However, several outcomes
and risk factors were assessed and there was no loss to follow up.
In conclusion, this study has found significant interactions between the TCF7L2 SNP
rs12255372 and dietary factors on HDL-C in this Asian Indian population. The results of
this study indicate that high total fat and PUFA intakes may be associated with lower
HDL-C whereas low intake is associated with higher HDL among the risk allele carriers.
More research is required to better understand the interactions between the TCF7L2 gene
variant and lifestyle factors on cardio-metabolic traits. Exact mechanisms identifying the
effect of different fatty acids on HDL-C and whether/how high fat- and PUFA- intake may
reduce HDL-C should also be established before public health recommendations and per-
sonalised nutrition advice can be developed for this Asian Indian population in order to
reduce the burden of cardiometabolic diseases.
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